

---

# Unraveling The Mystery of Insulin Resistance: From Principle Mechanistic Insights and Consequences to Therapeutic Interventions

---

[Prof M Muzaffar Mir](#)\*, [Mohammed Jeelani](#), [Muffarah Hamid Alharthi](#), [Syeda Fatima Rizvi](#), [Shahzada Khalid Sohail](#), [Javed Iqbal Wani](#), [Zia UL Sabah](#), Waad Fuad BinAfif, [Partha A. Nandi](#), [Abdullah M. Alshahrani](#), [Jaber Alfaifi](#), [Adnan Jehangir](#), [Rashid Mir](#)

Posted Date: 24 February 2025

doi: 10.20944/preprints202502.1814.v1

Keywords: Insulin signaling; Insulin resistance; signal transduction; T2DM; dyslipidemia; metabolic disease; lipotoxicity; inflammasome



Preprints.org is a free multidisciplinary platform providing preprint service that is dedicated to making early versions of research outputs permanently available and citable. Preprints posted at Preprints.org appear in Web of Science, Crossref, Google Scholar, Scilit, Europe PMC.

Copyright: This open access article is published under a Creative Commons CC BY 4.0 license, which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.

Review

# Unraveling The Mystery of Insulin Resistance: From Principle Mechanistic Insights and Consequences to Therapeutic Interventions

Mohammad Muzaffar Mir <sup>1,\*</sup>, Mohammed Jeelani <sup>2</sup>, Muffarah Hamid Alharthi <sup>3</sup>, Syeda Fatima Rizvi <sup>4</sup>, Shahzada Khalid Sohail <sup>4</sup>, Javed Iqbal Wani <sup>5</sup>, Zia Ul Sabah <sup>5</sup>, Waad Fuad Bin Afif <sup>6</sup>, Partha Nandi <sup>3</sup>, Abdullah M Alshahrani <sup>3</sup>, Jaber Alfaifi <sup>7</sup>, Adnan Jehangir <sup>8</sup> and Rashid Mir <sup>9</sup>

<sup>1</sup> Department of Clinical Biochemistry, College of Medicine, University of Bisha, Bisha, 61922, Saudi Arabia

<sup>2</sup> Department of Physiology, College of Medicine, University of Bisha, Bisha, 61922, Saudi Arabia

<sup>3</sup> Department of Family and Community Medicine, College of Medicine, University of Bisha, Bisha, 61922, Saudi Arabia

<sup>4</sup> Department of Pathology, College of Medicine, University of Bisha, Bisha, 61922, Saudi Arabia

<sup>5</sup> Department of Internal Medicine, College of Medicine, King Khalid University, Abha 61421, Saudi Arabia

<sup>6</sup> Department of Internal Medicine, College of Medicine, University of Bisha, Bisha 61922, Saudi Arabia

<sup>7</sup> Department of Child Health, College of Medicine, University of Bisha, Bisha, 61922, Saudi Arabia

<sup>8</sup> Biomedical Sciences Department, College of Medicine, King Faisal University, Al Ahsa, KSA

<sup>9</sup> Prince Fahd Bin Sultan Research Chair, Department of MLT, Faculty of Applied Medical Sciences, University of Tabuk, Tabuk 71491, Saudi Arabia

\* Correspondence: mmmir@ub.edu.sa or mirmuzaffar11@gmail.com

**Abstract:** Insulin resistance (IR) is a significant factor in the development and progression of metabolic-related diseases like dyslipidemia, T2DM, hypertension, nonalcoholic fatty liver disease, cardiovascular and cerebrovascular disorders and cancer. The pathogenesis of IR depends on multiple factors including age, genetic predisposition, obesity, oxidative stress and other factors. Abnormalities in the insulin signaling cascade lead to IR in the host, including insulin receptor abnormalities, internal environment disturbances, and metabolic alterations in the muscle, liver and cellular organelles. The complex and multifaceted characteristics of insulin signaling and insulin resistance envisage its thorough and comprehensive understanding at the cellular and molecular level. Therapeutic strategies for IR include exercise, dietary interventions and pharmacotherapy. However, there are still gaps to be addressed, and more precise biomarkers for associated chronic diseases and lifestyle interventions are needed. Understanding these pathways is essential for developing effective treatments for IR, reducing healthcare costs and improving quality of patient life.

**Keywords:** Insulin signaling; Insulin resistance; signal transduction; T2DM; dyslipidemia; metabolic disease; lipotoxicity; inflammasome

## 1. Introduction

As early as the 1930s, it was recognized that there existed patients who were severely hyperglycemic and/or diabetic yet were unresponsive to exogenous therapy with insulin. It was subsequently recognized that insulin-resistant states are characterized by resistance to the metabolic actions of insulin, rather than true insulin insufficiency, and may coexist with either obesity and/or other features of the metabolic syndrome, or acanthosis nigricans or acanthosis nigricans [1–3].

Insulin resistance (IR) predicts future weight gain, cardiovascular disease, and type 2 diabetes [4,5]. Whether obesity or IR is the primary defect, the two often coexist and clearly interact, and it is the combination of these two factors that appear particularly detrimental [1,6,7]. As the obesity epidemic worsens, it is also reasonable to anticipate even more cases of IR [8]. IR is a hallmark of the pathophysiology of prediabetes and metabolic syndrome [6,9]. In fact, IR has been defined as the cardinal manifestation of the metabolic syndrome [9,10]. At a molecular level, primarily in settings of obesity and obesity-related IR, there are clear physiologic underpinnings whereby metabolic intermediates exert inhibitory effects and can specifically block insulin signal transduction [6–8]

However, human genetic studies argue that IR can also be the initial hit that promotes obesity and associated sequelae [9,11]. If this dichotomy has any significance, it is to accurately realize that a deep and precise understanding of these notions can guide both the exact processes of how insulin signal transduction is altered and be successfully probed for therapeutic approaches [1,9].

## 2. Definition and Clinical Relevance

IR refers to a reduction in the ability of target tissues to respond to the hormone insulin, leading to impaired glucose uptake and, eventually, to the development of T2DM [6,8,9]. IR is widely recognized as a significant risk factor for many different disorders, including cardiovascular diseases, metabolic syndromes, nonalcoholic fatty liver disease, chronic kidney disease, inflammation, and age-related cognitive impairment [3,4,12–15]. Despite the high prevalence and large disease burden of IR, the mechanistic underpinnings of the syndrome and useful strategies for ameliorating or preventing its development are poorly understood and continue to be areas of intense research investigation [1,6].

The key hallmark of IR is impaired insulin-mediated glucose disposal by peripheral microvascular endothelium, adipose tissue, and skeletal muscle in response to the metabolic needs of the whole body [1,2,6]. The primary etiological factor that leads to the development of IR is the maladaptation of various intrinsically interconnected physiological processes that together govern whole-body glucose homeostasis [9,15]. Available evidence suggests that IR and the associated vascular and neuronal dysfunctions likely develop in parallel [8,16].

More importantly, IR and its related disorders often coexist, and patients with IR are prone to more rapid progression of these various conditions. Here, we review important basic knowledge about the biochemical and molecular mechanisms that have a role in causing and maintaining IR. These mechanisms range from abnormalities in the transport of plasma glucose into peripheral microvascular endothelium, adipose tissue, and skeletal muscle to mitochondrial oxidative stress [1,6,9]. Certain forms of IR are known to develop *de novo*, while others manifest themselves as part of a complex syndrome. Type 2 diabetes is a clear example of *de novo* development, in this instance associated primarily with adipose tissue dysfunction, as well as systemic metabolic and hormonal changes [1,6,9,17]. In contrast, obesity is associated with adipose tissue inflammation and is associated more with metabolic complications [8,9]. Of the well-established factors that contribute to IR, obesity related to lipid-overloaded conditions, with enhanced release of fatty acids from adipose tissue in plasma, associated with oxidative stress, systemic disease, and impaired glucose tolerance, are known to be particularly involved [1,6,11,14]. IR has further been linked to post-receptor intracellular aberrations in insulin signaling pathways, leading to reduced phosphorylation of intracellular insulin receptor substrates [18,19]. Specifically, the major underlying factors associated with systemic manifestations of the insulin-resistant state, such as mitochondria-induced cellular stress, impaired endothelial insulin transporter, and a loss of the endothelial glycocalyx barrier protecting against oxidative damage, have been identified [1,9,20].

## 3. Risk and Contributing Factors


IR is a complex, multifactorial condition. Factors that have been implicated in the etiology of IR can be broadly divided into genetic, environmental, and lifestyle risk factors [1,2,8]. There is good

evidence that even in genetically predisposed individuals, environmental and lifestyle risk factors play a significant role [9,10]. With regard to environmental factors, childhood obesity and low birth weight may contribute to an increased risk of IR in later life [8,11]. There is also a suggestion from some studies that exposures such as smoking, pollutants, certain microorganisms, and some nutritional elements may also contribute to the development of IR [8,21–23].

Obesity is the major contributing factor to the development of IR [6,24]. There is, however, some evidence to suggest that a sedentary lifestyle in the absence of severe obesity can also result in significant IR [25]. An emerging field of research indicates that dietary intake and dietary composition are critical in the etiology of IR [25]. For example, excessive fructose intake influences IR via hepatic de novo lipogenesis and ectopic fat storage [9,25]. There is also substantial epidemiologic evidence linking accelerated aging with increased IR [8].

#### 4. Global Epidemiology of IR

The global epidemic of IR is a well-known fact and there is a variation in its prevalence across different regions ranging from Europe through to South America and Asia [8,26,27]. There has been a lot of focus on the research related to IR over the last two decades and a continuous growth in the number of published articles in high impact journals. A comparison of 10 highest contributors is presented in Figure 1 which shows United states as the country with highest number of publications. This demonstrates the perpetual increase in the public perceptions about the increasing relevance of understanding the impact of insulin resistance and metabolic health globally.



**Figure 1.** Global impact of the Insulin resistance research. Ranking of top ten nations in terms of overall number of publications related to IR research during the period 2002 to 2021. The numbers on the Y axis represent the number of total publications. US is on top with 7360 and France has 858 publications.

The incidence and prevalence of IR are rapidly increasing globally. The prevalence of IR in Southeast Asia from 2016 to 2021 was 44.3 percent [28,29]. A recent study revealed that 33.7% of the rural Brazilian population is afflicted by IR [30]. Approximately 40% of individuals in the United States aged 18 to 40 years are impacted by IR syndrome, rendering it a reasonably prevalent illness [31]. The latest International Diabetes Federation reported that 73 million persons in the Middle East have been diagnosed with diabetes, which is strongly correlated with a heightened frequency of IR [32–34].

In the Arab world, rates are reported as high as the USA, although data are not fully systematic to make any direct comparison. Nevertheless, several investigations were undertaken in Arabic nations to assess IR. A recent survey conducted by the Fahad et al. group assessed the IR in Lebanon at 38.0% [35]. The nationwide survey in Qatar indicated that the prevalence of IR among females reached 37 percent [36]. Strong evidence shows that IR rates can vary within a country [37]. Populations in transition, or through urbanization, display the largest rises in IR, for example in Southeast China in comparison to rural rates and in the rapid rises in the UAE in the 1970s, most probably because of the population mobilization for oil revenue [38,39].

The persistent global nutritional shift is expected to perpetually elevate these figures; nevertheless, it remains uncertain whether IR will persist alongside diabetes and obesity or diminish at some point due to long-term dietary trends that may benefit the metabolic profile [37–39]. Numerous studies on various chronic diseases indicate that diabetes and IR are influenced by components of the urban obesogenic diet and lifestyle, potentially through the induction of obesity-mediated vascular inflammation [24,25,28]. Obesity is the primary factor contributing to diabetes in both industrialized and developing nations; the alteration in dietary patterns cannot surpass the significance of obesity in creating an insulin-resistant condition [10,13,37].


## 5. Prevalence of IR in Specific Populations

There is a significant variation between different ethnic groups regarding the prevalence of IR and type 2 diabetes [4,37,38]. The prevalence of IR also varies significantly depending on wage, employment status, and other indicators of socioeconomic status, with the poorest and least employed persons having the highest rates of IR [37–39]. Certain age groups have been shown to have a disproportionately high level of IR when compared to older or younger adults [28,39,40].

Lifestyle factors and inherited genetic risk factors could explain prevalence disparities in specific demographic groups [6,22,39]. Certain racial and ethnic groups have a higher prevalence of IR compared to the overall population [38,39]. Findings also suggest a vast proportion of Hispanic and African American people are at high risk for complications associated with IR and suggest targeted intervention with these populations [37–39].

## 6. Molecular Mechanisms of Insulin Signaling

Insulin, a peptide hormone synthesized by the beta cells of pancreas, is a positive regulator of numerous metabolic pathways, which, when stimulated, act to lower circulating glucose levels. Insulin and insulin-like growth factors (IGF) are involved in the process of the insulin signaling pathway that involves multiple stages [40,41]. The first stage involves the participation of insulin and IGF, which bind to insulin and IGF receptors respectively. In the second step, an insulin receptor is responsible for binding to its direct substrates. These substrates include growth factor receptor-bound protein 2 (GRB2), Src homology 2 domain-containing adapter protein (SHC), insulin receptor substrate (IRS), SH2B adapter protein 2/adaptor protein with a PH and SH2 domain (SH2B2/APS), and growth factor receptor-bound protein 10 (GRB10) [40,42]. Because of this interaction, multiple cellular signaling pathways that are involved in mitogenesis, and metabolism could be activated. A schematic illustration of the insulin signaling cascade is given in Figure. 2.



**Figure 2.** A schematic illustration of insulin signaling mechanism. The initiation of a chain reaction of phosphorylation events is triggered when insulin and IGF-1 receptors are activated by their respective ligand (insulin). During the process of ligand binding, the receptors undergo a conformational change and undergo autophosphorylation. This results in the recruitment and phosphorylation of receptor substrates, such as IRS and Shc proteins. The Ras-MAPK pathway is activated by Shc, whereas the PI3K-Akt route is primarily activated by IRS proteins. This is accomplished by the recruitment and activation of PI3K, which ultimately results in the production of the second messenger PIP3. PIP3 that is linked to the membrane has the ability to recruit and activate PDK-1, which then phosphorylates and activates Akt as well as atypical PKCs. In addition to regulating glucose transport, lipid synthesis, gluconeogenesis, and glycogen synthesis, Akt is responsible for mediating the majority of insulin's metabolic actions. Akt also regulates the cell cycle and the survival behavior of cells. The Shc-Grb2-SosRas-Raf-MAPK pathway is responsible for controlling the transcription of genes and the proliferation of cells. This image was drawn using BioRender software.

### 6.1. Insulin Receptor: Structure and Function

Insulin and IGF-1 exert their biological effects through the insulin receptor and the IGF-1 receptor (IGF-1R). These closely related tyrosine kinase receptors belong to a family that includes the orphan insulin receptor-related receptor (IRR) [6,19,40]. Insulin and IGF-1 primarily bind to their respective receptors, although both ligands can also interact with the alternative receptor, albeit with diminished affinity [41]. The insulin receptor, IGF-1R, and IRR are tetrameric proteins composed of two extracellular " $\alpha$ " subunits and two transmembrane " $\beta$ " subunits linked by disulfide bonds. Both subunits are produced from a singular big precursor through proteolytic cleavage. The insulin receptor messenger RNA (mRNA) experiences alternative splicing of exon 11, resulting in two isoforms: isoform A, which excludes, and isoform B, which includes a 12 amino-acid sequence in the carboxy-terminal region of the  $\alpha$  subunit [43,44]. IR-A is primarily expressed in fetal tissues and the brain, exhibits a greater affinity for both insulin and IGF-2, demonstrates a higher internalization rate than the type-B isoform, and is often up-regulated in cancer while IR-B expression is most pronounced in the liver [44,45]. Heterotetramers consisting of an  $\alpha/\beta$  dimer of insulin receptor, and an  $\alpha/\beta$  dimer of insulin-like growth factor 1 receptor (IGF-1R) can create hybrid receptor complexes that exhibit a preference for binding IGF-1 and IGF-2 rather than insulin [45,46]. Their creation seems

to occur randomly in cells expressing both receptors and is contingent upon the relative expression levels of each receptor type [43–45]. The varied effects of insulin and IGF-1 *in vivo* primarily depend on hormone concentration and the relative expression levels of receptors across various tissues, rather than the ability of insulin receptor and IGF-1R to transmit distinct signaling pathways [47,48].

## 6.2. Intracellular Signaling Pathways

Insulin signaling triggered at its receptors exerts multifaceted effects on the metabolic processes, cell survival, and multiplication of specific cells. Insulin accomplishes its effects via insulin receptors that activate many pathways, including protein and lipid phosphorylation, modulation of transport processes, regulation of enzymatic systems, and control of transcriptional factors [40]. As the insulin binds to IR and/or IGF-1R, their alpha subunits undergo a conformational change, activating beta subunit kinase activity. Transphosphorylation of beta subunits activates the kinase, and the engagement of receptor substrates starts. Insulin receptor substrates 1-6 (IRS-1-IRS-6), which organize and mediate signaling complexes, are the best-characterized substrates [49].

IRS proteins' amino terminus pleckstrin homology (PH) and phosphotyrosine binding (PTB) domains recruit them to the membrane and activated receptors [50]. Activated receptors phosphorylate numerous tyrosine residues to produce binding sites for intracellular SH2 domain molecules [51]. Although they share tyrosine phosphorylation patterns, these substrates have distinct *in vivo* activities [51]. IRS-1 KO mice had adequate glucose tolerance but retarded development and reduced insulin action, especially in muscle [52]. IRS-2 KO animals show faulty hepatic insulin signaling and growth reduction in specific neurons and islet cells, which leads to diabetes when  $\beta$  cells are lost [52]. IRS-1 KO preadipocytes differentiate abnormally, while IRS-2 KO preadipocytes differentiate correctly but exhibit decreased insulin-stimulated glucose transport. IRS-1 is needed for myoblast development and glucose metabolism in skeletal muscle cells; however, IRS-2 is needed for lipid metabolism and ERK activation [53].

IRS-3 and IRS-4 have narrower tissue distributions. IRS-3 is abundant in mouse adipocytes, liver, and lungs, but in humans, the gene is a pseudogene that produces no protein [53,54]. In mice, IRS3 gene disruption alone does not cause problems, whereas IRS-1 loss causes a severe adipogenesis deficiency [52,53]. IRS-4 mRNA is found in skeletal muscle, liver, heart, brain, and kidney and IRS-4 KO mice had little growth retardation and glucose intolerance [47,52,53]. It has also been reported that IRS-5 (DOK4) and IRS-6 (DOK5) have low tissue expression and poor IR substrates [51,52].

Besides IRS proteins, insulin and IGF-1 receptors can phosphorylate additional substrates [47,54,55]. IR and IGF-1R tyrosine phosphorylate Shc proteins, activating the Ras/ERK pathway. IR, IGF-1R, and other receptors bind to Grb2-associated binder (GAB) proteins [54,55]. GAB proteins, which lack a protein tyrosine phosphatase (PTP) domain, may participate in insulin/IGF-1 signaling in cells with low IRS protein levels. APS (SHB2) and Cbl, IR/IGF-1R substrates, attract CAP to the insulin-signaling complex [54,55]. The latter regulates insulin-stimulated glucose absorption [47,53] SH2B1 directly binds to insulin receptors and IRS proteins to increase insulin sensitivity by catalyzing receptor catalysis and blocking IRS protein tyrosine dephosphorylation [47,54,55].

PI3K/Akt is the key route connecting IRS proteins to insulin metabolism. The interaction of two SH2 domains in the regulatory subunits to tyrosine-phosphorylated IRS proteins dictates the role of PI3K and its activation [47,49]. The catalytic subunit quickly phosphorylates phosphatidylinositol 4,5-bisphosphate (PIP2) to produce the linking molecule PIP3. The latter attracts Akt to the plasma membrane, where activation activates consequent signaling.

Three genes encode PI3K regulatory subunit isoforms. *Pik3r1* encodes 65%–75% of regulatory subunits, predominantly p85 alpha but also p55 alpha and p50 alpha. *Pik3r2* encodes p85 beta and 20% of regulatory subunits. *Pik3r3* encodes p55 gamma, which is identical to p55 alpha but expressed at low levels in most tissues [6,56]. Three genes produce the catalytic subunits p110a, beta, and delta. The regulatory subunit binds to a catalytic subunit to stabilize and inhibit it. Binding the regulatory subunit to IRS protein phosphotyrosine residues reactivates it [47,57,58].

Mouse liver-specific p110 alpha and beta ablation causes glucose intolerance and insulin resistance [59]. Surprisingly, PI3K regulatory subunit knockouts like heterozygous p85 alpha deletion, p85 beta KO, and p50 alpha /p55 alpha double KO boost insulin sensitivity [60]. Reducing regulatory subunit concentration has been shown to increase insulin action through various ways. Catalytic subunits are usually less abundant than regulatory subunits, thus they compete with the enzymatically competent p85/p110 heterodimer for IRS protein binding. PTEN regulation is also connected to the p85 alpha monomer [47,61].

Recent studies have showed that p85 alpha binds to XBP-1 and modifies the unfolded protein response, contributing to insulin resistance [57,58]. IRS proteins recruit insulin and IGF-1-related proteins besides PI3K. According to proteomics studies of IRS-1 and IRS-2's phosphotyrosine interactome, most interacting proteins, such as adaptor proteins Grb2 or Crk or phosphatase SHP2, bind to both substrates. Several interaction partners bind exclusively to IRS-1 (Csk) or IRS-2 (Shc, DOCK-6, and DOCK-7 [62].

### 6.3. Role of Kinases and Phosphatases

The AGC family comprises around 60 human protein kinases that have been significantly conserved during eukaryotic evolution and can be categorized into 14 subfamilies. AGC protein kinase family members, including Akt/protein kinase B (PKB), p70 ribosomal S6 kinase (S6K), serum- and glucocorticoid-induced protein kinase (SGK), and several PKC isoforms, particularly the atypical PKCs, mediate most of the physiological effects of PI3K-generated PIP3 [63]. Serine and threonine phosphorylation activates AGC kinases, which have similar structures [64]. PDK-1 is the major upstream kinase that activates PI3K-regulated AGC kinases [63]. PH domain of PDK-1 interacts with membrane-bound PIP3 and activates AGC protein kinases at serine/threonine residues like Akt Thr-308 [65]. Akt must be phosphorylated at Ser-473 by mTORC2 for complete activation [63–65]. DNAPK (DNA-dependent protein kinase) phosphorylates and activates Akt in response to DNA damage [63] and controls insulin dependent regulation of metabolic genes such fatty acid synthase [66]. Different genes encode three serine/threonine protein kinases in the Akt/PKB family [65,66]. All isoforms use PH domains to attract PIP3 to the plasma membrane. Insulin affects metabolism largely through Akt2 in insulin-sensitive tissues. Unlike Akt1 and Akt3 KO mice, Akt2 KO mice develop diabetes and are insulin resistant [63].

Activation of Akt via PDK-1 and mTORC2 leads to phosphorylation and activation of downstream targets [6,61]. TSC-2 phosphorylation by Akt degrades the tumor suppressor complex of TSC-2 and TSC-1 and activates mTORC1. The mTORC1 inhibitor PRAS40 can be activated by Akt by phosphorylating it [67,68]. The mTORC1 complex then phosphorylates and inhibits 4E-binding protein1 (4E-BP1), activates S6K1 and S6K2 and SREBP1, and regulates metabolism, protein synthesis, and cell development genes [67,68]. Foxo transcription factors control lipogenic and gluconeogenic genes. Akt phosphorylates Foxos widely, giving docking sites for 14-3-3 family proteins. This interaction keeps Foxo out of the nucleus, limiting transcription [69,70]. Foxo1 liver ablation normalizes excessive glucose production and severe hepatic insulin resistance in animals lacking Akt1 and Akt2. This shows that insulin modulates hepatic glucose synthesis independently of the Akt/Foxo1 axis [69].

Several other Akt substrates impact insulin. TBC1D4, also known as AS160, and its homolog TBC1D1, which are implicated in insulin- and contraction-mediated glucose absorption, are phosphorylated by Akt. Inactivating and activating glycogen synthase kinase3 with Akt increase hepatic glycogen [6,71]. Akt-dependent PGC-1alpha suppresses gluconeogenesis and fatty acid oxidation [67,68]. Akt activation activates PDE3B and reduces cyclic AMP, which inhibits adipocyte lipolysis and b cell insulin release [72].

### 6.4. AKT Pathway of Insulin Action

Akt regulates enzymes, transcription factors, cell cycle regulators, apoptosis and survival proteins, and other insulin activities [74]. Murine double minute 2 (Mdm2), phosphorylated by Akt,



reduces p53-mediated apoptosis and promotes cancer [75]. By phosphorylating the cell cycle inhibitors p21 IKK/WAF1 and p27Kip1, Akt causes cytoplasmic localization, cell proliferation, and apoptosis suppression [75,76]. Akt phosphorylates and inhibits Bax, Bad, and caspase-9 to increase cell survival. IKK phosphorylation by Akt promotes NF- $\kappa$ B [77]. Akt induced phosphorylation and activation of endothelial nitric oxide synthase (eNOS), which produces the vasodilator and anti-inflammatory molecule NO, may relate insulin resistance to cardiovascular disease [77]. “Serum and glucocorticoid-induced” protein family of kinases (SGKs) are very similar to Akt but rarely studied in insulin signaling. They are activated by simultaneous phosphorylation by PDK-1 and mTORC2 in a PI3K-dependent manner and share several subsequent substrates with Akt [78].

### 6.5. Interplay of PKC Isoforms

The role of PKC isoforms is well established in the regulation of metabolic influences of insulin. The PKC family has three main groups: the atypical PKCs (aPKCs), which include the  $\zeta$  and  $\iota/\lambda$  isoforms; the novel PKCs (nPKCs), which include the  $\theta$ ,  $\eta$ ,  $\epsilon$ , and  $\delta$  isoforms; and the classical PKCs (cPKCs), which include the  $\alpha$ ,  $\beta$ I,  $\beta$ II, and  $\gamma$  isoforms [79,80]. The obese and diabetic individuals have lower expression and activation of the atypical PKCs (aPKCs) [81,82] which otherwise play an important role in insulin dependent uptake of glucose and lipid biosynthesis. The activation of most of PKC isoforms is dependent on the phosphorylation cascade by Phosphoinositide-dependent kinase-1 (PDK-1 [83]. PKC-I and PKC-  $\zeta$  facilitate insulin dependent glucose uptake I and a consequent IR [84]. In mice lacking PKC-I in the liver, insulin-induced SREBP1c expression and triglycerides are reduced, improving insulin sensitivity [85].

From this perspective, the majority of aPKC-dependent processes would be seen as “good” as each of these metabolic processes is necessary for survival and overall health during times of sporadic and restricted food intake [84,85]. However, the remarkable effectiveness of aPKC-dependent processes in the liver that lead to excessive increases in lipogenic, glucogenic, and cytokine-producing enzymes would be conducive to the development of metabolic syndrome features, which in turn would lead to type 2 diabetes mellitus and atherosclerosis, in situations where food intake is frequent and excessive. Furthermore, as is known to occur in type 2 diabetes, a concurrent deficit in aPKC activation in muscle would exacerbate the propensities for the development of metabolic and diabetic disorders [6].

### 6.6. Alternate Insulin Signaling: GRB2-SOS-RAS-MAPK Cascade

Another important insulin/IGF-1 signaling pathway branch is Grb2-SOS-Ras-MAPK, activated independently of PI3K/Akt. IRS and activated receptors bind to Grb2 and Shc adaptor molecules with SH2 domains [9]. Grb2's amino-terminal domain binds to proline-rich proteins like son-of-sevenless (SOS), a guanine exchange factor, whereas its carboxy-terminal SH3 domain binds Gab-1. Ras bound SOS catalyzes the transformation of membrane-bound Ras from inactive-GDP to active-GTP form. Consequently, Ras-GTP boosts downstream effectors like Raf, MEK1 and 2 which in turn phosphorylate and activate ERK1 and 2. ERK1/2 phosphorylation and activation of cytosol and nucleus targets affects gene expression, extra-nuclear activities, and cytoskeletal reorganization to promote cell proliferation or differentiation [6,9,85]

### 6.7. Modulation of Insulin Action

Given the magnitude of Insulin and IGF-1 actions, the whole cascade needs to be tightly regulated to prevent metabolic disruptions and cancer development. Signal intensity and duration greatly affect pleiotropic effect response specificity. Turning off the insulin signal rapidly in multiple dimensions is a metabolic necessity to prevent the undesired influences. These inhibitory systems can change the pathophysiological dynamics and inadvertently lead insulin resistance.

Cytoplasmic and transmembrane protein tyrosine phosphatases like PTP1B and LAR reduce IR, IGF-1R, and IRS activity by dephosphorylation of their tyrosine residues [47,86]. The role LAR role in insulin signaling in vivo is debatable, PTP1B is crucial to insulin action. PTP1B KO mice had better insulin sensitivity, enhanced muscle and liver IR phosphorylation, and resistance to high-fat diet-induced obesity and insulin resistance [87]

PP1 (serine/threonine phosphatase protein phosphatase 1) controls glucose and lipid metabolism rate-limiting enzymes including glycogen synthase, hormone-sensitive lipase, and acetyl CoA carboxylase (6, 47). PP2A regulates Akt, PKC, S6K, ERK, cyclin-dependent kinases, and IKK, which account for 80% of cell serine/threonine phosphatase activity [88]. Several studies show hyperactivated PP2A in diabetics (89). There are other serine/threonine phosphatases that too have been reported to impact insulin action. Akt is dephosphorylated by calcineurin (protein phosphatase 2B or PP2B) [90]. The novel PH domain leucine-rich repeat protein phosphatases PHLPP-1 and -2 regulate insulin action by dephosphorylating Akt and PKCs. By suppressing Akt and glycogen synthase kinase 3, PHLPP1 overexpression reduces glycogen synthesis and glucose transport [91,92]. In obese and diabetic adipose tissue and skeletal muscle, PHLPP-1 levels are increased while Akt2 phosphorylation is decreased [91,92].

#### 6.8. Role of Lipid Phosphatases

Lipid signaling is now a recognized mechanistic underpinning of insulin action. Lipid molecules from all known classes serve as signaling entities for important cellular responses. Disruptions of cellular lipid homeostasis often lead to lipid oversupply and buildup of different bioactive lipid intermediates or “lipotoxicity” in non-adipose tissues [6,93]. PIP3 levels are essential for regulation of insulin action and are under the constant influence of phosphatases. PTEN dephosphorylation of PIP3 impairs cell PI3K signaling [94,95]. It has been reported that insulin sensitivity rises in mice with muscle, adipose, or liver PTEN loss. Whole-body PTEN haploinsufficient mice have better glucose tolerance and insulin sensitivity [96,97]. Recent reports show that the p85alpha regulatory subunit of PI3K directly binds to and promotes PTEN activity, forming a unique PIP3 synthesis and degradation interface [58,98]

Two enzymes, SH2 domain-containing inositol 5-phosphatases (SHIP) 1 and 2 are involved in the dephosphorylation of PIP3. More efficient is SHIP2 modulation in insulin signaling as this enzyme is more ubiquitous [99]. Its role in glucose and energy balance is reiterated by SHIP2 deficiency in mice, which causes hypoglycemia, insulin-induced Akt activation, and resistance to high-fat diet-induced obesity [100]. However, SHIP2-overexpressing animals exhibit decreased liver, fat, and skeletal muscle insulin-induced Akt activation [100,101].

#### 6.9. Regulatory Roles of Grb, SOCS, Trb3 and IP7


It has been reported Grb10 and Grb14 inhibit IR and IGF1R activity and restrict substrate availability to active receptors [102,103]. Grb10 gene deficient mice have shown enhanced growth, insulin signaling, and glucose tolerance [104,105]. On the other hand, growth impairment, glucose intolerance, and insulin resistance result from Grb10 overexpression [47,106]. Insulin-resistant animal models and T2DM patients have elevated Grb14 expression in adipose tissue, while Grb14 KO mice had enhanced glucose tolerance and insulin sensitivity, suggesting Grb14 suppresses insulin signaling [102,103]. Because they do not boost insulin signaling, Grb10 and Grb14 work similarly. SOCS (suppressors of cytokine signaling) adaptor proteins inhibit cytokine and growth factor signaling. SOCS proteins, especially SOCS1 and SOCS3, negatively affect insulin signaling, linking cytokine signaling to insulin resistance [107,108]. In obesity, their expression increases, and they impede the insulin receptor's tyrosine kinase activity, compete for receptor binding, or degrade IRS proteins, causing insulin resistance [47,109].

The expression of a pseudokinase, Trb3 (Tribbles homolog 3) is upregulated in liver during fasting and diabetic states. The resultant Trb3-Akt binding impairs insulin signaling. Trb3 knockdown increases mouse glucose tolerance [47,110,111]. Trb3 overexpression lowers insulin-

stimulated S6K activation in cultured cells, while Trb3 reduction promotes it [110, 111]. Trb3 apparently works independently of Akt in adipose tissue. Trb3 ubiquitinates and destroys acetyl-CoA carboxylase to accelerate lipolysis, while insulin stimulates lipogenesis. Transgenic mice overexpressing Trb3 in adipose tissue demonstrated greater insulin sensitivity and fatty acid oxidation, protecting them from diet-induced obesity [111,112]. Inositol phosphate (IP7) is another negative regulator of insulin signaling [113,114]. Insulin and IGF-1 increase IP7, which blocks Akt translocation to the plasma membrane and activation, perhaps reducing insulin signaling [114]. The deletion of the enzyme Inositol hexakisphosphate kinase 1 (IP6K1), responsible for IP7 synthesis, boosts insulin responsiveness in mice [47,115]. More research is needed to understand these phenomena in human health and disease.

#### 6.10. Role of Phosphorylation Cascade Induced Activated Serine -Threonine Kinases

It is well established that Insulin receptor, IGF-1R and IRS proteins need phosphorylation on their selective tyrosine residues for their optimum functionality in the insulin signaling [47,53]. However, serine and threonine phosphorylation of IRS complex mostly lowers insulin signaling [47,55]. These events are schematically represented in Figure 3.



**Figure 3.** A schematic illustration of the activation of Ser/Thr kinases leading to the phosphorylation cascade on insulin receptor, insulin receptor substrates and Akt culminating in "Insulin Resistance". 1- dyslipidemia; 2- inflammatory processes; 3- hyperglycemia; 4-reactive oxygen/mitochondrial stress; 5-endoplasmic reticulum stress; 6-protein kinases C and A phosphorylating insulin receptor; 7- IRS-1 phosphorylation by multiple kinases including classical and novel PKC, JNK, IKK, S6K1, GSK3, SIK2, MAPK, mPLK1; 8- iRS-2 phosphorylation involving JNK and GSK3; 9-Akt phosphorylation involving atypical PKC. This image was drawn using BioRender software.

Cytokines, fatty acids, hyperglycemia, mitochondrial dysfunction, ER stress, and insulin *per se* induce inhibitory Ser/Thr phosphorylation of IR, notably IRS-1 and -2, via JNK, IKK, traditional and novel PKCs, mTORC1/S6K, and MAPK [6,47,116]. Insulin-resistant rats and humans have shown enhanced IR serine phosphorylation and decreased tyrosine kinase activity equally [47,117]. As can be visualized in Figure 3, PKA-dependent inhibitory serine phosphorylation of IR occurs when cAMP levels rise [47,118]. The phosphorylation at Ser-307 is the most prevalent of serine phosphorylations, although it occurs at other sites as well [119,120]. It has been reported that obese and diabetic mice

show enhanced IRS-1 Ser-307 phosphorylation rises [119,120]. This suppresses insulin receptor kinase activity, which may cause insulin resistance, however some authors disagree with this phenomenon [47,119,120]. Human insulin *per se* can activate IRS-1 phosphorylation on Ser-307 and mice fed on a high-fat diet with an IRS-1 Ser307Ala mutant exhibited more severe insulin resistance than controls, demonstrating that Ser-307 is essential for insulin signaling. Thus, higher IRS-1 Ser307 phosphorylation has been linked to insulin resistance, but its “cause and effect” relationship needs more investigation [47,121,122].

DAGs (diacylglycerols), a product of from lipid metabolism can activate classical and novel protein kinase C members to phosphorylate IRS proteins and IR at Thr-1336, Thr-1348, and Ser-1305/1306, impairing insulin signaling [18,40,47]. The deletion of any novel PKC family members decreases IRS-1 Ser-307 phosphorylation, reducing liver and skeletal muscle insulin resistance [47,119]. Serine phosphorylation of IRS-1 and Akt under the influence of atypical PKC- $\zeta$  inhibits the recruitment of the latter to the plasma membrane and inhibits insulin signaling [1,118,121]. mTORC1 constitutes yet another component of the negative modulator of the insulin signaling. Enabling mTOR and S6K activity increases serine phosphorylations and lowers IRS tyrosine phosphorylation, limiting insulin signaling [53,116,117]. This type of phenomenon with increased insulin sensitivity has been found in lean S6K null mice [53,116,117]. In addition, it has also been reported that Grb10 is phosphorylated and stabilized by mTORC1, blocking insulin [122,123].

## 7. Cellular and Tissue Specificity of Insulin Action

During development, the functional diversity of cells and tissues is reflected in the utilization of numerous regulatory systems, of which insulin is particularly important. This is underscored by the complexity and versatility of the mechanisms responsible for insulin action, operative in the formation of a multiplicity of fibers within a single muscle, for instance, or of diverse patterns of gene expression within the liver or adipose depots. These manifestations of cellular and tissue specialization enact modifications in the entire molecular organization responsive to insulin in conjunction with those attributable to differences in the propensity for different elements of an insulin signal transduction mechanism.

### 7.1. Adipose Tissue

The primary physiological role of insulin in white adipose tissue is to inhibit lipolysis, hence diminishing hepatic glucose production by lowering gluconeogenic substrates [124]. The mechanism by which insulin suppresses lipolysis remains incompletely elucidated, but it is thought to be mediated by phosphodiesterase 3B (PDE3B) via diminished cyclic adenosine monophosphate (cAMP)-dependent protein kinase A (PKA) activity [6,116]. Moreover, PP1 and protein phosphatase-2A (PP2A) seem to facilitate the inhibition of PI3K-dependent insulin-induced lipolysis by dephosphorylating lipolytic regulatory proteins [116,124]. Insulin facilitates glucose transport by signaling the phosphorylation of targets related to vesicle tethering, docking, and fusion; nonetheless, its role in overall glucose disposal is relatively insignificant [125]. Insulin facilitates lipogenesis in white adipose tissue by activating SREBP-1c, signaling the translocation of glucose or fatty acid transport proteins (FATPs), enhancing fatty acid esterification, and stimulating adipogenesis via the transcription factor peroxisome proliferator-activated receptor- $\gamma$  (PPAR $\gamma$ ) [126].

### 7.2. Skeletal Muscle

Insulin signaling in skeletal muscle facilitates glucose absorption and overall glycogen production. Insulin enhances glucose transport activity through the orchestrated translocation and fusion of glucose transporter type 4 (GLUT4) storage vesicles (GSVs) with the plasma membrane in skeletal muscle [47,127]. Upon activation by insulin signaling, Akt inactivates AS160 (GTPase-activating protein [GAP] AKT substrate of 160 kDa, often referred to as TBC1D4), hence activating tiny Rab GTPase protein switches that regulate vesicle trafficking [128]. Insulin-stimulated Akt

enhances the guanosine triphosphate (GTP)-bound variant of Ras-related C3 botulinum toxin substrate 1 (RAC1), facilitating GLUT4 translocation through the induction of cortical actin rearrangement [129]. Conversely, insulin regulates net glycogen synthesis in skeletal muscle by inhibiting glycogenolysis and facilitating glycogen synthesis. Insulin signaling enhances glycogen synthase (GYS) activity through Akt-mediated phosphorylation of glycogen synthase kinase 3 (GSK3) and the activation of protein phosphatase 1 (PP1), which facilitates GYS dephosphorylation. Furthermore, insulin modulates glycogen phosphorylase activity through the dephosphorylation of phosphorylase kinase [130].

### 7.3. Hepatic Insulin action

Insulin in the liver stimulates IRTK, which phosphorylates IRS1 and IRS2, finally activating Akt2, so reducing HGP, promoting glycogen synthesis, and transcriptionally stimulating lipogenesis [121]. The principal role of hepatic insulin signaling is to diminish hepatic glucose production (HGP) by inhibiting gluconeogenesis through Akt-mediated phosphorylation of forkhead box O1 (FOXO1), which sequesters FOXO1 from the nucleus, thereby obstructing the transcriptional activation of gluconeogenic genes, including glucose-6-phosphatase (G6PC) and phosphoenolpyruvate carboxylase (PEPCK) [6,121]. Insulin not only inhibits gluconeogenic gene expression but also suppresses hepatic gluconeogenesis by restraining adipocyte lipolysis, thereby diminishing the substrates available for gluconeogenesis in the liver [121]. Moreover, in addition to inhibiting HGP, insulin enhances hepatic glycogen production via modulating GYS (particularly GYS2 in the liver) and glycogen phosphorylase via GSK3 and PP1, similar to the process in skeletal muscle [131]. Insulin stimulates lipid anabolism by upregulating sterol regulatory element-binding protein 1c (SREBP-1c), a principal transcriptional regulator of hepatic de novo lipogenesis, thereby enhancing the transcription of various lipogenic genes, including acetyl-CoA carboxylase 1 (ACC1), fatty acid synthase (FAS), and glycerol-3-phosphate acyltransferase 1 (GPAT1) [121,132].

## 8. Insulin Resistance

The hall mark of insulin action is the homeostasis of body glucose levels which is achieved by different and intricate network of reactions as discussed above. Insulin resistance is a multifaceted pathophysiological condition, characterized by diminished bodily response to insulin, leading to increased blood glucose levels, which ultimately may manifest as T2DM and metabolic syndrome [9]. In humans, IR is a significant public health issue and its link T2DM, metabolic syndrome, and cardiovascular disease is well established [133, 134]. In addition to the dysglycemia, it is also associated with aberrant lipid buildup, and heightened lipid catabolism in adipocytes [133,134]. Insulin resistance thus fosters obesity, T2DM and its complications, non-alcoholic fatty liver disease (NAFLD), tumors, cardiovascular disease, and other metabolic disorders [134,135]. As a result, IR poses a significant hazard to human health and impacts quality of life. Therefore, it is imperative to understand IR comprehensively and explore innovative therapeutic approaches to mitigate the disease burden.

### 8.1. Factors Contributing to Insulin Resistance

Various factors contribute to the so-called multifactorial insulin resistance, including genetic, molecular, physiological, and metabolic pathways that result in diminished insulin action in peripheral tissues, such as muscle and adipose tissue. The development of multifactorial insulin resistance is significantly influenced by both genetic predisposition and environmental factors, which frequently interact with one another. Among several environmental factors, inappropriate nutrition, insufficient physical activity, or excessive physical activity coupled with inadequate sleep are critical. Additionally, beyond an unhealthy diet and insufficient physical activity, insulin resistance is considerably affected by factors such as endocrine dysfunctions and socio-economic conditions. These multiple factors are discussed one by one.

### 8.1.1. Obesity and Adipose Tissue Dysfunction

Obesity and overnutrition cause lipotoxicity in muscle, heart, liver, pancreas, and other cells due to persistent FFA overproduction and dietary lipid accumulation [130,136]. It has been reported that ectopic fat deposition and fat accumulation in adipose tissues generate pro-inflammation and consequent insulin resistance [137,138]. Ectopic fat produces harmful lipids such as ceramides and DAG, alters the PI3K pathway, upregulates PKC, JNK, and IKK complex and results in the ROS production [137,138]. In addition, the harmful effects of these fats include ER stress, membrane stiffness, inflammation, and apoptosis [137,138]. Some investigators reported no significant connection between total DAG and insulin resistance [7,139]. Dietary lipids activate MAPK and NF $\kappa$ B signaling pathways, leading to increased NALP3 expression and systemic inflammation [7,140]. Dietary fat and chylomicron formation increase plasma LPS levels and liver absorption, which decreases hepatic intracellular lipid/LPS metabolism and causes inflammation [7,140]. LPS cause inflammation by activating TLR4 and NF- $\kappa$ B, P38 MAPK, and other pathways [141,142]. Sun *et al.* (2016) reported that NOX4 mediates LPS-induced inflammation in human peripheral blood mononuclear cells [143]. LPS has also been reported to interact with mouse and human caspases and produce IL-1 $\beta$  after stimulating inflammasomes [144].

Holland *et al.* (2011) reported that TLR4 needs saturated fatty acids to cause insulin resistance, and IKK $\beta$  is crucial for TLR4-mediated pro-inflammation and ceramide production in muscles [145]. Obese mice produce and activate ceramides from absorbed and esterified fatty acids in several organs [145]. Ceramide levels rise in skeletal muscles of obese and serum of T2DM patients, whereas exercise lowers them and increases insulin sensitivity [146,147]. Ceramides activate PKC $\zeta$ , which phosphorylates the PH domain of PKB/Akt on threonine residues, reducing PIP3 binding and insulin responsiveness [148]. Activating PKC $\zeta$  leads to increased CD36-mediated fatty acid absorption in the liver [149]. Ceramides activate PP2A, prevent PKB/Akt translocation to the plasma membrane, and dephosphorylate Akt/PKB in differentiated adipocytes [150]. Excess FFAs increase ceramide levels, resulting in NO production in  $\beta$ -cells [150]. Two independent reports found that obese mice lacking *Cers6* and *Cers1* (ceramide modulation genes) were protected from diet-induced insulin resistance and hepatic lipid unitization separately [151,152]. Most significantly, insulin resistance causes human hepatic de novo lipogenesis, which increases liver ceramide and lipid accumulation and decreases insulin sensitivity [153].

### 8.1.2. Inflammatory Mechanisms in Insulin Resistance

The advent and progression of obesity involves multiple stages and events. Weight gain leads to an appreciable rise in adipocyte size, resulting in heightened adipocyte mortality due to insufficient oxygen delivery amid the expansion of adipose tissue [154,155]. The hypertrophied adipocytes and adipose tissues subsequently generate FFAs, ROS, and pro-inflammatory adipokines [156,157]. It is postulated that fatty acids activating NF- $\kappa$ B and P38 MAPK signaling via MyD88 and TRIF-mediated downstream pathways subsequent to TLR4 (Toll-like receptor 4) activation in resident adipocytes and macrophages, which intensifies ER stress, generates ROS, and stimulates the release of pro-inflammatory cytokines [158].

The adipose tissues in obese individuals release many pro-inflammatory adipokines, including MCP-1, TNF- $\alpha$ , IL-1 $\beta$  and IL-6. MCP-1 recruits monocytes during chemotaxis by attracting C-C motif chemokine receptor 2 to obese adipose tissues [159,160]. As part of the inflammasome, monocytes develop into macrophages [160]. The adipose tissue macrophages metamorphose from an anti-inflammatory M2 to a pro-inflammatory M1 phenotype [161]. Resident pro-inflammatory M1 macrophages secrete cytokines such as MCP1, IL-1 $\beta$ , and IL6, which may attract more monocytes, contingent upon adipocyte size and environmental factors [161,162]. The macrophages encircling the necrotic adipocytes form a crown-like structure (CLS) to phagocytize the deceased adipocytes; consequently, lipids from these adipocytes are absorbed by macrophages, disrupting their normal function. The occurrence of CLS is significantly associated with metabolic disorders and inflammation [162,163].

Dysfunctional adipose cells from chronic overnutrition and obesity create FFAs, ROS, and pro-inflammatory substances in the systemic milieu, causing low-grade systemic inflammation [161–163]. Increased systemic TNF- $\alpha$  in obesity leads to increased activity of IKK, p38 MAPK, JNK, and PKC proteins, which modify IRS protein serine residues and hinder tyrosine phosphorylation, causing insulin resistance in adipose tissues, muscles, and liver [47,163]. PTP1B stimulation by TNF- $\alpha$  inhibits insulin signaling by dephosphorylating phospho-tyrosine residues in the insulin receptor and IRS protein [163,164]. Elevated IL6 can activate JAK-STAT signaling pathways and increase SOCS1 and SOCS3 protein expression, which may downregulate insulin receptor function by sterically blocking IRS protein interaction or changing kinase activity [164]. STAT3 activation by IL-6 and IL-1 $\beta$  leads to increased TLR-4 gene expression and NF- $\kappa$ B activity in hepatocytes, leading to inflammation [165]. IL-1 $\beta$  causes p38 MAPK activation via its receptor and inhibits insulin signaling by serine phosphorylation of IRS1/2 [7,164]. TNF- $\alpha$  may be believed to reduce  $\beta$ -cell insulin sensitivity via nitric oxide mediation, contrary to the belief that a pro-inflammatory state affects  $\beta$ -cell function [164, 165].

### 8.1.3. Role of Oxidative Stress

It is well documented that in human adipocytes, hepatocytes, and skeletal muscles, obesity increases ROS generation and lipid peroxidation [166]. Obesity-related mitochondrial dysfunction leads to increases the production of ROS including nitric oxide [7,166].

Plasma membrane NADPH oxidase (NOX) normally generates ROS to kill microbes [167]. ROS has many isoforms. Insulin-activated NOX4 increases H<sub>2</sub>O<sub>2</sub> generation in healthy adipocytes, inhibiting PTP1b, promoting adipocyte development and enhances insulin sensitivity [166–168]. In obesity, NOX increases oxidative stress that inactivates metabolic enzymes, damages cellular components, and promotes lipid peroxidation [169,170].

In differentiated adipocytes, NOX4 inhibition lowers reactive oxygen species creation and MCP-1 expression, while glucose and free fatty acids increase NOX4 catalyzed ROS generation [170,171]. It has been reported that NOX4 deletion in adipocytes delays adipose tissue inflammation and insulin resistance [172]. NOX4 overexpression reported in excessive food intake reduced PTP1B inhibition and enhanced insulin resistance in adipocytes [6,7]. The levels and activities of antioxidant enzymes like SOD1, Catalase and GPX have been found to be lower in obese individuals [170,172,173]. NOX is detected in human and mouse pancreatic islets and increases oxidative stress in T2DM animals [173,174]. De Vallance et al. (2019) found that obesity-related hyperglycemia and hyperlipidemia increase ROS formation through NOX, which may reduce Akt levels and cause skeletal muscle insulin resistance [168]. NOX2 activates macrophage chemotaxis and polarization in obese rats, promoting inflammation [172]. Infiltrating macrophages, like obese adipocytes, generate ROS through NOX2 in response to elevated fatty acid and glucose levels [6,7]. After 72 hours of in vitro exposure, excess FFAs are reported to increase vascular cell NOX synthesis via a PKC-dependent mechanism [167]. Fat accumulation and excess lipids increase mitochondria malfunction in obese individuals elevate ROS levels leading to metabolic dysfunction and excessive expression of proinflammatory markers [154,168].

Overexposure to reactive oxygen species causes oxidative stress, activating transcription factors such NF- $\kappa$ B, increasing systemic pro-inflammatory cytokines and insulin resistance [170,172]. Fructose metabolism also produces ROS, which accumulates citrate in the TCA cycle and increases substrate availability for *de novo* lipogenesis, promoting lipid buildup and lipotoxicity. ROS affects oxidative phosphorylation, superoxide production by NOX, glyceraldehyde auto-oxidation, chronic inflammation, PKC activation, and hyperleptinemia [167,171]. Serine/threonine kinase cascades activated by reactive oxygen species interact with numerous insulin signaling substrates. ROS mostly target the insulin receptor and IRS protein family. ROS activate serine kinases, hyperphosphorylating serine/threonine residues. This reduces insulin signaling catalytic activity by inhibiting IRS-1 and IRS-2 tyrosine phosphorylation [7,9]. The serine/threonine cascade, involving IKK $\beta$ , JNK, and P38 MAPK kinases, promotes pro-inflammatory reactions in the NF- $\kappa$ B pathway and causes insulin resistance as illustrated in Figure 2.

#### 8.1.4. Mitochondrial Distress

Mitochondrion creates ATP catalytically to maintain normal physiological function. Mitophagy, apoptosis, fusion, and fission let it adapt to metabolic changes. Energy production, mitochondrial integrity, and metabolic changes such chronic mitochondrial fusion, abnormal elongation, and loss of functioning are all affected by mitochondrial dynamics disruption [173,174]. In order to prevent anomalies, the fission mechanism divides mitochondria into two, reducing their energy production capacity and reducing their size [175,176]. Dysfunctional mitochondrial DNA may affect energy synthesis, generate reactive oxygen species, and cause oxidative stress and mortality [172,174]. Mitophagy, lysosome fusion to destroy damaged mitochondria increases with mitochondrial failure [174,175]. Mitophagy reduces mitochondrial quantity, indicating lower energy expenditure, which can cause lipid buildup, lipotoxicity, and mitochondria-mediated cellular death under overnutrition.

Due to their roles in high-energy processes and excessive food and lipid overload, obesity is thought to cause mitochondrial dysfunction in adipose tissue, muscle, and liver [176]. In mice fed a high-fat diet, the expression of fusion markers mitofusin 1 and 2 (Mfn1 and Mfn2) is significantly reduced, while the fission-related protein Drp1 is elevated. In obese humans, Mfn2 is reduced, but Mfn1 was not measured [177,178]. Obese adipose tissue mitochondrial dysfunctions increase biogenesis, metabolism, respiration, and fatty acid oxidation, increasing acetyl-CoA production [180,181]. In mice, a high-fat diet or obesity increased Drp1 levels in the skeletal muscles, but Mfn1 and Mfn2 levels remained unaltered [177,178]. In obese type 2 diabetics, Mfn2 mRNA expression reduced [139,140]. Excessive uptake of free fatty acids in skeletal muscle increases  $\beta$ -oxidation [9]. Due to increased mitochondrial fission, obese people's skeletal muscle mitochondria shrink in size and length, resulting in mitochondrial dysfunction and insulin resistance [178,179].

In a mouse model, mitochondrial fission increased in the liver, similar to adipose tissues and skeletal muscles of obese insulin-resistant people, while mitochondrial fusion (Mfn2) decreased [180–182]. Acute exposure to high glucose levels in cultured hepatocytes and myocytes increases mitochondrial fragmentation and ROS production due to Drp-1 inhibition, while mitochondrial fusion reduces ROS production [175,177]. In diet-induced obesity, increased  $\beta$ -oxidation and VLDL production reduce hepatic lipid buildup [183]. However, mitochondrial fission reduces mitochondrial respiratory capacity and protein expression [182,183]. Obese hepatocytes increase  $\text{Ca}^{2+}$  transport from the endoplasmic reticulum to mitochondria via mitochondria-associated ER membrane, causing  $\text{Ca}^{2+}$  overload, mitochondrial dysfunction, and ER stress signaling [184]. Obesity alters mitochondrial structure, biogenesis, lipid peroxides, and inefficient fatty acid oxidation produces DAG, acetyl CoA, and ceramides [184]. Obesity and related comorbidities caused by ROS generation beyond antioxidant defense systems, causing enhanced oxidative stress which damage DNA, lipid membranes, proteins, and enzymes in the mitochondrial respiratory chain [184]. After mitochondrial dysfunction and oxidative stress, oxidized intracellular components such lipids, proteins, and nuclear and mitochondrial DNA are released as damage-associated molecular patterns (DAMPs) that cause pro-inflammatory responses [185,186].

#### 8.1.5. Lysosomal Distress

A vital organelle in eukaryotic cells, the lysosome degrades and recycles long-lived, superfluous, or malfunctioning proteins, lipids, and organelles while generating ATP, new ones, and autophagy [187]. Stress reduction, neutralization of ROS, and cellular homeostasis depend on autophagy [187]. High carbohydrate, fatty acid, and amino acid intake increases mTOR, which reduces autophagy [185]. In contrast, AMPK inhibits mTOR and promotes autophagy during dietary deprivation [187,188]. In obesity and overnutrition, mTOR phosphorylates ULK1 protein at Ser637 and Ser757 and Atg13 at Ser258 in the ULK1 complex, inhibiting autophagosome formation [188]. mTOR-independent pathways regulate autophagosome formation in addition to the direct mTOR pathway. Obesity and lipotoxicity raise cytosolic  $\text{Ca}^{2+}$ , which stresses the endoplasmic reticulum and reduces autophagic flow, potentially preventing autophagosome-lysosome fusion [189]. Lipid buildup reduces autophagy, hydrolase activity, and lysosomal acidification, increasing the likelihood of



hepatocyte dysfunction [185,189]. In diet-induced obese mice, liver-specific deletion of *atg7* and TFEB genes, which are associated to autophagy, worsens steatosis, while overexpression reduces weight gain and metabolic problems [188]. This shows that autophagy enhances S-nitrosylation of lysosomal proteins, causing malfunction and autophagy impairment [189]. Defective hepatic autophagy increases misfolded or unfolded proteins and lipids, which worsens endoplasmic reticulum stress and mitochondrial dysfunction, causing systemic inflammation and insulin resistance. Autophagy suppression in adipocytes by adipose-specific *atg7* deletion reduces tissue content, increases mitochondrial amount, and improves insulin sensitivity [188,189].

Enhanced autophagy reduces mitochondrial number in differentiated adipocytes; however, the exact mechanism is still unknown. Adipose-specific *atg7* deletion mice have lower plasma triglycerides, cholesterol, and leptin levels and resist high-fat diet-induced obesity [188,189]. Obese people have more autophagy in their subcutaneous adipose tissue and higher systemic insulin resistance [184,189]. Mouse knockout of  $\beta$ -cell-specific *Atg7* reduced  $\beta$ -cell mass, caused mild ER stress and hyperglycemia, and reduced pancreatic insulin levels [190]. By mating  $\beta$ -cell-specific *Atg7* animals with leptin-deficient mice, endoplasmic reticulum stress and diabetes were seen, highlighting the importance of autophagy in maintaining  $\beta$ -cell homeostasis [186]. Obesity and overeating increase lysosomal autophagy in adipose tissues but decrease it in the liver and pancreas, leaving muscle tissues unaffected. Some reports contradict autophagy and ER stress-induced  $\beta$ -cell apoptosis, suggesting that its significance in T2DM needs more clarity [190,191]. Animal studies suggest that high-fat diets may cause  $\beta$ -cell failure through endoplasmic reticulum stress, lysosomal dysfunction, and mitochondrial dysfunction after a few weeks [190,191].

#### 8.1.6. Dysfunction of Endoplasmic Reticulum

Another crucial organelle, the endoplasmic reticulum (ER) is not involved only in the synthesis, processing and transport of proteins but also modulates  $\text{Ca}^{2+}$  homeostasis, synthesis of cholesterol, phospholipids, and ceramides [191,192]. Endoplasmic reticulum stress is now thought to cause obesity-related metabolic abnormalities [191,193]. Obesity and overnutrition cause ER stress and chronic inflammation in mice adipose tissue and liver due to lipid and protein buildup [191,194]. Lipopolysaccharides, glucose, and saturated fatty acids also stress differentiated primary human endoplasmic reticulum in adipocytes [195]. Saturated fatty acids and hyperglycemia cause endoplasmic reticulum stress in hepatocytes and promote lipid accumulation via the mTORC1 pathway; AMPK activation suppresses this signaling and reduces nutrient-induced hepatic lipid accumulation [195]. Palmitic acid directly causes endoplasmic reticulum (ER) stress in human and mouse myotubes and  $\beta$ -cells, although oleic acid reduces the effects of insulin resistance [196,197]. Another report, on the contrary claimed that palmitic acid-induced insulin resistance is independent to muscle cell ER stress [198].

Comprehensive ER stress activation is needed to create PTP1B, which promotes insulin resistance in mice fed a high-fat diet [195]. High glucose levels in obesity, like FFAs, negatively impact  $\beta$ -cell function, causing glucotoxicity, ER stress, insulin production inhibition, and irreversible  $\beta$ -cell death via TXNIP pathway apoptosis [199]. Chronic overnutrition and obesity increase liver lipogenesis and gluconeogenesis for energy storage, causing excessive lipid buildup [200]. Excess lipids limit protein synthesis and encourage lipid formation in the endoplasmic reticulum. The high "Phosphatidylcholine/ Phosphatidylethanolamine" ratio causes endoplasmic reticulum stress and releases extra liver lipids into the bloodstream, worsening hyperinsulinemia [201]. Alternatively, high cytoplasmic  $\text{Ca}^{2+}$  has also been associated with ER stress and apoptosis [201]. Saturated fatty acids increase ER membrane stiffness and activate c-Jun N-terminal kinase (JNK), which decreases ER membrane fluidity and inhibits SERCA, increasing cytosolic  $\text{Ca}^{2+}$  [202,210]. Li et al. claim that NF- $\kappa$ B activation is mediated by endoplasmic reticulum stress, which involves  $\text{Ca}^{2+}$  efflux and reactive oxygen species generation due to SERCA suppression [202]. In healthy mice, FFA increase cytosolic  $\text{Ca}^{2+}$  levels and insulin production in pancreatic  $\beta$ -cells [201]. Increased FFA intake causes  $\text{Ca}^{2+}$  depletion in ER of pancreatic  $\beta$ -cells and hepatocytes, causing ER stress [200,201,2023]

Multiple pathways cause systemic pro-inflammatory responses and contribute to ER stress. To reduce stress, the ER produces PKR-like ER kinase (PERK), inositol-requiring enzyme 1 (IRE1), and activating transcription factor 6 (ATF-6). [199,203]. PERK-mediated phosphorylation of eIF2 $\alpha$  reduces protein translation and reduces ER stress. However, it also inhibits the I $\kappa$ B protein, releasing NF- $\kappa$ B from the IKK complex and promoting pro-inflammatory protein expression [199,203]. The PERK-eIF2 $\alpha$ -ATF5 and IRE-1 pathways promote TXNIP-NLRP3 protein synthesis, leading to IL-1 $\beta$  secretion [203]. IRE-1 promotes the development of IKK $\beta$ , XBP1s, and JNK proteins, leading to inflammation [203]. Additionally, the ATF-6 pathway activates pro-inflammatory responses via NF- $\kappa$ B and inhibits anti-inflammatory PKB/AKT. Fat buildup and consequent ER stress causes insulin resistance by releasing pro-inflammatory molecules [203].

#### 8.1.7. Genetic Factors in Insulin Resistance

Insulin resistance and metabolic disorders often manifest within families due to the interaction of environmental and genetic factors; however, the complete genetic framework of these conditions remains inadequately understood [1,2,204]. Genetic factors connected with insulin resistance can be classified into genetic defects leading to abnormal insulin structure, genetic mutations in the insulin signaling system, genetic defects related to substance metabolism, and other relevant genetic anomalies [204,205]. Mutations in particular insulin-related genes lead to variant human insulins, including Chicago insulin (F25BL\*), Los Angeles insulin (F25BS), and Wakayama insulin (V3AL), which demonstrate significantly reduced insulin bioactivity and lower binding affinity to the insulin receptor, consequently impacting insulin sensitivity [2,204,205]. Uncommon mutations in insulin receptor genes lead to a reduced number of cell surface receptors and compromised insulin receptor signaling pathways, resulting in hereditary insulin resistance, which is evident in patients with genetic syndromes marked by severe insulin resistance, such as type A syndrome, leprechaunism, Rabson-Mendenhall syndrome, and Donohue syndrome [204,206]. Furthermore, since numerous molecular pathways are involved in energy homeostasis and metabolism, IR results from various mutations in multiple genes, including those linked to GLUT4, glucokinase, and PPAR nuclear receptor family, among others [1,204,206].

Modifications in lipid metabolic pathways, encompassing mutations in adipocyte-derived hormones like leptin, adiponectin, and resistin or their receptors, alterations in peroxisome proliferator-activated receptors alpha, gamma, and delta, mutations in the lipoprotein lipase gene, and other genetic variations linked to adipose tissue development can affect the advancement of glycolipid metabolism and IR [204,207]. The mutation of AKT2/PKCb in cultured cells may disrupt insulin signaling and diminish AKT/PKB co-expression [208]. Recent breakthroughs in high-throughput genomics have clarified the relationship between protein tyrosine phosphatase N1 (PTPN1) and IR, with this association being affected by differences in DNA sequences outside the coding region of PTPN1 [204]. Healthy carriers of the T allele of TCF7L2 rs7903146 may exhibit increased insulin production, leading to impaired  $\beta$ -cell function, which is associated with an elevated risk of T2DM [204,209].

#### 8.1.8. Lifestyle and Nutritional Factors in Insulin Resistance Risk

Proactive advertising and ready availability of the energy dense and highly processed food stuff has changed the social landscape of the eating behaviors [210]. Recreational amenities have compounded the situation by promoting physical inactivity and unhealthy eating and consequently increased rates of obesity [211]. Many communities have witnessed more than 2-fold increase in the obese individuals [212].

A critical 32-year prospective dataset found that an individual's likelihood of being obese increased by 57% if a friend became obese during a 4-year period [11,212]. Same-sex people influence each other more than opposite-sex people [11,212]. Heating and cooling systems in vehicles, residences, and workplaces ensures comfortable ambient temperatures and diminishes energy consumption. Prolonged exposure to the thermo-neutral zone increases the risk of obesity [213].

Industrialization, urbanization and rising income have replaced traditional diets with sugary, fatty, and animal-protein-rich ones [214]. Westernization in middle and low-income countries is increasing obesity and nutritional deficits [214, 215]. Glucose, sucrose, maltose, dextrose, and fructose are added to foods as added sugars that also contribute to long term obesity [214,215]. All of these are reported to decrease the expression and the activity of GLUT 4. Elevated glucose levels instantly reduce hepatocyte insulin sensitivity and cause glucotoxicity, which can cause various clinical issues. The weight of three middle-aged cohorts who consumed sugar-sweetened beverages, potato chips, and processed and unprocessed red meats varied by 1.63–5.24 pounds every four years, compared to those who ate vegetables, fruits, whole grains, nuts, and yogurts [215]. Childhood obesity is linked to inadequate breastfeeding, high early calorie consumption, and sugary drinks. Lipotoxicity increases inflammation and lows insulin sensitivity as discussed above [216].

#### 8.1.9. Relationship Between Age and Insulin Resistance

The fact that body composition changes as a function of age is well known. Ectopic fat formation in the liver and skeletal muscle and visceral fat deposition in the abdomen grow with age as the overall fat mass reorganizes and leads to lipotoxicity which has long term consequences. Numerous studies show that decreasing energy expenditure dramatically results in age dependent fat storage. After age 20, resting energy consumption decreases by 2–3% every decade, while skeletal muscle mass reduces by 40% between 20 and 70 [217,218]. Lower physical activity and a sedentary lifestyle reduce energy expenditure by 50% in older people [217]. Elderly people irrespective of gender have a higher ratio of body fat to muscle mass than young adults, even when their body fat percentage decreases [218]. These phenomena generally lead to long term insulin resistance.

## 9. Tissue Specific Insulin Resistance

### 9.1. Role of Skeletal Muscle in Insulin Resistance

Skeletal muscle absorbs glucose, with GLUT4 playing a key role [219]. Insulin also boosts skeletal muscle free fatty acid absorption. Insulin controls glucose metabolism through complicated and highly controlled signaling cascades that influence skeletal muscle differently [1,219]. Insulin regulates systemic energy balance by facilitating skeletal muscle glycogen synthesis, glucose absorption, and lipid consumption and storage [1,219]. Skeletal muscle is a major insulin resistance site in T2DM [219,220].

Insulin resistance reduces plasma membrane GLUT4 translocation to skeletal muscle cells, preventing glucose transport [219,220]. The majority of insulin-mediated systemic glucose absorption occurs in skeletal muscle. Recent research links skeletal muscle insulin resistance to a shorter lifespan [219]. It has been found that mice lacking IRS1 and IRS2 in skeletal and cardiac muscles had impaired glucose uptake and shorter lifespans [220,221]. These mice lived shorter than those defective in both IRS1 and IRS2 solely in the myocardium, despite insulin resistance in the myocardium being thought to be the cause [221]. Due to skeletal muscle 5' adenosine monophosphate-activated protein kinase activation, mice lacking IRS1 and IRS2 in cardiac and skeletal muscles did not develop hyperinsulinemia or hyperglycemia [220]. These results show that skeletal muscle glucose homeostasis is flexible. Muscle-specific mTORC2 knockout animals had reduced glucose absorption, while mTORC1 knockout mice had muscular atrophy and a shorter lifespan. Recent research showed muscle-specific Akt deletion mice have osteosarcopenia and a shorter lifespan [221]. The data suggest that sarcopenia may regulate lifespan via skeletal muscle insulin activity. The insertion of a constitutively active Akt in skeletal muscle improved insulin signaling and increased skeletal muscle growth and lowered fat pad weight in mice [222]. Thus, selectively activating Akt in muscle tissue may help prevent skeletal muscle degeneration caused by obesity and diabetes [223]. Skeletal muscle drives whole-body glycemic regulation as the main tissue for insulin-stimulated glucose homeostasis. Muscle contraction or exercise increases insulin sensitivity in skeletal muscle [1,219].

### 9.2. Role of Liver in Insulin Resistance

The liver has a profound role in glucose and lipid metabolism systemically. Abnormal hepatic insulin action is assumed to be a very important cause of insulin resistance, in which elevated insulin levels are needed to maintain glucose homeostasis in blood [224]. Insulin decreases glycogenic enzymes and activates glycolysis and fatty acid synthesis enzymes via Akt2, which is downstream of insulin signaling [224,225]. Insulin reduces glycogenolysis and glycogenesis, increases glycogen synthesis, and increases glycogen and lipid storage in the liver. Recently it was reported that liver-specific genetically engineered mice showed impaired liver insulin activity, increased dyslipidemia and HGP [225,226]. In contrast to control mice, liver-specific insulin receptor deletion animals had hyperglycemia and hyperinsulinemia due to decreased insulin activity in suppressing hepatic glucose synthesis and regulating gene expression [225].

Due to low LDLR expression, these mice fed an atherogenic diet developed hypercholesterolemia and atherosclerosis after 12 weeks [227]. Furthermore, deletion of IRS1 and IRS2, located downstream of insulin receptor in the liver, disrupts lipid metabolism and causes severe glucose intolerance [228]. Due to decreased hepatic Akt signaling, these animals had reduced brain insulin action and increased hepatic glucose synthesis, showing a complicated organ system where hepatic insulin resistance causes insulin resistance in other organs [227,228]. In experiments conducted on mice, it has been found that overexpression of an intrinsic liver Akt variant caused decreased blood glucose levels, elevated hepatic lipid depots, and increased levels of TG in blood [224]. This is due to insulin promoting glycogen storage, lowering blood glucose, and stimulating hepatocyte lipogenesis. Thus, increasing liver insulin signaling may not fix glycolipid metabolism issues. The differential hepatic insulin activity suggests that downhill from Akt intervention, it controls lipogenesis and hepatic glucose production via different and independent mechanisms [224]. Insulin-resistant liver pathophysiology cannot be explained by directly evaluating this model in mice in view of the fact that insulin regulates hepatic glucose homeostasis through direct and indirect processes [224,226,228]. More studies are warranted to understand fully the mystery of liver in insulin resistance and the consequence thereof.

### 9.3. Role of Adipose Tissue in Insulin Resistance

In addition to adipose tissue being crucial for energy storage, it is an endocrine organ that releases hormones and cytokines, such as adiponectin, leptin, TNF- $\alpha$ , and many chemokines [229]. The insulin sensitivity requires these molecules in adipose and other tissues. Recent studies show that adipose tissue macrophages express IL-10 during feeding and complement the insulin action to suppress hepatic glucose production, helping us comprehend that many organs are affected by adipose tissue [229]. Adipose tissue needs insulin to absorb glucose and prevent lipolysis, as a result its expansion reduces systemic insulin resistance by preventing extra lipids from accumulating in muscle, liver, and pancreas [229]. We understand that obesity, inflammation, and insulin resistance in adipose tissue, which contribute to T2DM are worsened by overnutrition [229,230]. This adipose tissue insulin sensitivity reduction causes lipolysis and free fatty acid release, which increases liver and skeletal muscle ectopic fat deposition [230,231]. Obesity-related metabolic disorders are exacerbated by excess adipose tissue infiltrating other organs, reducing insulin effectiveness [230,231]. This necessitates the need to understand the genesis of insulin resistance in adipose tissue to formulate treatment modalities of T2DM. Insulin receptor knockout studies in adipocytes have reported conflicting results. Adipocyte-specific PTEN knockout mice had increased Akt signaling in adipose tissue, decreased hepatic fat accumulation, and improved obesity-related metabolic disorders [229]. Increasing insulin signaling in adipocytes allowed "healthy adipose tissue expansion" without inflammation or fibrosis. This shows that specifically increasing insulin signaling in adipose tissue may be a viable therapeutic strategy for metabolic diseases associated with obesity.

#### 9.4. Role of Myocardial Tissue in Insulin Resistance

Research on insulin signaling has predominantly concentrated on cells and tissues that regulate systemic metabolic homeostasis, including adipose tissue, liver, skeletal muscle, and brain. Nevertheless, insulin sensitivity is equally crucial in other organs, including the heart. Effective insulin signaling in cardiac muscle regulates various cellular activities, such as cell proliferation, cell survival, apoptosis, and diverse metabolic functions [7,219,232]. Effective Insulin signaling has a significant role in the Akt-mediated regulation of cardiac development as demonstrated by the decreased heart size in insulin receptor KO mice as compared to normal mice [232]. A downregulation of genes associated with the electron transport chain was also reported in these insulin receptor knockout mice thereby interfering with the cardiac metabolism and energy outputs and reiterating the profound influence of insulin signaling in cardiomyocytes [232].

Cardiomyocytes demonstrate significant IR expression, while the insulin-like growth factor receptor-1 (IGF1R) displays comparable levels, indicating substantial overlap in their pathways within the myocardium [232]. In cardiomyocytes exhibiting insulin resistance, insulin receptor signaling is partly complemented by insulin-like growth factor 1 receptor signaling. The interplay between IR and IGF-1R signaling is crucial for maintaining normal cardiac metabolism and function [232]. The presence of a permanently active form of Akt in the myocardium enhances insulin signaling has been reported to lead to moderate preservation of systolic function, and cardiovascular protection [7, 232]. Addressing Akt activation in the myocardium may serve as an effective therapeutic approach for treating heart failure associated with metabolic diseases. Further research is needed to explore these possibilities in near future.

#### 9.5. Role of other Cell Types and Tissues in Insulin Resistance

##### 9.5.1. Hypothalamic Neurons

In addition to suppression of appetite by insulin through the activation of hypothalamic neurons, it also promotes adipose tissue expansion through sympathetic effects and suppresses hepatic glucose production via potassium sensitive ATP channels [7,233]. Given the immense role of hypothalamus in energy homeostasis, its Agouti-related protein (AgRP) and pro-opiomelanocortin (POMC) neurons play a crucial role in feeding behavior [233,234]. Mice deficient in insulin receptors in AgRP neurons IR knockout exhibited diminished insulin action in inhibiting HGP, while POMC IR knockout mice demonstrated reduced insulin efficacy in suppressing lipolysis [235]. Insulin signaling is shown to regulate glucose metabolism in AgRP neurons, while in POMC neurons, it influences adipose tissue lipolysis and improves hepatic steatosis [235]. Insulin resistance in the hypothalamus contributes to disruptions in glycolipid metabolism and diminished regulation of hunger. As a result, targeting insulin action particularly in the hypothalamus seems to be a viable therapeutic method for treating obesity-related disorders such as irregularities in hunger phenomena, increased hepatic glucose production, and dyslipidemia in liver.

##### 9.5.2. Pancreatic $\beta$ Cells

Insulin is released by pancreatic  $\beta$ -cells to regulate blood glucose levels and maintain metabolic balance. Overexpression of IRs in pancreatic  $\beta$ -cells greatly boosts insulin gene transcription and content. In mice with  $\beta$ -cell-specific KO of IRS2 glucose load significantly reduced  $\beta$ -cell mass and insulin production [236]. The activation of constitutive Akt1 leads to  $\beta$ -cell proliferation and hypertrophy [7,237].

A recent report that used an *Ins1<sup>cre</sup>* knock-in allele to delete *Insr* specifically in  $\beta$ -cells of both female and male mice indicates that  $\beta$ -cell insulin resistance, characterized by decreased  $\beta$ -cell *Insr*, plays a role in hyperinsulinemia during glucose stimulation, thus enhancing glucose homeostasis regardless of gender and fed state in mice [237]. To treat obesity-induced diabetes and minimize  $\beta$ -cell mortality, specifically increasing insulin signaling may be effective treatment modality. More

research is needed to comprehend how  $\beta$ -cell insulin signaling impacts diabetes in bigger sample sizes.

### 9.5.3. Vascular Endothelial Cells


In vascular endothelial cells (VECs), insulin activates eNOS, lowering VCAM-1 expression and alleviating atherosclerotic events [7,238]. VEC-specific IR KO mice prevent nitric oxide induced vasodilation, increase VCAM-1-dependent leukocyte adhesion, and impair insulin's anti-atherosclerotic activity [239,240]. Vascular endothelial cell-specific dominant-negative IR transgenic mice have reduced vasorelaxation [240]. In addition, genetic deletion of Akt1, a downstream target of insulin signaling, lowered VEC eNOS phosphorylation. In contrast, mice overexpressing IRS1 specifically in VECs increased insulin signaling and reduced atherosclerosis [239]. The involvement of FoxOs downstream of insulin signaling in VECs is further studied. Atherosclerosis in low-density lipoprotein receptor KO mice caused insulin resistance in major arteries and decreased FoxO1 and FoxO3a phosphorylation, showing that FoxOs are activated in atherosclerotic vasculature [239]. Vascular endothelial cell-specific deletion of all three FoxOs (FoxO1, FoxO3a, and FoxO4) increased eNOS-derived NO production and decreased iNOS expression in LDLR KO mice's VECs, suppressing atherosclerosis development [239,240]. This shows how FoxOs integrate many atherosclerosis pathways and may be therapeutic targets. These findings show that insulin signaling in VECs inhibits atherosclerosis and that insulin resistance increases atherosclerotic plaques and long-term complications.

### 9.5.4. Macrophages

Insulin-resistant human monocytes displayed lower IR tyrosine kinase activity, and the monocyte/macrophage insulin resistance theory is gaining momentum [8,241]. In obese mice, poor insulin signaling in intraperitoneal macrophages increased CD36 expression and oxidized LDL binding and absorption, accelerating atherosclerosis [242]. Mice lacking IR in macrophages due to bone marrow transplantation had increased cholesterol absorption in aortic plaque lesions, which worsened atherosclerosis [241]. One study employing macrophage-specific IR KO mice demonstrated that insulin resistance in macrophages reduces atherosclerosis which is in variance with other reports [241]. In obese and atherosclerotic mice, insulin resistance activates macrophage transcription factors, FoxOs [8,241,242]. Myeloid-specific FoxO KO (FoxO1, FoxO3a, and FoxO4), which was elevated in atherosclerotic mice' macrophages, surprisingly worsened atherosclerosis by stimulating bone marrow cell growth [241]. Thus, FoxOs are activated in macrophages and VECs in an insulin-resistant animal model, but their pathophysiological role in atherosclerosis differs. It is now well known that diminished insulin signaling in macrophages may cause atherosclerosis.

## 10. Consequences of Insulin Resistance

The alterations in the insulin signaling lead to a repertoire of metabolic and associated diseases which are summarized in Figure 4 and briefly discussed as follows.



**Figure 4.** A pictorial representation of the consequences of insulin resistance.

IR is related to diabetes and its associated complications [243,244]. Diabetes will affect 643 million people worldwide by 2030 and 783 million by 2045, assuming epidemic proportions that underscores the importance of this association [243,244]. Insulin resistance has a profound influence on lipid metabolism and contributes to dyslipidemia; an abnormal lipid profile characterized by elevated triglycerides, low HDL cholesterol, and often increased small, dense LDL particles. The alterations in the lipid metabolism in IR include increased influx of free fatty acids (FFA) into circulation. Liver uses the excess FFAs to synthesize triglycerides, which are then packaged into VLDL particles and secreted into the bloodstream. Elevated VLDL levels contribute to hypertriglyceridemia (high triglycerides), a hallmark of dyslipidemia in IR [9,245]. Lipoprotein lipase (LPL) levels are reduced, impairing the clearance of triglyceride-rich lipoproteins (VLDL and chylomicrons) from the bloodstream. This further exacerbates hypertriglyceridemia [245,246]. HDL cholesterol levels are often low in insulin resistance. This is because HDL particles are remodeled and cleared more rapidly in the presence of high triglycerides. Insulin resistance also promotes the formation of small, dense LDL particles, which are more atherogenic (more likely to contribute to plaque formation in arteries). This occurs because triglyceride-rich VLDL particles exchange triglycerides with LDL particles via CETP, leading to the formation of smaller, denser LDL particles [245,246]. Additionally, insulin resistance disrupts the regulation of key enzymes involved in lipid metabolism, such as acetyl-CoA carboxylase and fatty acid synthase, further promoting dyslipidemia [9,245].

Insulin resistance is considered a significant risk factor for cardiovascular diseases across various populations, including those with euglycemia and those with diabetes [247]. Mathematical modeling suggests that IR accounts for approximately 42% of myocardial infarctions, making it the most significant single cause of coronary artery disease [247]. It is reported patients with elevated HOMA-IR values ( $\geq 4.14$ ) exhibited significantly reduced global longitudinal strain (GLS), increased vascular stiffness, and heightened pulse wave velocity (PWV) in the carotid artery, compared to those with lower HOMA-IR values [10,248]. Hyperinsulinemia causes diabetic cardiomyopathy through impaired insulin signaling, cardiac mitochondrial dysfunction, endoplasmic reticulum stress, autophagy, calcium handling, abnormal coronary microcirculation, neurohumoral activation, and maladaptive immune responses [246–248].

Insulin resistance has been linked to ischemic cerebrovascular illness in a data analysis spanning 1999–2022 study [250]. In two studies on Korean and Japanese subjects, it was reported that insulin resistance is an independent risk factor for silent lunar infarct (SLI) and is positively linked with its

occurrence and severity [251,252]. A recent meta-analysis of 11 cohort studies found a positive connection between the Ty-G index and ischemic stroke risk [253].

Insulin resistance has been identified as the primary predictor of non-alcoholic fatty liver disease (NAFLD) in both obese and lean individuals. Research indicates a strong correlation between serum insulin levels and hepatic lobular inflammation, as well as histological progression, including ballooning [254]. In patients with NAFLD, there was a significant increase in glycerol appearance and lipid oxidation, alongside an elevation in insulin resistance corresponding to the degree of steatosis [254].

Polycystic ovarian syndrome (PCOS) that affects 6–7% of the global population has been linked with IR [255]. Excess insulin secretion activates pituitary gland insulin receptors, stimulating androgen secretion from the ovaries and adrenal glands via the pituitary-ovary and adrenal axes and increasing free testosterone by suppressing SHBG synthesis [255,256].

Recent experimental, epidemiological, and clinical evidence indicates a synergistic relationship between IR and compensatory hyperinsulinemia in the development and progression of various cancers, including breast, colorectal, prostate, pancreatic, adrenocortical, and endometrial cancers [9,257,258]. The mechanisms underlying the association between IR and tumors remain unclear; however, they may involve multiple pathways and are likely to differ across various cancer types. IR-related factors, such as chronic persistent hyperinsulinemia, INSRs, IGF1Rs, INSR/IGF1R hybrids, chronic inflammation, ncRNAs, and microbiota, have been proposed as influential elements in all stages of tumor development [9,259,260]. The mitogen-activated protein kinase (MAPK) insulin pathway underlies numerous obesity-related malignancies that regulate cell growth and mitosis. Insulin directly facilitates cell proliferation and survival through the phosphatidylinositol-3-kinase/protein kinase B (PI3K/Akt) and Ras/MAPK pathways [260,261].

IR is a significant risk factor for the decline of renal function in non-diabetic chronic kidney disease and hypertension [262]. Insulin resistance has been linked to liver cirrhosis [263]. It has also been reported that insulin resistance may influence the relationship between insulinemia and bone mass and lead to risk of osteoporosis when HOMA- $\beta \geq 100$  and HOMA-IR $\geq 2$  [264]. Insulin resistance has also been associated with other conditions like postburn trauma, post-adolescent acne and gastroesophageal reflux disease [9,244,265].

## 11. Therapeutic Modalities Targeting Insulin Resistance

The defining characteristic of insulin resistance is hyperglycemia, which is thought to result from obesity, chronic inflammation, genetic susceptibility, and ectopic fat accumulation. Thus, treatment strategies frequently seek to adjust these fundamental underlying causes. An integrated and multipronged strategy is essential to attain the optimal objectives.

### 11.1. Lifestyle Modifications

A healthy lifestyle includes exercise, which improves health and lowers IR in obese children and adolescents. The current literature suggests that aerobic, resistance, and combination training reduce IR in obese children and adolescents. Although it is uncertain which sort of exercise is best, aerobics and mixed training tend to improve IR more than resistance training.

“Exercise snacks” are a short duration frequent bouts of physical activity and provide an efficient way to help sedentary populations, encourage exercise regimens, and raise awareness of the health benefits of exercise [266]. Sedentary people can increase their cardiovascular fitness, metabolic capacity, and muscular function with exercise snacks, which are faster and easier than traditional exercise. The short duration and high intensity of exercise snacks allow rapid mobilization of various organ systems, which improves skeletal muscle oxygen and glucose utilization, muscle protein synthesis, and other Musculoskeletal functions [266]. However, many issues remain unresolved about the benefits of various modes of exercise and needs further research.


Diet is a crucial way to treat IR in youngsters. Balanced normocaloric or hypocaloric diets work depending on the child’s age and intervention stage. Long-term effects of diet macronutrient content



on cardiometabolic risk, including IR, have not been studied. A low-carbohydrate diet may treat IR in children and adolescents, but more study is needed before recommendations. In dietary intervention techniques for children with metabolic disorders, carbohydrate quality is becoming important. The awareness about glycemic index of different diets should be increased and patients should be taught how meals affect glucose metabolic parameters [267]. They should also follow the Mediterranean diet, which may alleviate obesity and related conditions. Finally, insulin index diet research may help create new dietary therapies for obese adolescents with IR, but clinical trials are needed to prove this. To determine how nutritional supplementation and microbiome-based therapies affect IR, prospective randomized studies with extended monitoring periods are needed.

### 11.2. Pharmacologic Interventions

In alignment with the multifaceted etiology of insulin resistance, various therapeutic modalities are available that directly or indirectly address distinct aspects of insulin resistance. Figure 5 summarizes the therapeutic modalities targeting IR and T2DM and the same are discussed briefly in the forthcoming sections.



**Figure 5.** Graphic illustration of therapeutic strategies targeted at insulin resistance and T2DM. The currently used modalities are shown in green color. The future therapeutic options are summarized in blue color. Drugs like sulfonylureas, glucagon-like peptide 1 (GLP-1) agonists, and dipeptidyl peptide-4 (DPP-4) inhibitors augment the insulin secretion. Thiazolidinediones (TZDs) and metformin are insulin-sensitizing agents, targeting fat storage capacity of adipose tissue and Hepatic glucose production (HGP). The potential agents targeting enhancement of  $\beta$  oxidation in liver and skeletal muscle and stimulation of muscle quality. Mit-Mitochondria; ER-Endoplasmic reticulum; FFA-free fatty acid; ACC-Acetyl-CoA carboxylase; GPAT -Glycerol-3-phosphate acyltransferase; DGAT2, diacylglycerol acyl transferase 2; UCP3-Uncoupling proetin3; MSTN-Myostatin; PPAR $\gamma$ - Peroxisome proliferator-activated receptor- $\gamma$ ; SGLT2-Sodium glucose cotransporter2.

#### 11.2.1. Currently Used Medications

The currently used pharmacological agents to alleviate the effects of insulin resistance include biguanides, thiazolidinediones, sodium-glucose cotransporter inhibitors, glucagon-like peptide-1

receptor agonists, dipeptidyl peptidase-4 inhibitors and sulfonylureas. Their brief mechanisms of action and other details are explained in Table 1.

**Table 1.** Currently used medications against IR.

| Role                                | Drug Class   | Examples   | Mechanism  | Citation  |
|-------------------------------------|--|--|--|-----------|
| Decrease Hepatic glucose production | Biguanides   | Metformin  | The precise mechanism of metformin is still elusive and is thought to reduce HGP, a process that is facilitated by the stimulation of mitochondrial activity or the suppression of glucagon signaling via AMPK activation and increased expression of GLUT4 glucose transporter.   | [268]     |
| Increase insulin sensitivity        | Thiazolidinediones                                   | Rosiglitazone<br>Pioglitazone  | Thiazolidinediones function through their interaction with the PPAR- $\gamma$ to enhance the sensitivity of adipose muscle and liver to insulin.   | [268]     |
| Inhibit renal glucose reabsorption  | Sodium-Glucose Cotransporter Inhibitors (SGLT-2i)    | Empagliflozin<br>Dapagliflozin   | SGLT-2is facilitate insulin-independent glucose reduction by inhibiting glucose reabsorption in the proximal renal tubules, thereby decreasing blood glucose levels. Additionally, these medications are linked to reliable and well documented weight loss and decreases in blood pressure  | [268,269] |
| Increase insulin sensitivity        | Glucagon-like Peptide-1 Receptor Agonists (GLP 1 RA) | Semaglutide<br>Dulaglutide<br>Liraglutide<br>Exenatide   | GLP 1RAs increase insulin sensitivity in peripheral tissues and also have notable anti-inflammatory and anti-obesity effects, protective benefits for lung health, and favorable impact on gut microbiome composition. However, GLP-1RAs are linked to prevalent gastrointestinal adverse effects, impacting over one-third of patients and other complications. | [268,270] |
| Increase insulin secretion          | Dipeptidyl Peptidase-4 Inhibitors (DPP-4i)           | Vildagliptin<br>Alogliptin<br>Linagliptin<br>Gemigliptin<br>Teneligliptin<br>Trelagliptin<br>Saxagliptin | DPP-4is Inhibit incretin degradation and facilitates postprandial insulin secretion. Their advantages include the reduction of HbA1c levels, renal microalbuminuria and decreases in inflammation.   | [268,271] |
| Increase insulin secretion          | Sulfonylureas  | Glimepiride<br>Gliclazide  | Sulfonylureas reduce blood glucose levels by enhancing insulin secretion from beta cells through the inhibition of KATP channels. They also inhibit gluconeogenesis and lipid breakdown into fatty acids. They also promote insulin sensitivity.   | [268,272] |

### 11.2.2. Recent Drug Targets for Insulin Resistance

Recently developed drug targets include some pharmacologic agents that act as agonists for many signal transducers/receptors and mediators of metabolic signals. These drug targets have been developed in a series of rigorous molecular and clinical studies. A brief description of these recent drug targets is presented in Table 2.


**Table 2.** Recent drug targets aimed at insulin resistance.

| Role  | Drug target  | Examples  | Mechanism   | Citation  |
|---|--|---|---|-----------|
| Increase insulin secretion                      | Glucose-dependent insulinotropic polypeptide (GIP) | Tirzepatide                                     | GIP is present in $\beta$ -cells, adipose tissue, and the brain and increases intracellular cAMP by binding to its receptor. High cAMP levels activate PKA, and exchange protein activated cAMP2. Depolarizing voltage-gated calcium channels raises intracellular $Ca^{2+}$ and promotes insulin release from $\beta$ -cells. Recently, tirzepatide, a novel dual GIP/GLP 1 receptor agonist, not only achieved significantly improved glycemic control but also allowed the majority of participants to attain a mean weight reduction exceeding 10% from baseline, which is a notable outcome in the realm of current pharmacotherapy. Its safety profile is being investigated, and it offers a lot of promise as of now. | [273,274] |
| ↑ Insulin release<br>↓ HGP                      | G-Protein coupled receptor (GPCR 119)              | GSK1292263, MBX-2982 DS-8500a APD668 BMS-903452 | GPR119, a Class-I G protein coupled receptor, is found in muscles, liver, and pancreatic $\beta$ -cells. Similar to incretin hormones, GPR119 activation may enhance insulin synthesis and secretion when agonists bind to its binding site. GPR119 enhances glucose homeostasis via direct $\beta$ -cell insulin release and indirect GLP-1 and GIP release in enteroendocrine cells. More than 40 GPR 119 agonists have been reported to show promising effects on glucose homeostasis by depressing HGP and increasing insulin synthesis in both humans and/or animal models. The efficacy and the safety profile of these agonists is under continuous scrutiny.  | [275,276] |
| ↑ Incretin hormone Release<br>↑ Insulin release | Free-fatty acid receptor-1 agonists                | TAK-875 TSL1806                                 | G-protein coupled receptor-40 (FFA1) is a Class-A receptor and is expressed in mammalian pancreas, gut, taste buds, and CNS FFA1 affects blood glucose levels by increasing incretin hormones and promoting insulin release from pancreatic $\beta$ -cells. Synthetic GPR40/FFA1 receptor agonists such as TAK-875 and TSL1806 have been tried in the last many years but their side effects including hepatotoxicity are a matter of concern which is being investigated.  | [277,278] |
| Target Fatty acid oxidation                     | PPAR full agonists                                 | Chiglitazar Sodium                              | Chiglitazar Sodium is a peroxisome proliferator-activated receptor (PPAR) full agonist simultaneously activates three subtypes of PPAR receptors ( $\alpha$ , $\gamma$ , and $\delta$ ). It can induce the expression of downstream target genes related to insulin sensitivity, fatty acid oxidation, energy conversion and lipid transport, and inhibit the phosphorylation of PPAR $\gamma$ receptors associated with insulin resistance.  | [279]     |
| ↑ Insulin release                               | Melatonin (neuroendocrine hormone)                 | Melatonin                                       | Melatonin modulates glucose levels via its melatonin receptors MT1 and MT2 in diverse cells. Melatonin supplementation has been   | [280]     |

|  |  |  |   |  |
|--|--|--|---|--|
|  |  |  | reported to ameliorate hyperinsulinemia, insulin resistance, and insulin sensitivity by many investigators and there is enough evidence to use it as an adjuvant therapy. |  |
|  |  |  |   |  |

### 11.2.3. Future Insulin Resistance Drug Targets

Future targets against IR are possible molecular receptors or sites that could be used to develop new lead molecules for the treatment of IR in general and T2DM in particular. Although not much is currently known about their involvement in diabetes, these targets may be extremely important in the management of the disease. By offering safe, efficient therapy without sacrificing patient compliance, future targets provide a viable way to get beyond the drawbacks of traditional and existing methods [281]. A brief description of the potential future targets is schematically presented in Figure 6 and is discussed below



**Figure 6.** A schematic view of the future drug targets aiming at insulin resistance. 11  $\beta$ -DH- 11 $\beta$  Hydroxysteroid dehydrogenase; PEDF-Pigment epithelium-derived factor); GPER (G protein-coupled estrogen receptor); METRNL-Meteorin-like.

#### 11.2.3.1. 11 $\beta$ Hydroxysteroid Dehydrogenase (11 $\beta$ -HSD)

This enzyme transforms the glucocorticoid, cortisone into its active form, cortisol.

11-hydroxysteroid dehydrogenase type 1 (11 $\beta$ -HSD1) and 11 $\beta$ -hydroxysteroid dehydrogenase type 2 (11 $\beta$ -HSD2) are the two isoforms that are currently accessible [282]. Maintaining the levels of the 11 $\beta$ -HSD1 enzyme naturally enhances insulin sensitivity because it is well established that high blood glucocorticoid levels can lead to glucose intolerance. According to research published in 11 $\beta$ -HSD1 knockout mice, there was a reduction in blood glucose levels, enhanced insulin sensitivity, improved glucose tolerance and a lack of in vivo glucocorticoid biosynthesis [282]. Thus, by controlling the insulin signaling transduction system, blocking 11 $\beta$ -HSD1 may help lower insulin resistance and thereby raise insulin sensitivity. Considering all that has been reported so far, 11 $\beta$ -HSD1 represents a unique molecular target for targeting IR and for the treatment of T2DM [282].

#### 11.2.3.2. ACRP-30 (Adiponectin)

Adipose tissue is well-established for its capacity to store fats; however, recent studies indicate that it also functions as a source of hormones such as resistin, adiponectin, leptin, TNF- $\alpha$ , and ACRP30 [283,284]. Research indicates that serum protein ACRP-30 plays a significant role in the regulation of diabetes mellitus, while TNF- $\alpha$  is a principal pro-inflammatory mediator implicated in insulin resistance. Studies reveal that Acrp30 levels are diminished in various obesity and diabetes models due to elevated TNF- $\alpha$  levels, indicating a negative correlation between this protein and diabetes [283,284]. Additionally, mice deficient in Acrp30 exhibit insulin resistance, contributing to the onset of diabetes mellitus. Increasing circulating levels of Acrp30 may enhance insulin sensitivity and facilitate the management of blood glucose levels, positioning Acrp30 as a promising therapeutic target for diabetes mellitus treatment [284].

#### 11.2.3.3. Fetuin-A

Synthesized predominantly in the liver and released into the bloodstream, Fetuin-A is the principal protein necessary for transporting FFA into circulation and is implicated in the inflammation of  $\beta$ -cells, which can result in  $\beta$ -cell degeneration in the pancreas, hence contributing to insulin resistance and many metabolic diseases [285]. Fetuin-A, in conjunction with insulin, is a significant protein that can attach to the external area of the insulin receptor. Fetuin-A inhibits the autophosphorylation of the tyrosine kinase, a major enzyme in insulin signaling, which is entirely contrary to insulin's effect [285].

The primary interaction between insulin and tyrosine kinase regulates blood glucose levels; however, an increase in Fetuin-A concentration in the bloodstream may lead to insulin resistance and, eventually, T2DM [285]. Research indicated an enhancement in insulin sensitivity in mice possessing Fetuin-A deletion genes, demonstrating a negative correlation between Fetuin-A and insulin sensitivity in diabetes. These criteria suggest that Fetuin-A has the potential to serve as an innovative target for the management of T2DM in the near future [286].

#### 11.2.3.4. Visfatin/NAMPT (Nicotinamide Phosphoribosyl Transferase)

Visfatin is a protein that has multiple functions and is also referred to as nicotinamide phosphoribosyl transferase. Discovered in the year 2005 in the visceral adipose tissue, however it can be found in a variety of organs and tissues as well. In the past, it was also known as the Pre-B colony Enhancing Factor (PBEF). It possesses insulin-like properties, which means that it helps to regain insulin sensitivity. Research has demonstrated that the concentration of visfatin in the serum rises in tandem with the progression of T2DM, thereby establishing a connection between visfatin and T2DM [287]. It has been demonstrated in recent research that visfatin binds to the insulin receptor in a region that is different from where insulin does [287]. This indicates that visfatin has an activity that is like that of insulin and that it promotes cell proliferation. The exact role of visfatin in the therapeutic interventions targeting IR and T2DM is under active research.

#### 11.2.3.5. Metrnl

Metrnl is an adipokine sourced from adipose tissues, predominantly found in subcutaneous white fat, and is crucial for the regulation of glucose homeostasis. The Metrnl gene, located on mouse chromosome 11 and human chromosome 17 (17q25.3), encodes this protein. It exhibits 40% homology with the neurotrophic factor Meteorin and was therefore initially designated as Meteorin-like [288]. Metrnl is significant in regulating energy metabolism, lipid metabolism, cardiovascular function, immunological inflammation, and insulin sensitivity [288]. Researchers found that it operates through the upregulation of the PPAR $\gamma$  pathway, resulting in increased insulin sensitivity in a mouse model [288,289]. It is concurrently observed that it promotes adipose tissue browning, resulting in increased energy expenditure and improved glucose tolerance.

Metrnl participates in multiple pharmacological pathways via intracellular signaling among cells. In nerve cells, it facilitates neurite outgrowth through the JAK-STAT3 and MEK-ERK signaling

pathways. In adipocytes, the upregulation of *Metrn1* enhances lipid metabolism, mitigates inflammation induced by a high-fat diet, and promotes adipose remodeling via the upregulation of PPAR $\gamma$ , thereby improving insulin resistance [281,289]. In muscle cells, or myocytes, there is an enhancement of PPAR $\gamma$  signaling, which leads to increased phosphorylation of AMPK due to elevated intracellular calcium levels. This process also facilitates the phosphorylation of TBC1D1, HDAC5, and p38 MAPK through an AMPK-mediated mechanism. Consequently, this promotes the expression and translocation of GLUT4, thereby improving insulin sensitivity and reducing inflammation [288,289]. Given its role in the multiple metabolic pathways, it is a promising target directed at insulin resistance and metabolic syndrome [281].

#### 11.2.3.6. PEDF (Pigment Epithelium-Derived Factor)

PEDF, a glycoprotein that is secreted from human retinal pigment cells and adipose tissue is a member of the serine protease inhibitor family. It facilitates the breakdown of triglycerides into glycerol and free fatty acids, which then leads to the transfer of the free fatty acids into the systemic circulation, which is believed to lead to inflammation of the cells [290,291]. Because of the initiation of the kinase-mediated Serine/Threonine phosphorylation cascade of IRS (insulin receptor substrate), insulin signaling is reduced, which leads to insulin resistance in the cells of the body. In addition, it allows the release of inflammatory mediators including TNF- $\alpha$  and iIL-1, which ultimately results in insulin insensitivity inside the body [290]. The administration of PEDF caused a decrease in insulin sensitivity, which was then restored after the administration of anti-PEDF, according to the findings of a study that investigated the effect of PEDF administration in animals [291]. PEDF has been shown to have a positive connection with insulin resistance in both children and adults [290,291]. A decrease in the levels of PEDF that are found in circulation has the potential to improve insulin sensitivity, which would position PEDF as a possible novel therapeutic target for diabetes mellitus and other metabolic disorders respectively [281].

#### 11.2.3.7. Vaspin (Serpine A12)

Vaspin, also known as Serpin A12, is a glycoprotein found in serum that belongs to the protein family known as serpins. Produced by adipocytes, it is reported to modulate insulin action [292,293]. It has been demonstrated through research that the serum levels of vaspin begin to decrease with increasing severity of diabetes [292,293]. This observation led to the belief that increasing the vaspin levels would be beneficial in the management of diabetes mellitus. In addition, it has been shown that the administration of vaspin in experimental mice results in an improvement in insulin sensitivity as well as an increase in glucose tolerance [293]. As a result of these evidence, it has the potential to be a target for the treatment of metabolic aberrations such as obesity and T2DM [292,293]. By inhibiting the KLK7 (kallikrein 7) enzyme, which is an insulin-degrading enzyme that degrades insulin and decreases the insulin half-life, vaspin is able to accomplish its function and achieve its desired effect. The inhibition of KLK7 results in an improvement in insulin signaling, as well as an increase in the half-life of insulin, which contributes to a reduction in the levels of glucose in the blood [293]. It also performs some other actions that indirectly reduce the blood glucose from the body, such as reducing the amount of food that is consumed, which ultimately reduces the amount of glucose that is produced by the liver (hepatic glucose production) through the hepatic branch of the vagus nerve. This is accomplished by decreasing the accumulation of soluble lipids in the liver and increasing the amount of insulin signaling in the liver. In white adipose tissue and brown adipose tissue, it decreases inflammation and boosts insulin signaling. In the central nervous system, it reduces food intake by activating the vagus nerve, which is responsible for the regulation of appetite [281].

#### 11.2.3.8. G Protein-Coupled Estrogen Receptor (GPER)

GPER), alternatively referred to as G protein-coupled receptor 30 (GPR30), is a protein encoded by the GPER gene in humans. GPER interacts with and is stimulated by the female sex hormone estradiol, facilitating certain fast cellular actions of estradiol. It's an orphan seven-transmembrane G-protein-coupled receptor and is implicated in estrogen signaling [294]. Integral to the cellular membranes, play phenomenal roles in controlling hyperglycemia and cellular proliferation among its vast array of functions [294,295]. A GPER-deficient female mice model exhibited inadequate insulin levels, a situation that aggravates the glucose homeostasis and induces T2DM [281]. It is well established that premenopausal women have higher levels of estrogens, estrogen levels are elevated and beneficial in the control of blood pressure, lipid metabolism, glucose balance and mitigating inflammation. Subsequent to menopause, women's susceptibility to insulin resistance and other metabolic problems increases as a result of altered estrogen levels. The role of GPER becomes essential under such circumstances, and it has been reported that a selective agonism of GPER by the agonist G-1 can mitigate obesity and metabolic dysfunction symptoms in many murine models, thereby curtailing weight gain, diminishing insulin resistance and inflammation, and enhancing glucose and lipid homeostasis in vivo [294]. Consequently, GPER constitutes a groundbreaking therapeutic target, with G-1 serving as a first-in-class therapeutic drug for the treatment of obesity and its related comorbidities, such T2DM [281,296].

#### 11.2.3.9. Gene Therapy

Gene therapy involves the modification of a gene of interest to treat or cure disease. It involves replacing a disease-causing gene with a healthy copy, inactivating a defective gene, or adding a new or modified gene. Many gene therapy delivery strategies are available with continuous improvement. Gene therapy for T1D aims to restore insulin production or prevent  $\beta$  cell loss while it involves improvements in glucose tolerance, insulin resistance, and energy expenditure in T2DM [297]. There are many gene therapy methods involving ex vivo therapy, in vivo therapy and viral or non-viral vector delivery. Engineering bacterial vectors to prevent infection and deliver therapeutic genes to human cells is under active investigation [281,297]. Non-viral liposomes and nanoparticles deliver DNA or RNA to low-immunogenic cells. Pluripotent stem cells (iPSCs) can be genetically altered to become insulin-producing beta cells via stem cell-based gene therapy. Immune modulation boosts Treg FOXP3 and IL-10, protecting beta cells from autoimmune attacks [].

Current animal studies on diabetic gene therapy provide basic insights and proof-of-concept for human therapeutic applications. In diabetic mice, lentiviruses targeting NeuroD1 and Betacellulin boosted islet neogenesis and insulin production, providing a way to promote endogenous insulin synthesis [298]. In diabetic rats, intraportal INS-lentiviral particle injection maintained hepatic insulin expression and blood glucose levels, suggesting a long-term glycemic management method [281,298]. Intramuscular insulin and glucokinase-expressing AAV vectors enhanced glucose homeostasis and insulin production in diabetic dogs and mice [281,299]. AAV delivery of INS, PDX1, and GCK improved diabetic mice's blood glucose management and insulin sensitivity, validating gene therapy's metabolic regulation [299]. Gene therapy's revolutionary potential for diabetes treatment is shown in these animal studies, laying the groundwork for human trials and better diabetes outcomes [281,299].

In human gene therapy trials it has been demonstrated that plasmid VEGF improves neuropathic symptoms and pain in type 1 and type 2 diabetics [300]. Recombinant adeno-associated virus carrying the human insulin gene improved glucose and insulin production over time, suggesting diabetics may attain sustained glycemic control [300]. In 2023, Kupczynska et al. reported that a bicistronic VEGF165/HGF plasmid enhanced diabetic foot syndrome patients' ischemic lesions and angiogenesis, improving wound management and preventing limb amputation [301]. VM202, an HGF gene therapy, reduced discomfort and may ameliorate diabetic peripheral neuropathy [301,302].

Human and animal gene therapy research targeting insulin resistance offers significant prospects for future treatments. Clinical benefits include improved glucose control, insulin

production, and considerable pain reduction in diabetes complications. Constant improvement and long-term solutions may reduce the need for pharmacological intervention and improve patient quality of life with this strategy [281,298]

## 12. Personalized Therapies for Insulin Resistance

Treating each patient as an individual with a personalized, tailored approach to treat IR is very appealing. Indeed, very soon we will be able to distinguish biomarkers and apply the appropriate therapy for each patient. These approaches may include stem cell therapy, gene editing using CRISPER based technologies, cell based and peptide therapies. This approach has already started with the generation of pancreatic islet transplantation; however, even in patients with long-standing T1D, the results are transient. Personalized therapies for insulin resistance require a comprehensive approach that integrates genetic, metabolic, and lifestyle factors. Advances in precision medicine, wearable technology, and AI are enabling more tailored and effective interventions. Collaboration between healthcare providers, dietitians, and patients is essential to achieve optimal outcomes.

## 13. Conclusions

Insulin resistance is a major contributor to metabolic-related diseases like dyslipidemia, T2DM, hypertension, and cancer. It is caused by abnormalities in the insulin signaling cascade, including insulin receptor abnormalities and metabolic disturbances. The global prevalence of diabetes is projected to reach 700 million by 2045, and the rapidly rising incidence of metabolic disease is now regarded as a major global health crisis. Risk factors include genetic, environmental, and lifestyle factors. Childhood obesity, low birth weight, smoking, pollutants, microorganisms, and certain nutritional elements may contribute to IR development. IR rates vary within countries, with urban populations showing the largest rises. The prevalence of IR varies between ethnic groups and depends on socioeconomic status. Lifestyle factors and inherited genetic risk factors could explain prevalence disparities in specific demographic groups, suggesting targeted intervention. In this backdrop, understanding societal and molecular pathways leading to IR is crucial for developing effective treatments, reducing healthcare costs, and improving patient life quality. Increased physical activity is strongly recommended to minimize health consequences of IR. "Exercise snacks" are short, regular workouts that help sedentary people get active and increase their cardiovascular fitness, metabolic capacity, and muscle function faster and easier than regular exercise. Short and intense exercise snacks mobilize organ systems quickly, boosting skeletal muscle oxygen and glucose consumption, muscle protein synthesis, and other musculoskeletal activities. Balanced normocaloric or hypocaloric diets depending upon the individual requirements need to be recommended in consultation with the treating physician and the dieticians. Currently used and recently introduced medications target the different aspects of IR and are paying dividends. However, the associated side effects and the ease of availability of some of these therapeutic agents to certain sections of societies are posing a great challenge in this ongoing fight against insulin resistance and its consequences. Emerging therapeutic targets are being investigated to develop novel lead compounds targeting IR and T2DM that are expected to change the landscape of IR treatment.

**Ethical Clearance:** Not applicable

**Acknowledgement:** The authors are thankful to the Deanship of Graduate Studies and Scientific Research at University of Bisha for supporting this work through the Fast-Track Research Support Program.

**Conflict of interest:** None

## Abbreviations

|             |                          |
|-------------|--------------------------|
| <i>T1DM</i> | Type-1 diabetes mellitus |
| <i>T2DM</i> | Type-2 diabetes mellitus |
| <i>IR</i>   | Insulin resistance       |



|                 |  |
|-----------------|--|
| <i>HOMA-IR</i>  | Homeostatic model assessment for insulin resistance            |
| <i>IGF</i>      | Insulin like growth factor                                     |
| <i>GRB</i>      | Growth factor receptor-bound protein                           |
| <i>SHC</i>      | Src homology 2 domain-containing adapter protein               |
| <i>PH</i>       | Pleckstrin homology  |
| <i>SH2</i>      | Src homology -2  |
| <i>IRS</i>      | Insulin receptor substrate                                     |
| <i>APS</i>      | Adapter protein with a PH and SH2 domain                       |
| <i>Ras</i>      | Rat sarcoma virus oncogene                                     |
| <i>MAPK</i>     | Mitogen activated protein kinase                               |
| <i>IRR</i>      | Insulin related receptor                                       |
| <i>IGF-1R</i>   | IGF-1 receptor   |
| <i>mMRA</i>     | messenger RNA  |
| <i>IR-A</i>     | Insulin recept-A   |
| <i>KO</i>       | knockout   |
| <i>ERK</i>      | Extracellular signal-regulated kinase                          |
| <i>DOK4</i>     | Docking protein4   |
| <i>GTP</i>      | Guanosine triphosphate   |
| <i>GAB</i>      | Grb2-associated binder   |
| <i>Cbl gene</i> | Casitas B-lineage Lymphoma gene                                |
| <i>CAP</i>      | catabolite activator protein                                   |
| <i>DOK</i>      | Docking protein  |
| <i>PI3K</i>     | Phosphatidylinositol 3-kinase                                  |
| <i>AKT</i>      | serine/threonine-protein kinase also known as protein kinase B |
| <i>Pik3r1</i>   | Phosphoinositide-3-Kinase Regulatory Subunit 1                 |
| <i>Src</i>      | Steroid receptor coactivator                                   |
| <i>Csk</i>      | C-Terminal Src Kinase  |
| <i>DOCK</i>     | Dedicator of cytokinesis protein                               |
| <i>Crk</i>      | Proto-oncogene c-Crk protein                                   |
| <i>PKB</i>      | Protein kinase B   |
| <i>mTORC</i>    | Mammalian target of rapamycin complex 1                        |
| <i>DNAPK</i>    | DNA-dependent protein kinase                                   |
| <i>FOXO1</i>    | Forkhead box protein O1  |
| <i>TBC1D4</i>   | TBC1D4 (TBC1 Domain Family Member 4)                           |
| <i>PGC</i>      | Peroxisome proliferator-activated receptor-gamma coactivator   |
| <i>PDE3B</i>    | PDE3B phosphodiesterase 3B                                     |
| <i>c-AMP</i>    | Cyclic adenosine monophosphate                                 |
| <i>Cip 1</i>    | Cdk-interacting protein-1                                      |
| <i>WAF 1</i>    | wildtype p53-activated fragment 1                              |
| <i>p27Kip1</i>  | Cyclin-dependent kinase inhibitor 1B                           |
| <i>IKK</i>      | IκB kinase   |
| <i>PKC</i>      | Protein Kinase C   |
| <i>nPKCs</i>    | Novel protein kinases  |
| <i>aPKCs</i>    | atypical protein kinases                                       |
| <i>SREBP1</i>   | Sterol regulatory element-binding protein 1                    |
| <i>SOS</i>      | Son of Sevenless ( a set of genes)                             |
| <i>MEK</i>      | Mitogen-activated protein kinase kinas                         |
| <i>PTP1B</i>    | Protein tyrosine phosphatase 1B                                |
| <i>LAR</i>      | leukocyte common antigen-related protein                       |
| <i>PP2A</i>     | Protein Phosphatase 2A   |
| <i>PP2B</i>     | Protein Phosphatase 2B   |
| <i>S6K</i>      | S6 kinase p70  |
| <i>PHLPP-1</i>  | PH domain leucine-rich repeat protein phosphatase 1            |
| <i>PTEN</i>     | Phosphatase and tensin homolog                                 |
| <i>SHIP</i>     | SH2 domain-containing inositol 5-phosphatases                  |
| <i>SOCS</i>     | Suppressor of Cytokine Signaling                               |
| <i>IP7</i>      | Inositol pyrophosphate   |
| <i>IP6K1</i>    | Inositol hexakisphosphate kinase 1                             |
| <i>Trb3</i>     | Tribbles homolog 3   |

|                                 |   |
|---------------------------------|---|
| <i>JNK</i>                      | c-Jun N-terminal kinase                                       |
| <i>Ser-307</i>                  | Serine residue at position 307                                |
| <i>DAG</i>                      | Diacylglycerol  |
| <i>PKA</i>                      | Protein kinase A  |
| <i>PPAR<math>\gamma</math></i>  | Peroxisome proliferator-activated receptor- $\gamma$          |
| <i>GLUT</i>                     | Glucose transporter   |
| <i>GAP</i>                      | GTPase-activating protein                                     |
| <i>RAC-1</i>                    | Ras-related C3 botulinum toxin substrate 1                    |
| <i>GYS</i>                      | Glycogen synthase   |
| <i>GSK</i>                      | Glycogen synthase kinase                                      |
| <i>IRTK</i>                     | Insulin-Induced Receptor Tyrosine Kinase                      |
| <i>HGP</i>                      | Hepatic glucose production                                    |
| <i>G6PC1</i>                    | Glucose-6-phosphatase catalytic subunit 1                     |
| <i>PEPCK</i>                    | Phosphoenolpyruvate carboxylase                               |
| <i>SREBP-1</i>                  | Sterol regulatory element-binding protein                     |
| <i>ACCI</i>                     | Acetyl-CoA carboxylase 1                                      |
| <i>GPAT1</i>                    | Glycerol-3-phosphate acyltransferase                          |
| <i>NAFLD</i>                    | Non-alcoholic fatty liver disease                             |
| <i>ROS</i>                      | Reactive oxygen species                                       |
| <i>ER</i>                       | Endoplasmic reticulum   |
| <i>NF<math>\kappa</math>B</i>   | Nuclear factor kappa B  |
| <i>TLR4</i>                     | Toll-like receptor 4  |
| <i>CerS</i>                     | Ceramide synthase   |
| <i>FFA</i>                      | Free fatty acids  |
| <i>MCP-1</i>                    | Monocyte chemoattractant protein-1                            |
| <i>TNF- <math>\alpha</math></i> | Tumor necrosis factor alpha                                   |
| <i>IL</i>                       | Interleukin   |
| <i>CLS</i>                      | Crown like structure  |
| <i>JAK-STAT</i>                 | Janus kinase signal transducer and activator of transcription |
| <i>NOX</i>                      | NADPH oxidase   |
| <i>GPX</i>                      | Glutathione peroxidase  |
| <i>Mfn1</i>                     | Mitofusin1  |
| <i>Drp1</i>                     | Dynamain-related protein 1                                    |
| <i>VLDL</i>                     | Very low density lipoprotein                                  |
| <i>DAMP</i>                     | Damage-associated molecular patterns                          |
| <i>ULK1</i>                     | Unc-51 like autophagy activating kinase 1                     |
| <i>SERCA</i>                    | Sarcoendoplasmic reticulum calcium transport ATPase           |
| <i>TFEB</i>                     | Transcription factor EB                                       |
| <i>PC</i>                       | Phosphatidylcholine   |
| <i>PERK</i>                     | Protein kinase R like protein kinase                          |
| <i>ATF</i>                      | Activating transcription factor                               |
| <i>IRE-1</i>                    | Inositol-requiring enzyme type 1                              |
| <i>XBP1</i>                     | X-box binding protein 1                                       |
| <i>F25BS</i>                    | Los Angeles insulin   |
| <i>F25BL</i>                    | Chicago insulin   |
| <i>PTPN1</i>                    | Protein tyrosine phosphatase N1                               |
| <i>LDLR</i>                     | Low density lipoprotein receptor                              |
| <i>IGF1R</i>                    | Insulin-like growth factor receptor-1                         |
| <i>AgRP</i>                     | Agouti-related protein  |
| <i>POMC</i>                     | Pro-opiomelanocortin  |
| <i>Ins1</i>                     | Insulin 1 gene  |
| <i>VEC</i>                      | Vascular endothelial cell                                     |
| <i>VCAM</i>                     | Vascular cell adhesion molecule                               |
| <i>eNOS</i>                     | endothelial nitric-oxide synthase                             |
| <i>iNOS</i>                     | Inducible nitric-oxide synthase                               |
| <i>CVD</i>                      | Cardiovascular disease  |
| <i>SLI</i>                      | silent lacunar infarction                                     |
| <i>Ty-G</i>                     | Triglyceride-glucose index                                    |
| <i>END</i>                      | Early neurological degeneration                               |

PCOS                      Polycystic ovarian syndrome  
INSR                      Insulin receptor

## References

1. Lee SH, Park SY, Choi CS. Insulin Resistance: From Mechanisms to Therapeutic Strategies. *Diabetes Metab J*. 2022;46(1):15-37. doi:10.4093/dmj.2021.0280
2. Freeman AM, Acevedo LA, Pennings N. Insulin Resistance. [Updated 2023 Aug 17]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK507839/>
3. Videira-Silva A, Albuquerque C, Fonseca H. Acanthosis nigricans as a clinical marker of insulin resistance among overweight adolescents. *Ann Pediatr Endocrinol Metab*. 2019;24(2):99-103. doi:10.6065/apem.2019.24.2.99
4. Buscemi C, Randazzo C, Barile AM, et al. Factors associated with body weight gain and insulin-resistance: a longitudinal study. *Nutr Diabetes*. 2024;14(1):21. Published 2024 Apr 22. doi:10.1038/s41387-024-00283-5
5. Kosmas CE, Bousvarou MD, Kostara CE, Papakonstantinou EJ, Salamou E, Guzman E. Insulin resistance and cardiovascular disease. *J Int Med Res*. 2023;51(3):3000605231164548. doi:10.1177/03000605231164548
6. Taylor R. Insulin resistance and type 2 diabetes. *Diabetes*. 2012;61(4):778-779. doi:10.2337/db12-0073
7. Petersen MC, Shulman GI. Mechanisms of Insulin Action and Insulin Resistance. *Physiol Rev*. 2018;98(4):2133-2223. doi:10.1152/physrev.00063.2017
8. Ahmed B, Sultana R, Greene MW. Adipose tissue and insulin resistance in obese. *Biomed Pharmacother*. 2021;137:111315. doi: 10.1016/j.biopha.2021.111315
9. Janssen JAMJL. Hyperinsulinemia and Its Pivotal Role in Aging, Obesity, Type 2 Diabetes, Cardiovascular Disease and Cancer. *Int J Mol Sci*. 2021;22(15):7797. Published 2021 Jul 21. doi:10.3390/ijms22157797
10. Zhao X, An X, Yang C, Sun W, Ji H, Lian F. The crucial role and mechanism of insulin resistance in metabolic disease. *Front Endocrinol (Lausanne)*. 2023; 14:1149239. Published 2023 Mar 28. doi:10.3389/fendo.2023.1149239
11. Heindel JJ, Lustig RH, Howard S, Corkey BE. Obesogens: a unifying theory for the global rise in obesity. *Int J Obes (Lond)*. 2024;48(4):449-460. doi:10.1038/s41366-024-01460-3
12. Spoto B, Pisano A, Zoccali C. Insulin resistance in chronic kidney disease: a systematic review. *Am J Physiol Renal Physiol*. 2016;311(6):F1087-F1108. doi:10.1152/ajprenal.00340.2016
13. Bugianesi E, Moscatiello S, Ciaravella MF, Marchesini G. Insulin resistance in nonalcoholic fatty liver disease. *Curr Pharm Des*. 2010;16(17):1941-1951. doi:10.2174/138161210791208875
14. Lee YS, Olefsky J. Chronic tissue inflammation and metabolic disease. *Genes Dev*. 2021;35(5-6):307-328. doi:10.1101/gad.346312.120
15. Tyagi A, Pugazhenth S. Targeting Insulin Resistance to Treat Cognitive Dysfunction. *Mol Neurobiol*. 2021;58(6):2672-2691. doi:10.1007/s12035-021-02283-3
16. Smith RL, Soeters MR, Wüst RCI, Houtkooper RH. Metabolic Flexibility as an Adaptation to Energy Resources and Requirements in Health and Disease. *Endocr Rev*. 2018;39(4):489-517. doi:10.1210/er.2017-00211
17. Arnold SE, Arvanitakis Z, Macauley-Rambach SL, et al. Brain insulin resistance in type 2 diabetes and Alzheimer disease: concepts and conundrums. *Nat Rev Neurol*. 2018;14(3):168-181. doi:10.1038/nrneurol.2017.185
18. Chathoth S, Ismail MH, Alghamdi HM, et al. Insulin resistance induced by de novo pathway-generated C16-ceramide is associated with type 2 diabetes in an obese population. *Lipids Health Dis*. 2022;21(1):24. Published 2022 Feb 20. doi:10.1186/s12944-022-01634-w
19. Le TKC, Dao XD, Nguyen DV, et al. Insulin signaling and its application. *Front Endocrinol (Lausanne)*. 2023;14:1226655. Published 2023 Aug 17. doi:10.3389/fendo.2023.1226655
20. Kumar S, Senapati S, Bhattacharya N, et al. Mechanism and recent updates on insulin-related disorders. *World J Clin Cases*. 2023;11(25):5840-5856. doi:10.12998/wjcc.v11.i25.5840
21. Fazakerley DJ, Minard AY, Krycer JR, et al. Mitochondrial oxidative stress causes insulin resistance without disrupting oxidative phosphorylation. *J Biol Chem*. 2018;293(19):7315-7328. doi:10.1074/jbc.RA117.001254

22. Caricilli AM, Saad MJ. The role of gut microbiota on insulin resistance. *Nutrients*. 2013;5(3):829-851. Published 2013 Mar 12. doi:10.3390/nu5030829
23. Kolb H, Martin S. Environmental/lifestyle factors in the pathogenesis and prevention of type 2 diabetes. *BMC Med*. 2017;15(1):131. Published 2017 Jul 19. doi:10.1186/s12916-017-0901-x
24. Yarıbeygi H, Maleki M, Sathyapalan T, Jamialahmadi T, Sahebkar A. Pathophysiology of Physical Inactivity-Dependent Insulin Resistance: A Theoretical Mechanistic Review Emphasizing Clinical Evidence. *J Diabetes Res*. 2021;2021:7796727. Published 2021 Oct 7. doi:10.1155/2021/7796727
25. Parker KM, Tucker LA, Bailey BW, Davidson LE. Relationship between Sitting Time and Insulin Resistance in 6931 U.S. Adults: The Mediating Role of Abdominal Adiposity. *J Diabetes Res*. 2023;2023:5015572. Published 2023 May 24. doi:10.1155/2023/5015572
26. Martins FO, Conde SV. Impact of Diet Composition on Insulin Resistance. *Nutrients*. 2022;14(18):3716. Published 2022 Sep 9. doi:10.3390/nu14183716
27. Zyoud SH. Mapping the landscape of research on insulin resistance: a visualization analysis of randomized clinical trials. *J Health Popul Nutr*. 2024;43(1):6. Published 2024 Jan 9. doi:10.1186/s41043-024-00497-4
28. Abildinova GZ, Benberin VV, Vochshenkova TA, et al. Global trends and collaborative networks in gut microbiota-insulin resistance research: a comprehensive bibliometric analysis (2000-2024). *Front Med (Lausanne)*. 2024;11:1452227. Published 2024 Aug 15. doi:10.3389/fmed.2024.1452227
29. The International Diabetes Federation (IDF). Diabetes Atlas 2021. The USA. IDF. 10th ed. ISBN: 978-2-930229-98-0. 2021: 2-3. Available at: [www.diabetesatlas.org](http://www.diabetesatlas.org). Accessed April 12, 2022.
30. Goh LPW, Sani SA, Sabullah MK, Gansau JA. The Prevalence of Insulin Resistance in Malaysia and Indonesia: An Updated Systematic Review and Meta-Analysis. *Medicina (Kaunas)*. 2022;58(6):826. Published 2022 Jun 19. doi:10.3390/medicina58060826
31. Ferreira JRS, Zandonade E, de Paula Alves Bezerra OM, Salaroli LB. Insulin resistance by the triglyceride-glucose index in a rural Brazilian population. *Arch Endocrinol Metab*. 2022;66(6):848-855. doi:10.20945/2359-3997000000509
32. Parcha V, Heindl B, Kalra R, et al. Insulin Resistance and Cardiometabolic Risk Profile Among Nondiabetic American Young Adults: Insights From NHANES. *J Clin Endocrinol Metab*. 2022;107(1):e25-e37. doi:10.1210/clinem/dgab645
33. El-Kebbi IM, Bidikian NH, Hneiny L, Nasrallah MP. Epidemiology of type 2 diabetes in the Middle East and North Africa: Challenges and call for action. *World J Diabetes*. 2021;12(9):1401-1425. doi:10.4239/wjd.v12.i9.1401
34. Elshebiny A, Alrashed A, Albuwaydi Z, Aljassim S, Alhammad F, Alhajji R. An Assessment of the 10-Year Risk of Developing Type 2 Diabetes Among Saudi Adults Based on the Finnish Diabetes Risk Score. *Cureus*. 2022;14(11):e32034. Published 2022 Nov 29. doi:10.7759/cureus.32034
35. Bukhari H. M. Sociodemographic Variables Associated with the Prevalence of Insulin Resistance Using a Non-Invasive Score System Among Adults in the Makkah Region of Saudi Arabia. *Curr Res Nutr Food Sci* 2023; 11(2). doi : <http://dx.doi.org/10.12944/CRNFSJ.11.2.19>
36. Fahed M, Abou Jaoudeh MG, Merhi S, et al. Evaluation of risk factors for insulin resistance: a cross sectional study among employees at a private university in Lebanon. *BMC Endocr Disord*. 2020;20(1):85. Published 2020 Jun 10. doi:10.1186/s12902-020-00558-9
37. Elrayess MA, Rizk NM, Fadel AS, Kerkadi A. Prevalence and Predictors of Insulin Resistance in Non-Obese Healthy Young Females in Qatar. *Int J Environ Res Public Health*. 2020;17(14):5088. Published 2020 Jul 15. doi:10.3390/ijerph17145088
38. GBD 2021 Diabetes Collaborators. Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021 [published correction appears in *Lancet*. 2023 Sep 30;402(10408):1132. doi: 10.1016/S0140-6736(23)02044-5]. *Lancet*. 2023;402(10397):203-234. doi:10.1016/S0140-6736(23)01301-6
39. Pham TM, Carpenter JR, Morris TP, Sharma M, Petersen I. Ethnic Differences in the Prevalence of Type 2 Diabetes Diagnoses in the UK: Cross-Sectional Analysis of the Health Improvement Network Primary Care Database. *Clin Epidemiol*. 2019;11:1081-1088. Published 2019 Dec 31. doi:10.2147/CLEP.S227621

40. Williams DR, Mohammed SA, Leavell J, Collins C. Race, socioeconomic status, and health: complexities, ongoing challenges, and research opportunities. *Ann N Y Acad Sci.* 2010;1186:69-101. doi:10.1111/j.1749-6632.2009.05339.x
41. Saltiel AR. Insulin signaling in health and disease. *J Clin Invest.* 2021;131(1):e142241. doi:10.1172/JCI142241
42. Belfiore A, Frasca F, Pandini G, Sciacca L, Vigneri R. Insulin receptor isoforms and insulin receptor/insulin-like growth factor receptor hybrids in physiology and disease. *Endocr Rev.* 2009;30(6):586-623. doi:10.1210/er.2008-0047
43. Wang D, Liu G, Meng Y, Chen H, Ye Z, Jing J. The Configuration of GRB2 in Protein Interaction and Signal Transduction. *Biomolecules.* 2024;14(3):259. Published 2024 Feb 22. doi:10.3390/biom14030259
44. Lawrence MC. Understanding insulin and its receptor from their three-dimensional structures. *Mol Metab.* 2021;52:101255. doi:10.1016/j.molmet.2021.101255
45. Kasuga M. Structure and function of the insulin receptor—a personal perspective. *Proc Jpn Acad Ser B Phys Biol Sci.* 2019;95(10):581-589. doi:10.2183/pjab.95.039
46. Frasca F, Pandini G, Scalia P, et al. Insulin receptor isoform A, a newly recognized, high-affinity insulin-like growth factor II receptor in fetal and cancer cells. *Mol Cell Biol.* 1999;19(5):3278-3288. doi:10.1128/MCB.19.5.3278
47. Benyoucef S, Surinya KH, Hadaschik D, Siddle K. Characterization of insulin/IGF hybrid receptors: contributions of the insulin receptor L2 and Fn1 domains and the alternatively spliced exon 11 sequence to ligand binding and receptor activation. *Biochem J.* 2007;403(3):603-613. doi:10.1042/BJ20061709
48. Boucher J, Kleinridders A, Kahn CR. Insulin receptor signaling in normal and insulin-resistant states. *Cold Spring Harb Perspect Biol.* 2014;6(1):a009191. Published 2014 Jan 1. doi:10.1101/cshperspect.a009191
49. Mendoza C, Hanegan C, Sperry A, et al. Insulin receptor-inspired soluble insulin binder. *Eur J Cell Biol.* 2023;102(2):151293. doi:10.1016/j.ejcb.2023.151293
50. Shaw LM. The insulin receptor substrate (IRS) proteins: at the intersection of metabolism and cancer. *Cell Cycle.* 2011;10(11):1750-1756. doi:10.4161/cc.10.11.15824
51. Nawaratne R, Gray A, Jørgensen CH, Downes CP, Siddle K, Sethi JK. Regulation of insulin receptor substrate 1 pleckstrin homology domain by protein kinase C: role of serine 24 phosphorylation. *Mol Endocrinol.* 2006;20(8):1838-1852. doi:10.1210/me.2005-0536
52. Wagner MJ, Stacey MM, Liu BA, Pawson T. Molecular mechanisms of SH2- and PTB-domain-containing proteins in receptor tyrosine kinase signaling. *Cold Spring Harb Perspect Biol.* 2013;5(12):a008987. Published 2013 Dec 1. doi:10.1101/cshperspect.a008987
53. Toyoshima Y, Nakamura K, Tokita R, et al. Disruption of insulin receptor substrate-2 impairs growth but not insulin function in rats. *J Biol Chem.* 2020;295(33):11914-11927. shdoi:10.1074/jbc.RA120.013095
54. Martínez Báez A, Ayala G, Pedroza-Saavedra A, González-Sánchez HM, Chihu Amparan L. Phosphorylation Codes in IRS-1 and IRS-2 Are Associated with the Activation/Inhibition of Insulin Canonical Signaling Pathways. *Curr Issues Mol Biol.* 2024;46(1):634-649. Published 2024 Jan 9. doi:10.3390/cimb46010041
55. Guijarro LG, Justo Bermejo FJ, Boaru DL, et al. Is Insulin Receptor Substrate4 (IRS4) a Platform Involved in the Activation of Several Oncogenes?. *Cancers (Basel).* 2023;15(18):4651. Published 2023 Sep 20. doi:10.3390/cancers15184651
56. Nagao H, Cai W, Wewer Albrechtsen NJ, et al. Distinct signaling by insulin and IGF-1 receptors and their extra- and intracellular domains. *Proc Natl Acad Sci U S A.* 2021;118(17):e2019474118. doi:10.1073/pnas.2019474118
57. Tsay A, Wang JC. The Role of PIK3R1 in Metabolic Function and Insulin Sensitivity. *Int J Mol Sci.* 2023;24(16):12665. Published 2023 Aug 11. doi:10.3390/ijms241612665
58. Wright SCE, Vasilevski N, Serra V, Rodon J, Eichhorn PJA. Mechanisms of Resistance to PI3K Inhibitors in Cancer: Adaptive Responses, Drug Tolerance and Cellular Plasticity. *Cancers (Basel).* 2021;13(7):1538. Published 2021 Mar 26. doi:10.3390/cancers13071538
59. Fox M, Mott HR, Owen D. Class IA PI3K regulatory subunits: p110-independent roles and structures. *Biochem Soc Trans.* 2020;48(4):1397-1417. doi:10.1042/BST20190845

60. Chattopadhyay M, Selinger ES, Ballou LM, Lin RZ. Ablation of PI3K p110- $\alpha$  prevents high-fat diet-induced liver steatosis. *Diabetes*. 2011;60(5):1483-1492. doi:10.2337/db10-0869
61. Brachmann SM, Ueki K, Engelman JA, Kahn RC, Cantley LC. Phosphoinositide 3-kinase catalytic subunit deletion and regulatory subunit deletion have opposite effects on insulin sensitivity in mice. *Mol Cell Biol*. 2005;25(5):1596-1607. doi:10.1128/MCB.25.5.1596-1607.2005
62. Ueki K, Fruman DA, Brachmann SM, Tseng YH, Cantley LC, Kahn CR. Molecular balance between the regulatory and catalytic subunits of phosphoinositide 3-kinase regulates cell signaling and survival. *Mol Cell Biol*. 2002;22(3):965-977. doi:10.1128/MCB.22.3.965-977.2002
63. Hanke S, Mann M. The phosphotyrosine interactome of the insulin receptor family and its substrates IRS-1 and IRS-2. *Mol Cell Proteomics*. 2009;8(3):519-534. doi:10.1074/mcp.M800407-MCP200
64. Saini V. Molecular mechanisms of insulin resistance in type 2 diabetes mellitus. *World J Diabetes*. 2010;1(3):68-75. doi:10.4239/wjd.v1.i3.68
65. Johnson JL, Yaron TM, Huntsman EM, et al. An atlas of substrate specificities for the human serine/threonine kinome. *Nature*. 2023;613(7945):759-766. doi:10.1038/s41586-022-05575-3
66. Somale D, Di Nardo G, di Blasio L, et al. Activation of RSK by phosphomimetic substitution in the activation loop is prevented by structural constraints. *Sci Rep*. 2020;10(1):591. Published 2020 Jan 17. doi:10.1038/s41598-019-56937-3
67. Yang Y, Liu S, Wang P, et al. DNA-dependent protein kinase catalytic subunit (DNA-PKcs) drives chronic kidney disease progression in male mice. *Nat Commun*. 2023;14(1):1334. Published 2023 Mar 11. doi:10.1038/s41467-023-37043-5
68. Glaviano A, Foo ASC, Lam HY, et al. PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer. *Mol Cancer*. 2023;22(1):138. Published 2023 Aug 18. doi:10.1186/s12943-023-01827-6
69. Zhang HH, Huang J, Düvel K, et al. Insulin stimulates adipogenesis through the Akt-TSC2-mTORC1 pathway. *PLoS One*. 2009;4(7):e6189. Published 2009 Jul 10. doi:10.1371/journal.pone.0006189
70. Marchelek-Mysliwiec M, Nalewajska M, Turoń-Skrzypińska A, et al. The Role of Forkhead Box O in Pathogenesis and Therapy of Diabetes Mellitus. *Int J Mol Sci*. 2022;23(19):11611. Published 2022 Oct 1. doi:10.3390/ijms231911611
71. Farhan M, Silva M, Xingan X, Huang Y, Zheng W. Role of FOXO Transcription Factors in Cancer Metabolism and Angiogenesis. *Cells*. 2020;9(7):1586. Published 2020 Jun 30. doi:10.3390/cells9071586
72. Cartee GD. Roles of TBC1D1 and TBC1D4 in insulin- and exercise-stimulated glucose transport of skeletal muscle. *Diabetologia*. 2015;58(1):19-30. doi:10.1007/s00125-014-3395-5
73. Aslam M, Ladilov Y. Emerging Role of cAMP/AMPK Signaling. *Cells*. 2022;11(2):308. Published 2022 Jan 17. doi:10.3390/cells11020308
74. Manning BD, Cantley LC. AKT/PKB signaling: navigating downstream. *Cell*. 2007;129(7):1261-1274. doi:10.1016/j.cell.2007.06.009
75. Chibaya L, Karim B, Zhang H, Jones SN. Mdm2 phosphorylation by Akt regulates the p53 response to oxidative stress to promote cell proliferation and tumorigenesis [published correction appears in Proc Natl Acad Sci U S A. 2021 Mar 2;118(9):e2101572118. doi: 10.1073/pnas.2101572118]. *Proc Natl Acad Sci U S A*. 2021;118(4):e2003193118. doi:10.1073/pnas.2003193118
76. Kreis NN, Louwen F, Yuan J. The Multifaceted p21 (Cip1/Waf1/CDKN1A) in Cell Differentiation, Migration and Cancer Therapy. *Cancers (Basel)*. 2019;11(9):1220. Published 2019 Aug 21. doi:10.3390/cancers11091220
77. Jeong SJ, Dasgupta A, Jung KJ, et al. PI3K/AKT inhibition induces caspase-dependent apoptosis in HTLV-1-transformed cells. *Virology*. 2008;370(2):264-272. doi:10.1016/j.virol.2007.09.003
78. Tran N, Garcia T, Aniq M, Ali S, Ally A, Nauli SM. Endothelial Nitric Oxide Synthase (eNOS) and the Cardiovascular System: in Physiology and in Disease States. *Am J Biomed Sci Res*. 2022;15(2):153-177.
79. Castel P, Ellis H, Bago R, et al. PDK1-SGK1 Signaling Sustains AKT-Independent mTORC1 Activation and Confers Resistance to PI3K $\alpha$  Inhibition. *Cancer Cell*. 2016;30(2):229-242. doi:10.1016/j.ccell.2016.06.004
80. Kikkawa U, Kishimoto A, Nishizuka Y. The protein kinase C family: heterogeneity and its implications. *Annu Rev Biochem*. 1989;58:31-44. doi: 10.1146/annurev.bi.58.070189.000335. PMID: 2549852.
81. Rosse C, Linch M, Kermorgant S, Cameron AJ, Boeckeler K, Parker PJ. PKC and the control of localized signal dynamics. *Nat Rev Mol Cell Biol*. 2010 Feb;11(2):103-12. doi: 10.1038/nrm2847. PMID: 20094051.

82. Geraldès P, King GL. Activation of protein kinase C isoforms and its impact on diabetic complications. *Circ Res.* 2010;106(8):1319-1331. doi:10.1161/CIRCRESAHA.110.217117
83. Farese RV, Sajan MP. Metabolic functions of atypical protein kinase C: “good” and “bad” as defined by nutritional status. *Am J Physiol Endocrinol Metab.* 2010;298(3):E385-E394. doi:10.1152/ajpendo.00608.2009
84. Cosentino-Gomes D, Rocco-Machado N, Meyer-Fernandes JR. Cell signaling through protein kinase C oxidation and activation. *Int J Mol Sci.* 2012;13(9):10697-10721. doi:10.3390/ijms130910697
85. Farese RV, Sajan MP, Yang H, et al. Muscle-specific knockout of PKC-lambda impairs glucose transport and induces metabolic and diabetic syndromes [published correction appears in *J Clin Invest.* 2007 Oct;117(10):3141]. *J Clin Invest.* 2007;117(8):2289-2301. doi:10.1172/JCI31408
86. Arcidiacono B, Iiritano S, Nocera A, et al. Insulin resistance and cancer risk: an overview of the pathogenetic mechanisms. *Exp Diabetes Res.* 2012;2012:789174. doi:10.1155/2012/789174
87. Galic S, Hauser C, Kahn BB, et al. Coordinated regulation of insulin signaling by the protein tyrosine phosphatases PTP1B and TCPTP. *Mol Cell Biol.* 2005;25(2):819-829. doi:10.1128/MCB.25.2.819-829.2005
88. Delibegovic M, Zimmer D, Kauffman C, et al. Liver-specific deletion of protein-tyrosine phosphatase 1B (PTP1B) improves metabolic syndrome and attenuates diet-induced endoplasmic reticulum stress. *Diabetes.* 2009;58(3):590-599. doi:10.2337/db08-0913
89. Millward TA, Zolnierowicz S, Hemmings BA. Regulation of protein kinase cascades by protein phosphatase 2A. *Trends Biochem Sci.* 1999;24(5):186-191. doi:10.1016/s0968-0004(99)01375-4
90. Arora DK, Machhadieh B, Matti A, Wadzinski BE, Ramanadham S, Kowluru A. High glucose exposure promotes activation of protein phosphatase 2A in rodent islets and INS-1 832/13  $\beta$ -cells by increasing the posttranslational carboxymethylation of its catalytic subunit. *Endocrinology.* 2014;155(2):380-391. doi:10.1210/en.2013-1773
91. Nygren PJ, Scott JD. Regulation of the phosphatase PP2B by protein-protein interactions. *Biochem Soc Trans.* 2016;44(5):1313-1319. doi:10.1042/BST20160150
92. Cha JH, Jeong Y, Oh AR, Lee SB, Hong SS, Kim K. Emerging roles of PHLPP phosphatases in metabolism. *BMB Rep.* 2021;54(9):451-457. doi:10.5483/BMBRep.2021.54.9.095
93. Baffi TR, Cohen-Katsenelson K, Newton AC. PHLPPing the Script: Emerging Roles of PHLPP Phosphatases in Cell Signaling. *Annu Rev Pharmacol Toxicol.* 2021;61:723-743. doi:10.1146/annurev-pharmtox-031820-122108
94. Metcalfe LK, Smith GC, Turner N. Defining lipid mediators of insulin resistance - controversies and challenges. *J Mol Endocrinol.* Published online August 1, 2018. doi:10.1530/JME-18-0023
95. Tariq K, Luikart BW. Striking a balance: PIP<sub>2</sub> and PIP<sub>3</sub> signaling in neuronal health and disease. *Explor Neuroprotective Ther.* 2021;1:86-100. doi:10.37349/ent.2021.00008
96. Lee MF, Trotman LC. PTEN: Bridging Endocytosis and Signaling. *Cold Spring Harb Perspect Med.* 2020;10(10):a036103. Published 2020 Oct 1. doi:10.1101/cshperspect.a036103
97. Pal A, Barber TM, Van de Bunt M, et al. PTEN mutations as a cause of constitutive insulin sensitivity and obesity. *N Engl J Med.* 2012;367(11):1002-1011. doi:10.1056/NEJMoa1113966
98. Peyrou M, Bourgoin L, Poher AL, et al. Hepatic PTEN deficiency improves muscle insulin sensitivity and decreases adiposity in mice. *J Hepatol.* 2015;62(2):421-429. doi:10.1016/j.jhep.2014.09.012
99. Kotzampasi DM, Premeti K, Papafotika A, et al. The orchestrated signaling by PI3K $\alpha$  and PTEN at the membrane interface. *Comput Struct Biotechnol J.* 2022;20:5607-5621. Published 2022 Oct 7. doi:10.1016/j.csbj.2022.10.007
100. Bradshaw WJ, Kennedy EC, Moreira T, et al. Regulation of inositol 5-phosphatase activity by the C2 domain of SHIP1 and SHIP2. *Structure.* 2024;32(4):453-466.e6. doi:10.1016/j.str.2024.01.005
101. Lehtonen S. SHIPping out diabetes-Metformin, an old friend among new SHIP2 inhibitors. *Acta Physiol (Oxf).* 2020;228(1):e13349. doi:10.1111/apha.13349
102. Kagawa S, Soeda Y, Ishihara H, et al. Impact of transgenic overexpression of SH2-containing inositol 5'-phosphatase 2 on glucose metabolism and insulin signaling in mice. *Endocrinology.* 2008;149(2):642-650. doi:10.1210/en.2007-0820
103. Holt LJ, Siddle K. Grb10 and Grb14: enigmatic regulators of insulin action--and more?. *Biochem J.* 2005;388(Pt 2):393-406. doi:10.1042/BJ20050216

104. Moorwood K, Smith FM, Garfield AS, Cowley M, Holt LJ, Daly RJ, Ward A. Grb7, Grb10 and Grb14, encoding the growth factor receptor-bound 7 family of signalling adaptor proteins have overlapping functions in the regulation of fetal growth and post-natal glucose metabolism. *BMC Biol.* 2024 Sep 30;22(1):221. doi: 10.1186/s12915-024-02018-5. PMID: 39343875; PMCID: PMC11441139.
105. Smith FM, Holt LJ, Garfield AS, Charalambous M, Koumanov F, Perry M, Bazzani R, Sheardown SA, Hegarty BD, Lyons RJ, Cooney GJ, Daly RJ, Ward A. Mice with a disruption of the imprinted Grb10 gene exhibit altered body composition, glucose homeostasis, and insulin signaling during postnatal life. *Mol Cell Biol.* 2007 Aug;27(16):5871-86. doi: 10.1128/MCB.02087-06. Epub 2007 Jun 11. PMID: 17562854; PMCID: PMC1952119.
106. Holt LJ, Lyons RJ, Ryan AS, Beale SM, Ward A, Cooney GJ, Daly RJ. Dual ablation of Grb10 and Grb14 in mice reveals their combined role in regulation of insulin signaling and glucose homeostasis. *Mol Endocrinol.* 2009 Sep;23(9):1406-14. doi: 10.1210/me.2008-0386. Epub 2009 Jun 18. PMID: 19541746; PMCID: PMC2737556.
107. Villanueva-Hayes C, Millership SJ. Imprinted Genes Impact Upon Beta Cell Function in the Current (and Potentially Next) Generation. *Front Endocrinol (Lausanne).* 2021 Apr 27;12:660532. doi: 10.3389/fendo.2021.660532. PMID: 33986727; PMCID: PMC8112240.
108. Ueki K, Kondo T, Kahn CR. Suppressor of cytokine signaling 1 (SOCS-1) and SOCS-3 cause insulin resistance through inhibition of tyrosine phosphorylation of insulin receptor substrate proteins by discrete mechanisms [published correction appears in *Mol Cell Biol.* 2005 Oct;25(19):8762]. *Mol Cell Biol.* 2004;24(12):5434-5446. doi:10.1128/MCB.24.12.5434-5446.2004
109. Sobah ML, Liongue C, Ward AC. SOCS Proteins in Immunity, Inflammatory Diseases, and Immune-Related Cancer. *Front Med (Lausanne).* 2021 Sep 16;8:727987. doi: 10.3389/fmed.2021.727987. PMID: 34604264; PMCID: PMC8481645
110. Li S, Han S, Jin K, Yu T, Chen H, Zhou X, Tan Z, Zhang G. SOCS2 Suppresses Inflammation and Apoptosis during NASH Progression through Limiting NF- $\kappa$ B Activation in Macrophages. *Int J Biol Sci.* 2021 Oct 11;17(15):4165-4175. doi: 10.7150/ijbs.63889. PMID: 34803490; PMCID: PMC8579457.
111. Du K, Herzig S, Kulkarni RN, Montminy M. TRB3: a tribbles homolog that inhibits Akt/PKB activation by insulin in liver. *Science.* 2003;300(5625):1574-1577. doi:10.1126/science.1079817
112. Liew CW, Bochenski J, Kawamori D, Hu J, Leech CA, Wanic K, Malecki M, Warram JH, Qi L, Krolewski AS, Kulkarni RN. The pseudokinase tribbles homolog 3 interacts with ATF4 to negatively regulate insulin exocytosis in human and mouse beta cells. *J Clin Invest.* 2010 Aug;120(8):2876-88. doi: 10.1172/JCI36849. Epub 2010 Jul 1. PMID: 20592469; PMCID: PMC2912176.
113. Jeong HW, Choi RH, Koh HJ. Obesity-induced TRB3 negatively regulates Brown adipose tissue function in mice. *Biochem Biophys Res Commun.* 2021 Apr 2;547:29-35. doi: 10.1016/j.bbrc.2021.01.103. Epub 2021 Feb 13. PMID: 33592376; PMCID: PMC7982054.
114. Shears SB, Wang H. Metabolism and Functions of Inositol Pyrophosphates: Insights Gained from the Application of Synthetic Analogues. *Molecules.* 2020 Oct 2;25(19):4515. doi: 10.3390/molecules25194515. PMID: 33023101; PMCID: PMC7583957.
115. Lee S, Kim MG, Ahn H, Kim S. Inositol Pyrophosphates: Signaling Molecules with Pleiotropic Actions in Mammals. *Molecules.* 2020 May 8;25(9):2208. doi: 10.3390/molecules25092208. PMID: 32397291; PMCID: PMC7249018.
116. Abdul-Hay SO, Kang D, McBride M, Li L, Zhao J, Leissring MA. Deletion of insulin-degrading enzyme elicits antipodal, age-dependent effects on glucose and insulin tolerance. *PLoS One.* 2011;6(6):e20818. doi:10.1371/journal.pone.0020818
117. Li M, Chi X, Wang Y, Setrerrahmane S, Xie W, Xu H. Trends in insulin resistance: insights into mechanisms and therapeutic strategy. *Signal Transduct Target Ther.* 2022 Jul 6;7(1):216. doi: 10.1038/s41392-022-01073-0. PMID: 35794109; PMCID: PMC9259665.
118. Copps KD, White MF. Regulation of insulin sensitivity by serine/threonine phosphorylation of insulin receptor substrate proteins IRS1 and IRS2. *Diabetologia.* 2012 Oct;55(10):2565-2582. doi: 10.1007/s00125-012-2644-8. Epub 2012 Aug 8. PMID: 22869320; PMCID: PMC4011499.



119. Liu Y, Chen J, Fontes SK, Bautista EN, Cheng Z. Physiological and pathological roles of protein kinase A in the heart. *Cardiovasc Res.* 2022 Jan 29;118(2):386-398. doi: 10.1093/cvr/cvab008. PMID: 33483740; PMCID: PMC8803072.
120. Ardito F, Giuliani M, Perrone D, Troiano G, Lo Muzio L. The crucial role of protein phosphorylation in cell signaling and its use as targeted therapy (Review). *Int J Mol Med.* 2017 Aug;40(2):271-280. doi: 10.3892/ijmm.2017.3036. Epub 2017 Jun 22. PMID: 28656226; PMCID: PMC5500920.
121. Rajan MR, Fagerholm S, Jönsson C, Kjølhed P, Turkina MV, Strålfors P. Phosphorylation of IRS1 at serine 307 in response to insulin in human adipocytes is not likely to be catalyzed by p70 ribosomal S6 kinase. *PLoS One.* 2013;8(4):e59725. doi:10.1371/journal.pone.0059725
122. Copps KD, Hancer NJ, Opore-Ado L, Qiu W, Walsh C, White MF. Irs1 serine 307 promotes insulin sensitivity in mice. *Cell Metab.* 2010;11(1):84-92. doi:10.1016/j.cmet.2009.11.003
123. Edick AM, Auclair O, Burgos SA. Role of Grb10 in mTORC1-dependent regulation of insulin signaling and action in human skeletal muscle cells. *Am J Physiol Endocrinol Metab.* 2020;318(2):E173-E183. doi:10.1152/ajpendo.00025.2019
124. Yu Y, Yoon SO, Poulgiannis G, et al. Phosphoproteomic analysis identifies Grb10 as an mTORC1 substrate that negatively regulates insulin signaling. *Science.* 2011;332(6035):1322-1326. doi:10.1126/science.1199484
125. Santoro A, McGraw TE, Kahn BB. Insulin action in adipocytes, adipose remodeling, and systemic effects. *Cell Metab.* 2021 Apr 6;33(4):748-757. doi: 10.1016/j.cmet.2021.03.019. PMID: 33826917; PMCID: PMC8078167.
126. Koh HE, van Vliet S, Pietka TA, Meyer GA, Razani B, Laforest R, Gropler RJ, Mittendorfer B. Subcutaneous Adipose Tissue Metabolic Function and Insulin Sensitivity in People With Obesity. *Diabetes.* 2021 Oct;70(10):2225-2236. doi: 10.2337/db21-0160. Epub 2021 Jul 15. PMID: 34266892; PMCID: PMC8576507.
127. Wu S, Tan J, Zhang H, Hou DX, He J. Tissue-specific mechanisms of fat metabolism that focus on insulin actions. *J Adv Res.* 2023 Nov;53:187-198. doi: 10.1016/j.jare.2022.12.009. Epub 2022 Dec 17. PMID: 36539077; PMCID: PMC10658304.
128. Wasserman DH. Insulin, Muscle Glucose Uptake, and Hexokinase: Revisiting the Road Not Taken. *Physiology (Bethesda).* 2022 May 1;37(3):115-127. doi: 10.1152/physiol.00034.2021. Epub 2021 Nov 15. PMID: 34779282; PMCID: PMC8977147.
129. Tan SX, Ng Y, Burchfield JG, Ramm G, Lambright DG, Stöckli J, James DE. The Rab GTPase-activating protein TBC1D4/AS160 contains an atypical phosphotyrosine-binding domain that interacts with plasma membrane phospholipids to facilitate GLUT4 trafficking in adipocytes. *Mol Cell Biol.* 2012 Dec;32(24):4946-59. doi: 10.1128/MCB.00761-12. Epub 2012 Oct 8. PMID: 23045393; PMCID: PMC3510527.
130. Takenaka N, Araki N, Satoh T. Involvement of the protein kinase Akt2 in insulin-stimulated Rac1 activation leading to glucose uptake in mouse skeletal muscle. *PLoS One.* 2019 Feb 8;14(2):e0212219. doi: 10.1371/journal.pone.0212219. PMID: 30735546; PMCID: PMC6368313.
131. Katz A. The role of glycogen phosphorylase in glycogen biogenesis in skeletal muscle after exercise. *Sports Med Health Sci.* 2022 Nov 12;5(1):29-33. doi: 10.1016/j.smhs.2022.11.001. PMID: 36994178; PMCID: PMC10040329.
132. Agius L. Role of glycogen phosphorylase in liver glycogen metabolism. *Mol Aspects Med.* 2015;46:34-45. doi:10.1016/j.mam.2015.09.002
133. Uehara K, Santoleri D, Whitlock AEG, Titchenell PM. Insulin Regulation of Hepatic Lipid Homeostasis. *Compr Physiol.* 2023 Jun 26;13(3):4785-4809. doi: 10.1002/cphy.c220015. PMID: 37358513; PMCID: PMC10760932.
134. Roberts CK, Hevener AL, Barnard RJ. Metabolic syndrome and insulin resistance: underlying causes and modification by exercise training. *Compr Physiol.* 2013 Jan;3(1):1-58. doi: 10.1002/cphy.c110062. PMID: 23720280; PMCID: PMC4129661.
135. Galicia-Garcia U, Benito-Vicente A, Jebari S, Larrea-Sebal A, Siddiqi H, Uribe KB, Ostolaza H, Martín C. Pathophysiology of Type 2 Diabetes Mellitus. *Int J Mol Sci.* 2020 Aug 30;21(17):6275. doi: 10.3390/ijms21176275. PMID: 32872570; PMCID: PMC7503727.

136. Jung I, Koo DJ, Lee WY. Insulin Resistance, Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus: Clinical and Experimental Perspective. *Diabetes Metab J*. 2024 May;48(3):327-339. doi: 10.4093/dmj.2023.0350. Epub 2024 Feb 2. PMID: 38310873; PMCID: PMC11140401.
137. Mann V, Sundaresan A, Shishodia S. Overnutrition and Lipotoxicity: Impaired Efferocytosis and Chronic Inflammation as Precursors to Multifaceted Disease Pathogenesis. *Biology (Basel)*. 2024 Apr 6;13(4):241. doi: 10.3390/biology13040241. PMID: 38666853; PMCID: PMC11048223.
138. Cheng X, Jiang S, Pan B, Xie W, Meng J. Ectopic and visceral fat deposition in aging, obesity, and idiopathic pulmonary fibrosis: an interconnected role. *Lipids Health Dis*. 2023 Nov 24;22(1):201. doi: 10.1186/s12944-023-01964-3. PMID: 38001499; PMCID: PMC10668383.
139. Snel M, Jonker JT, Schoones J, Lamb H, de Roos A, Pijl H, Smit JW, Meinders AE, Jazet IM. Ectopic fat and insulin resistance: pathophysiology and effect of diet and lifestyle interventions. *Int J Endocrinol*. 2012;2012:983814. doi: 10.1155/2012/983814. Epub 2012 May 24. PMID: 22675355; PMCID: PMC3366269.
140. Jayasinghe SU, Tankeu AT, Amati F. Reassessing the Role of Diacylglycerols in Insulin Resistance. *Trends Endocrinol Metab*. 2019;30(9):618-635. doi:10.1016/j.tem.2019.06.005
141. Xiao K, Liu C, Tu Z, Xu Q, Chen S, Zhang Y, Wang X, Zhang J, Hu CA, Liu Y. Activation of the NF- $\kappa$ B and MAPK Signaling Pathways Contributes to the Inflammatory Responses, but Not Cell Injury, in IPEC-1 Cells Challenged with Hydrogen Peroxide. *Oxid Med Cell Longev*. 2020 Jan 21;2020:5803639. doi: 10.1155/2020/5803639. PMID: 32411329; PMCID: PMC7204152.
142. Scarano F, Gliozzi M, Zito MC, Guarnieri L, Carresi C, Macrì R, Nucera S, Scicchitano M, Bosco F, Ruga S, Coppoletta AR, Mollace R, Maiuolo J, Bava I, Cardamone A, Ragusa M, Palma E, Musolino V, Mollace V. Potential of Nutraceutical Supplementation in the Modulation of White and Brown Fat Tissues in Obesity-Associated Disorders: Role of Inflammatory Signalling. *Int J Mol Sci*. 2021 Mar 25;22(7):3351. doi: 10.3390/ijms22073351. PMID: 33805912; PMCID: PMC8037903.
143. Sun Z, Li G, Tong T, Chen J. Micheliolide suppresses LPS-induced neuroinflammatory responses. *PLoS One*. 2017 Oct 17;12(10):e0186592. doi: 10.1371/journal.pone.0186592. PMID: 29040306; PMCID: PMC5645131.
144. Yi YS. Caspase-11 non-canonical inflammasome: a critical sensor of intracellular lipopolysaccharide in macrophage-mediated inflammatory responses. *Immunology*. 2017 Oct;152(2):207-217. doi: 10.1111/imm.12787. Epub 2017 Jul 31. PMID: 28695629; PMCID: PMC5588777.
145. Holland WL, Bikman BT, Wang LP, et al. Lipid-induced insulin resistance mediated by the proinflammatory receptor TLR4 requires saturated fatty acid-induced ceramide biosynthesis in mice. *J Clin Invest*. 2011;121(5):1858-1870. doi:10.1172/JCI43378
146. Kojta I, Chacirńska M, Błachnio-Zabielska A. Obesity, Bioactive Lipids, and Adipose Tissue Inflammation in Insulin Resistance. *Nutrients*. 2020 May 3;12(5):1305. doi: 10.3390/nu12051305. PMID: 32375231; PMCID: PMC7284998.
147. Adams JM 2nd, Pratipanawat T, Berria R, et al. Ceramide content is increased in skeletal muscle from obese insulin-resistant humans. *Diabetes*. 2004;53(1):25-31. doi:10.2337/diabetes.53.1.25
148. Kasumov T, Solomon TP, Hwang C, et al. Improved insulin sensitivity after exercise training is linked to reduced plasma C14:0 ceramide in obesity and type 2 diabetes. *Obesity (Silver Spring)*. 2015;23(7):1414-1421. doi:10.1002/oby.21117
149. Razak Hady H, Błachnio-Zabielska AU, Szczerbiński Ł, Zabielski P, Imierska M, Dadan J, Krętowski AJ. Ceramide Content in Liver Increases Along with Insulin Resistance in Obese Patients. *J Clin Med*. 2019 Dec 12;8(12):2197. doi: 10.3390/jcm8122197. PMID: 31842461; PMCID: PMC6947381.
150. Xia JY, Holland WL, Kusminski CM, et al. Targeted Induction of Ceramide Degradation Leads to Improved Systemic Metabolism and Reduced Hepatic Steatosis. *Cell Metab*. 2015;22(2):266-278. doi:10.1016/j.cmet.2015.06.007
151. Hage Hassan R, Pacheco de Sousa AC, Mahfouz R, Hainault I, Błachnio-Zabielska A, Bourron O, Koskas F, Górski J, Ferré P, Fougelle F, Hajduch E. Sustained Action of Ceramide on the Insulin Signaling Pathway in Muscle Cells: IMPLICATION OF THE DOUBLE-STRANDED RNA-ACTIVATED PROTEIN KINASE. *J Biol Chem*. 2016 Feb 5;291(6):3019-29. doi: 10.1074/jbc.M115.686949. Epub 2015 Dec 23. PMID: 26698173; PMCID: PMC4742763.

152. Turpin SM, Nicholls HT, Willmes DM, et al. Obesity-induced CerS6-dependent C16:0 ceramide production promotes weight gain and glucose intolerance. *Cell Metab.* 2014;20(4):678-686. doi:10.1016/j.cmet.2014.08.002
153. Turpin-Nolan SM, Hammerschmidt P, Chen W, et al. CerS1-Derived C<sub>18:0</sub> Ceramide in Skeletal Muscle Promotes Obesity-Induced Insulin Resistance. *Cell Rep.* 2019;26(1):1-10.e7. doi:10.1016/j.celrep.2018.12.031
154. Smith GI, Shankaran M, Yoshino M, Schweitzer GG, Chondronikola M, Beals JW, Okunade AL, Patterson BW, Nyangau E, Field T, Sirlin CB, Talukdar S, Hellerstein MK, Klein S. Insulin resistance drives hepatic de novo lipogenesis in nonalcoholic fatty liver disease. *J Clin Invest.* 2020 Mar 2;130(3):1453-1460. doi: 10.1172/JCI134165. PMID: 31805015; PMCID: PMC7269561.
155. Manna P, Jain SK. Obesity, Oxidative Stress, Adipose Tissue Dysfunction, and the Associated Health Risks: Causes and Therapeutic Strategies. *Metab Syndr Relat Disord.* 2015 Dec;13(10):423-44. doi: 10.1089/met.2015.0095. PMID: 26569333; PMCID: PMC4808277.
156. Fuster JJ, Ouchi N, Gokce N, Walsh K. Obesity-Induced Changes in Adipose Tissue Microenvironment and Their Impact on Cardiovascular Disease. *Circ Res.* 2016 May 27;118(11):1786-807. doi: 10.1161/CIRCRESAHA.115.306885. PMID: 27230642; PMCID: PMC4887147.
157. Kawai T, Autieri MV, Scalia R. Adipose tissue inflammation and metabolic dysfunction in obesity. *Am J Physiol Cell Physiol.* 2021 Mar 1;320(3):C375-C391. doi: 10.1152/ajpcell.00379.2020. Epub 2020 Dec 23. PMID: 33356944; PMCID: PMC8294624.
158. Lucas K, Maes M. Role of the Toll Like receptor (TLR) radical cycle in chronic inflammation: possible treatments targeting the TLR4 pathway. *Mol Neurobiol.* 2013 Aug;48(1):190-204. doi: 10.1007/s12035-013-8425-7. Epub 2013 Feb 26. PMID: 23436141; PMCID: PMC7091222.
159. He W, Wang H, Yang G, Zhu L, Liu X. The Role of Chemokines in Obesity and Exercise-Induced Weight Loss. *Biomolecules.* 2024;14(9):1121. Published 2024 Sep 4. doi:10.3390/biom14091121
160. Dash SP, Gupta S, Sarangi PP. Monocytes and macrophages: Origin, homing, differentiation, and functionality during inflammation. *Heliyon.* 2024 Apr 15;10(8):e29686. doi: 10.1016/j.heliyon.2024.e29686. PMID: 38681642; PMCID: PMC11046129.
161. Liang W, Qi Y, Yi H, et al. The Roles of Adipose Tissue Macrophages in Human Disease. *Front Immunol.* 2022;13:908749. Published 2022 Jun 9. doi:10.3389/fimmu.2022.908749
162. Li X, Ren Y, Chang K, Wu W, Griffiths HR, Lu S, Gao D. Adipose tissue macrophages as potential targets for obesity and metabolic diseases. *Front Immunol.* 2023 Apr 19;14:1153915. doi: 10.3389/fimmu.2023.1153915. PMID: 37153549; PMCID: PMC10154623.
163. Woo JR, Bae SH, Wales TE, et al. The serine phosphorylations in the IRS-1 PIR domain abrogate IRS-1 and IR interaction. *Proc Natl Acad Sci U S A.* 2024;121(17):e2401716121. doi:10.1073/pnas.2401716121
164. Sarvas JL, Khaper N, Lees SJ. The IL-6 Paradox: Context Dependent Interplay of SOCS3 and AMPK. *J Diabetes Metab.* 2013 May 24;Suppl 13:10.4172/2155-6156.S13-003. doi: 10.4172/2155-6156.S13-003. PMID: 24244888; PMCID: PMC3828628.
165. Chen L, Chen R, Wang H, Liang F. Mechanisms Linking Inflammation to Insulin Resistance. *Int J Endocrinol.* 2015;2015:508409. doi:10.1155/2015/508409
166. Masenga SK, Kabwe LS, Chakulya M, Kirabo A. Mechanisms of Oxidative Stress in Metabolic Syndrome. *Int J Mol Sci.* 2023 Apr 26;24(9):7898. doi: 10.3390/ijms24097898. PMID: 37175603; PMCID: PMC10178199.
167. Cipriano A, Viviano M, Feoli A, Milite C, Sarno G, Castellano S, Sbardella G. NADPH Oxidases: From Molecular Mechanisms to Current Inhibitors. *J Med Chem.* 2023 Sep 14;66(17):11632-11655. doi: 10.1021/acs.jmedchem.3c00770. Epub 2023 Aug 31. PMID: 37650225; PMCID: PMC10510401.
168. DeVallance E, Li Y, Jurczak MJ, Cifuentes-Pagano E, Pagano PJ. The Role of NADPH Oxidases in the Etiology of Obesity and Metabolic Syndrome: Contribution of Individual Isoforms and Cell Biology. *Antioxid Redox Signal.* 2019;31(10):687-709. doi:10.1089/ars.2018.7674
169. Den Hartigh LJ, Omer M, Goodspeed L, et al. Adipocyte-Specific Deficiency of NADPH Oxidase 4 Delays the Onset of Insulin Resistance and Attenuates Adipose Tissue Inflammation in Obesity. *Arterioscler Thromb Vasc Biol.* 2017;37(3):466-475. doi:10.1161/ATVBAHA.116.308749

170. Cota-Magaña AI, Vazquez-Moreno M, Rocha-Aguado A, et al. Obesity Is Associated with Oxidative Stress Markers and Antioxidant Enzyme Activity in Mexican Children. *Antioxidants (Basel)*. 2024;13(4):457. Published 2024 Apr 12. doi:10.3390/antiox13040457
171. Li N, Li B, Brun T, Deffert-Delbouille C, Mahiout Z, Daali Y, Ma XJ, Krause KH, Maechler P. NADPH oxidase NOX2 defines a new antagonistic role for reactive oxygen species and cAMP/PKA in the regulation of insulin secretion. *Diabetes*. 2012
172. Masenga SK, Kabwe LS, Chakulya M, Kirabo A. Mechanisms of Oxidative Stress in Metabolic Syndrome. *Int J Mol Sci*. 2023;24(9):7898. Published 2023 Apr 26. doi:10.3390/ijms24097898
173. Yu T, Wang L, Zhang L, Deuster PA. Mitochondrial Fission as a Therapeutic Target for Metabolic Diseases: Insights into Antioxidant Strategies. *Antioxidants (Basel)*. 2023;12(6):1163. Published 2023 May 27. doi:10.3390/antiox12061163
174. Kowalczyk P, Sulejczak D, Kleczkowska P, Bukowska-Ośko I, Kucia M, Popiel M, Wietrak E, Kramkowski K, Wrzosek K, Kaczyńska K. Mitochondrial Oxidative Stress-A Causative Factor and Therapeutic Target in Many Diseases. *Int J Mol Sci*. 2021 Dec 13;22(24):13384. doi: 10.3390/ijms222413384. PMID: 34948180; PMCID: PMC8707347.
175. Li A, Gao M, Liu B, Qin Y, Chen L, Liu H, Wu H, Gong G. Mitochondrial autophagy: molecular mechanisms and implications for cardiovascular disease. *Cell Death Dis*. 2022 May 9;13(5):444. doi: 10.1038/s41419-022-04906-6. PMID: 35534453; PMCID: PMC9085840.
176. Xia W, Veeragandham P, Cao Y, et al. Obesity causes mitochondrial fragmentation and dysfunction in white adipocytes due to RalA activation. *Nat Metab*. 2024;6(2):273-289. doi:10.1038/s42255-024-00978-0
177. Mann JP, Duan X, Patel S, Tábara LC, Scurria F, Alvarez-Guaita A, Haider A, Luijten I, Page M, Protasoni M, Lim K, Virtue S, O'Rahilly S, Armstrong M, Prudent J, Semple RK, Savage DB. A mouse model of human mitofusin-2-related lipodystrophy exhibits adipose-specific mitochondrial stress and reduced leptin secretion. *Elife*. 2023 Feb 1;12:e82283. doi: 10.7554/eLife.82283. PMID: 36722855; PMCID: PMC9937658.
178. Zheng P, Ma W, Gu Y, Wu H, Bian Z, Liu N, Yang D, Chen X. High-fat diet causes mitochondrial damage and downregulation of mitofusin-2 and optic atrophy-1 in multiple organs. *J Clin Biochem Nutr*. 2023 Jul;73(1):61-76. doi: 10.3164/jcbrn.22-73. Epub 2023 May 25. PMID: 37534099; PMCID: PMC10390808.
179. Jheng HF, Tsai PJ, Guo SM, Kuo LH, Chang CS, Su IJ, Chang CR, Tsai YS. Mitochondrial fission contributes to mitochondrial dysfunction and insulin resistance in skeletal muscle. *Mol Cell Biol*. 2012 Jan;32(2):309-19. doi: 10.1128/MCB.05603-11. Epub 2011 Nov 14. PMID: 22083962; PMCID: PMC3255771.
180. Shum M, Ngo J, Shirihai OS, Liesa M. Mitochondrial oxidative function in NAFLD: Friend or foe?. *Mol Metab*. 2021;50:101134. doi:10.1016/j.molmet.2020.101134
181. Li F, Guan Z, Gao Y, et al. ER stress promotes mitochondrial calcium overload and activates the ROS/NLRP3 axis to mediate fatty liver ischemic injury. *Hepatol Commun*. 2024;8(4):e0399. Published 2024 Mar 18. doi:10.1097/HC9.0000000000000399
182. Zong Y, Li H, Liao P, et al. Mitochondrial dysfunction: mechanisms and advances in therapy. *Signal Transduct Target Ther*. 2024;9(1):124. Published 2024 May 15. doi:10.1038/s41392-024-01839-8
183. Picca A, Lezza AMS, Leeuwenburgh C, et al. Fueling Inflamm-Aging through Mitochondrial Dysfunction: Mechanisms and Molecular Targets. *Int J Mol Sci*. 2017;18(5):933. Published 2017 Apr 28. doi:10.3390/ijms18050933
184. Gómez-Virgilio L, Silva-Lucero MD, Flores-Morelos DS, et al. Autophagy: A Key Regulator of Homeostasis and Disease: An Overview of Molecular Mechanisms and Modulators. *Cells*. 2022;11(15):2262. Published 2022 Jul 22. doi:10.3390/cells11152262
185. Wang YL, Zhou X, Li DL, Ye JM. Role of the mTOR-autophagy-ER stress pathway in high fructose-induced metabolic-associated fatty liver disease. *Acta Pharmacol Sin*. 2022;43(1):10-14. doi:10.1038/s41401-021-00629-0
186. He L, Zhang J, Zhao J, et al. Autophagy: The Last Defense against Cellular Nutritional Stress. *Adv Nutr*. 2018;9(4):493-504. doi:10.1093/advances/nmy011
187. Sinha RA. Autophagy: A Cellular Guardian against Hepatic Lipotoxicity. *Genes (Basel)*. 2023;14(3):553. doi:10.3390/genes14030553.

188. Settembre C, De Cegli R, Mansueto G, et al. TFEB controls cellular lipid metabolism through a starvation-induced autoregulatory loop [published correction appears in *Nat Cell Biol.* 2013 Aug;15(8):1016]. *Nat Cell Biol.* 2013;15(6):647-658. doi:10.1038/ncb2718
189. Menikdiwela KR, Ramalingam L, Rasha F, et al. Autophagy in metabolic syndrome: breaking the wheel by targeting the renin-angiotensin system. *Cell Death Dis.* 2020;11(2):87. Published 2020 Feb 3. doi:10.1038/s41419-020-2275-9
190. Hasnain SZ, Prins JB, McGuckin MA. Oxidative and endoplasmic reticulum stress in  $\beta$ -cell dysfunction in diabetes. *J Mol Endocrinol.* 2016;56(2):R33-R54. doi:10.1530/JME-15-0232
191. Diane A, Allouch A, Mu-U-Min RBA, Al-Siddiqi HH. Endoplasmic reticulum stress in pancreatic  $\beta$ -cell dysfunctionality and diabetes mellitus: a promising target for generation of functional hPSC-derived  $\beta$ -cells in vitro. *Front Endocrinol (Lausanne).* 2024;15:1386471. Published 2024 Jun 20. doi:10.3389/fendo.2024.1386471
192. Biwer LA, Isakson BE. Endoplasmic reticulum-mediated signalling in cellular microdomains. *Acta Physiol (Oxf).* 2017;219(1):162-175. doi:10.1111/apha.12675
193. Ajoalabady A, Liu S, Klionsky DJ, et al. ER stress in obesity pathogenesis and management. *Trends Pharmacol Sci.* 2022;43(2):97-109. doi:10.1016/j.tips.2021.11.011
194. Tripathi YB, Pandey V. Obesity and endoplasmic reticulum (ER) stresses. *Front Immunol.* 2012;3:240. Published 2012 Aug 7. doi:10.3389/fimmu.2012.00240
195. Li H, Min Q, Ouyang C, et al. AMPK activation prevents excess nutrient-induced hepatic lipid accumulation by inhibiting mTORC1 signaling and endoplasmic reticulum stress response. *Biochim Biophys Acta.* 2014;1842(9):1844-1854. doi:10.1016/j.bbadis.2014.07.002
196. Korbecki J, Bajdak-Rusinek K. The effect of palmitic acid on inflammatory response in macrophages: an overview of molecular mechanisms. *Inflamm Res.* 2019;68(11):915-932. doi:10.1007/s00011-019-01273-5
197. Mubarak SA, Otaibi AA, Qarni AA, Lee jhBakillah A, Iqbal J. Reduction in Insulin Mediated ERK Phosphorylation by Palmitate in Liver Cells Is Independent of Fatty Acid Induced ER Stress. *Nutrients.* 2022;14(17):3641. Published 2022 Sep 2. doi:10.3390/nu14173641
198. Hage Hassan R, Hainault I, Vilquin JT, et al. Endoplasmic reticulum stress does not mediate palmitate-induced insulin resistance in mouse and human muscle cells. *Diabetologia.* 2012;55(1):204-214. doi:10.1007/s00125-011-2328-9
199. Lee JH, Lee J. Endoplasmic Reticulum (ER) Stress and Its Role in Pancreatic  $\beta$ -Cell Dysfunction and Senescence in Type 2 Diabetes. *Int J Mol Sci.* 2022;23(9):4843. Published 2022 Apr 27. doi:10.3390/ijms23094843
200. Caputo T, Gilardi F, Desvergne B. From chronic overnutrition to metaflammation and insulin resistance: adipose tissue and liver contributions. *FEBS Lett.* 2017;591(19):3061-3088. doi:10.1002/1873-3468.12742
201. Krebs J, Agellon LB, Michalak M. Ca(2+) homeostasis and endoplasmic reticulum (ER) stress: An integrated view of calcium signaling. *Biochem Biophys Res Commun.* 2015;460(1):114-121. doi:10.1016/j.bbrc.2015.02.004
202. Li W, Jin K, Luo J, et al. NF- $\kappa$ B and its crosstalk with endoplasmic reticulum stress in atherosclerosis. *Front Cardiovasc Med.* 2022;9:988266. Published 2022 Sep 20. doi:10.3389/fcvm.2022.988266
203. Chen X, Shi C, He M, Xiong S, Xia X. Endoplasmic reticulum stress: molecular mechanism and therapeutic targets. *Signal Transduct Target Ther.* 2023;8(1):352. Published 2023 Sep 15. doi:10.1038/s41392-023-01570-w
204. Brown AE, Walker M. Genetics of Insulin Resistance and the Metabolic Syndrome. *Curr Cardiol Rep.* 2016;18(8):75. doi:10.1007/s11886-016-0755-4
205. Oliveri, A., Rebernick, R.J., Kuppa, A. et al. Comprehensive genetic study of the insulin resistance marker TG:HDL-C in the UK Biobank. *Nat Genet* 56, 212–221 (2024). <https://doi.org/10.1038/s41588-023-01625-2>
206. Islam MA, Bhayye S, Adeniyi AA, Soliman ME, Pillay TS. Diabetes mellitus caused by mutations in human insulin: analysis of impaired receptor binding of insulins Wakayama, Los Angeles and Chicago using pharmacoinformatics. *J Biomol Struct Dyn.* 2017;35(4):724-737. doi:10.1080/07391102.2016.1160258
207. Duszka K, Gregor A, Guillou H, König J, Wahli W. Peroxisome Proliferator-Activated Receptors and Caloric Restriction-Common Pathways Affecting Metabolism, Health, and Longevity. *Cells.* 2020;9(7):1708. Published 2020 Jul 16. doi:10.3390/cells9071708

208. Elangeeb ME, Elfaki I, Elkhaliifa MA, et al. In Silico Investigation of AKT2 Gene and Protein Abnormalities Reveals Potential Association with Insulin Resistance and Type 2 Diabetes. *Curr Issues Mol Biol.* 2023;45(9):7449-7475. Published 2023 Sep 12. doi:10.3390/cimb45090471
209. Velayutham K, Ramanathan B, Murugan J, Murugan A, Thavamani V, Gomathinayagam R. Carriers of the TCF7L2 rs7903146, rs12255372 Risk Alleles in the South Tamil Nadu T2DM Patients Present with Early Incidence and Insulin Dependence. *Indian J Endocrinol Metab.* 2019;23(5):563-569. doi:10.4103/ijem.IJEM\_540\_19
210. Arrona-Cardoza P, Labonté K, Cisneros-Franco JM, Nielsen DE. The Effects of Food Advertisements on Food Intake and Neural Activity: A Systematic Review and Meta-Analysis of Recent Experimental Studies. *Adv Nutr.* 2023;14(2):339-351. doi:10.1016/j.advnut.2022.12.003
211. Hanifah L, Nasrulloh N, Sufyan DL. Sedentary Behavior and Lack of Physical Activity among Children in Indonesia. *Children (Basel).* 2023;10(8):1283. Published 2023 Jul 26. doi:10.3390/children10081283
212. Hruby A, Hu FB. The Epidemiology of Obesity: A Big Picture. *Pharmacoeconomics.* 2015;33(7):673-689. doi:10.1007/s40273-014-0243-x
213. Habibi P, Razmjouei J, Moradi A, Mahdavi F, Fallah-Aliabadi S, Heydari A. Climate change and heat stress resilient outdoor workers: findings from systematic literature review. *BMC Public Health.* 2024;24(1):1711. Published 2024 Jun 26. doi:10.1186/s12889-024-19212-3
214. Popkin BM, Ng SW. The nutrition transition to a stage of high obesity and noncommunicable disease prevalence dominated by ultra-processed foods is not inevitable. *Obes Rev.* 2022;23(1):e13366. doi:10.1111/obr.13366
215. Mozaffarian D, Hao T, Rimm EB, Willett WC, Hu FB. Changes in diet and lifestyle and long-term weight gain in women and men. *N Engl J Med.* 2011;364(25):2392-2404. doi:10.1056/NEJMoa1014296
216. Sanyaolu A, Okorie C, Qi X, Locke J, Rehman S. Childhood and Adolescent Obesity in the United States: A Public Health Concern. *Glob Pediatr Health.* 2019;6:2333794X19891305. Published 2019 Dec 1. doi:10.1177/2333794X19891305
217. Huang LY, Liu CH, Chen FY, Kuo CH, Pitrone P, Liu JS. Aging Affects Insulin Resistance, Insulin Secretion, and Glucose Effectiveness in Subjects with Normal Blood Glucose and Body Weight. *Diagnostics (Basel).* 2023;13(13):2158. Published 2023 Jun 24. doi:10.3390/diagnostics13132158
218. Leon AS. Attenuation of Adverse Effects of Aging on Skeletal Muscle by Regular Exercise and Nutritional Support. *Am J Lifestyle Med.* 2016;11(1):4-16. Published 2016 Jun 23. doi:10.1177/1559827615589319
219. Merz KE, Thurmond DC. Role of Skeletal Muscle in Insulin Resistance and Glucose Uptake. *Compr Physiol.* 2020;10(3):785-809. Published 2020 Jul 8. doi:10.1002/cphy.c190029
220. Long YC, Cheng Z, Copps KD, White MF. Insulin receptor substrates Irs1 and Irs2 coordinate skeletal muscle growth and metabolism via the Akt and AMPK pathways [published correction appears in *Mol Cell Biol.* 2017 Jul 14;37(15):e00232-17. doi: 10.1128/MCB.00232-17]. *Mol Cell Biol.* 2011;31(3):430-441. doi:10.1128/MCB.00983-10
221. Sasako T, Umehara T, Soeda K, et al. Deletion of skeletal muscle Akt1/2 causes osteosarcopenia and reduces lifespan in mice. *Nat Commun.* 2022;13(1):5655. Published 2022 Oct 5. doi:10.1038/s41467-022-33008-2
222. Okuma H, Tsuchiya K. Tissue-specific activation of insulin signaling as a potential target for obesity-related metabolic disorders. *Pharmacol Ther.* 2024;262:108699. doi:10.1016/j.pharmthera.2024.108699
223. Lai KM, Gonzalez M, Poueymirou WT, et al. Conditional activation of akt in adult skeletal muscle induces rapid hypertrophy. *Mol Cell Biol.* 2004;24(21):9295-9304. doi:10.1128/MCB.24.21.9295-9304.2004
224. Santoleri D, Titchenell PM. Resolving the Paradox of Hepatic Insulin Resistance. *Cell Mol Gastroenterol Hepatol.* 2019;7(2):447-456. doi:10.1016/j.jcmgh.2018.10.016
225. Bo T, Gao L, Yao Z, et al. Hepatic selective insulin resistance at the intersection of insulin signaling and metabolic dysfunction-associated steatotic liver disease. *Cell Metab.* 2024;36(5):947-968. doi:10.1016/j.cmet.2024.04.006
226. Tao Y, Jiang Q, Wang Q. Adipose tissue macrophages in remote modulation of hepatic glucose production. *Front Immunol.* 2022;13:998947. Published 2022 Aug 24. doi:10.3389/fimmu.2022.998947
227. Torikai H, Chen MH, Jin L, He J, Angle JF, Shi W. Atherogenesis in *ApoE*<sup>-/-</sup> and *Ldlr*<sup>-/-</sup> Mice with a Genetically Resistant Background. *Cells.* 2023;12(9):1255. Published 2023 Apr 26. doi:10.3390/cells12091255

228. Toyoshima Y, Nakamura K, Taguchi Y, et al. Deletion of IRS-1 leads to growth failure and insulin resistance with downregulation of liver and muscle insulin signaling in rats. *Sci Rep.* 2025;15(1):649. Published 2025 Jan 8. doi:10.1038/s41598-024-84234-1
229. Clemente-Suárez VJ, Redondo-Flórez L, Beltrán-Velasco AI, et al. The Role of Adipokines in Health and Disease. *Biomedicines.* 2023;11(5):1290. Published 2023 Apr 27. doi:10.3390/biomedicines11051290
230. Zatterale F, Longo M, Naderi J, et al. Chronic Adipose Tissue Inflammation Linking Obesity to Insulin Resistance and Type 2 Diabetes. *Front Physiol.* 2020;10:1607. Published 2020 Jan 29. doi:10.3389/fphys.2019.01607
231. Kojta I, Chacińska M, Błachnio-Zabielska A. Obesity, Bioactive Lipids, and Adipose Tissue Inflammation in Insulin Resistance. *Nutrients.* 2020;12(5):1305. Published 2020 May 3. doi:10.3390/nu12051305
232. Caturano A, Galiero R, Vetrano E, et al. Insulin-Heart Axis: Bridging Physiology to Insulin Resistance. *Int J Mol Sci.* 2024;25(15):8369. Published 2024 Jul 31. doi:10.3390/ijms25158369
233. Ono H. Molecular Mechanisms of Hypothalamic Insulin Resistance. *Int J Mol Sci.* 2019;20(6):1317. Published 2019 Mar 15. doi:10.3390/ijms20061317
234. Nguyen V, Thomas P, Pemberton S, et al. Central nervous system insulin signaling can influence the rate of insulin influx into brain. *Fluids Barriers CNS.* 2023;20(1):28. Published 2023 Apr 19. doi:10.1186/s12987-023-00431-6
235. Shin AC, Filatova N, Lindtner C, et al. Insulin Receptor Signaling in POMC, but Not AgRP, Neurons Controls Adipose Tissue Insulin Action. *Diabetes.* 2017;66(6):1560-1571. doi:10.2337/db16-1238
236. Kubota N, Terauchi Y, Tobe K, et al. Insulin receptor substrate 2 plays a crucial role in beta cells and the hypothalamus. *J Clin Invest.* 2004;114(7):917-927. doi:10.1172/JCI21484
237. Skovso S, Panzhinskiy E, Kolic J, et al. Beta-cell specific Insr deletion promotes insulin hypersecretion and improves glucose tolerance prior to global insulin resistance. *Nat Commun.* 2022;13(1):735. Published 2022 Feb 8. doi:10.1038/s41467-022-28039-8
238. Park K, Mima A, Li Q, et al. Insulin decreases atherosclerosis by inducing endothelin receptor B expression. *JCI Insight.* 2016;1(6):e86574. doi:10.1172/jci.insight.86574
239. Tsuchiya K, Tanaka J, Shuiqing Y, et al. FoxOs integrate pleiotropic actions of insulin in vascular endothelium to protect mice from atherosclerosis. *Cell Metab.* 2012;15(3):372-381. doi:10.1016/j.cmet.2012.01.018
240. Luo S, Li L, Chen H, Wei J, Yang D. Glucose Metabolism Reprogramming of Vascular Endothelial Cells and Its Implication in Development of Atherosclerosis. *Rev Cardiovasc Med.* 2024;25(11):423. Published 2024 Nov 22. doi:10.31083/j.rcm2511423
241. Blagov AV, Markin AM, Bogatyreva AI, Tolstik TV, Sukhorukov VN, Orekhov AN. The Role of Macrophages in Pathogenesis of Atherosclerosis. *Cells.* 2023;12(4):522. Published 2023 Feb 5. doi:10.3390/cells12040522
242. Li H, Meng Y, He S, et al. Macrophages, Chronic Inflammation, and Insulin Resistance. *Cells.* 2022;11(19):3001. Published 2022 Sep 26. doi:10.3390/cells11193001
243. Mir MM, Alfaifi J, Sohail SK, et al. The Role of Pro-Inflammatory Chemokines CCL-1, 2, 4, and 5 in the Etiopathogenesis of Type 2 Diabetes Mellitus in Subjects from the Asir Region of Saudi Arabia: Correlation with Different Degrees of Obesity. *J Pers Med.* 2024;14(7):743. Published 2024 Jul 11. doi:10.3390/jpm14070743
244. Pop A, Clenciu D, Anghel M, et al. Insulin resistance is associated with all chronic complications in type 1 diabetes. *J Diabetes.* 2016;8(2):220-228. doi:10.1111/1753-0407.12283
245. Bjornstad P, Eckel RH. Pathogenesis of Lipid Disorders in Insulin Resistance: a Brief Review. *Curr Diab Rep.* 2018;18(12):127. Published 2018 Oct 17. doi:10.1007/s11892-018-1101-6
246. Kerr AG, Andersson DP, Dahlman I, Rydén M, Arner P. Adipose Insulin Resistance Associates With Dyslipidemia Independent of Liver Resistance and Involves Early Hormone Signaling. *Arterioscler Thromb Vasc Biol.* 2023;43(6):1054-1065. doi:10.1161/ATVBAHA.123.319227
247. Eddy D, Schlessinger L, Kahn R, Peskin B, Schiebinger R. Relationship of insulin resistance and related metabolic variables to coronary artery disease: a mathematical analysis. *Diabetes Care.* 2009;32(2):361-366. doi:10.2337/dc08-0854

248. Agbaje AO, Zachariah JP, Bamsa O, Odili AN, Tuomainen TP. Cumulative insulin resistance and hyperglycemia with arterial stiffness and carotid IMT progression in 1,779 adolescents: a 9-yr longitudinal cohort study. *Am J Physiol Endocrinol Metab.* 2023;324(3):E268-E278. doi:10.1152/ajpendo.00008.2023
249. Farhan S, Redfors B, Maehara A, et al. Relationship between insulin resistance, coronary plaque, and clinical outcomes in patients with acute coronary syndromes: an analysis from the PROSPECT study. *Cardiovasc Diabetol.* 2021;20(1):10. Published 2021 Jan 7. doi:10.1186/s12933-020-01207-0
250. Zhou X, Kang C, Hu Y, Wang X. Study on insulin resistance and ischemic cerebrovascular disease: A bibliometric analysis via CiteSpace. *Front Public Health.* 2023;11:1021378. Published 2023 Mar 6. doi:10.3389/fpubh.2023.1021378
251. Lee JE, Shin DW, Yun JM, et al. Insulin Resistance Is a Risk Factor for Silent Lacunar Infarction. *Stroke.* 2016;47(12):2938-2944. doi:10.1161/STROKEAHA.116.014097
252. Someya Y, Tamura Y, Kaga H, et al. Insulin resistance and muscle weakness are synergistic risk factors for silent lacunar infarcts: the Bunkyo Health Study. *Sci Rep.* 2021;11(1):21093. Published 2021 Oct 26. doi:10.1038/s41598-021-00377-5
253. Feng X, Yao Y, Wu L, Cheng C, Tang Q, Xu S. Triglyceride-Glucose Index and the Risk of Stroke: A Systematic Review and Dose-Response Meta-Analysis. *Horm Metab Res.* 2022;54(3):175-186. doi:10.1055/a-1766-0202
254. The liver plays a crucial role in regulating metabolic balance, and there exists a reciprocal relationship between insulin resistance and nonalcoholic fatty liver diseases (NAFLD).
255. Begum GS, Almashaikhi NAT, Albalushi MY, et al. Prevalence of Polycystic Ovary Syndrome (PCOS) and Its Associated Risk Factors among Medical Students in Two Countries. *Int J Environ Res Public Health.* 2024;21(9):1165. Published 2024 Sep 2. doi:10.3390/ijerph21091165
256. Aggarwal M, Chakole S. Prevalence of Polycystic Ovarian Syndrome and Its Link to Obesity in Adolescent Girls. *Cureus.* 2023;15(9):e45405. Published 2023 Sep 17. doi:10.7759/cureus.45405
257. Olatunde A, Nigam M, Singh RK, et al. Cancer and diabetes: the interlinking metabolic pathways and repurposing actions of antidiabetic drugs. *Cancer Cell Int.* 2021;21(1):499. Published 2021 Sep 17. doi:10.1186/s12935-021-02202-5
258. Zhang AMY, Wellberg EA, Kopp JL, Johnson JD. Hyperinsulinemia in Obesity, Inflammation, and Cancer [published correction appears in *Diabetes Metab J.* 2021 Jul;45(4):622. doi: 10.4093/dmj.2021.0131]. *Diabetes Metab J.* 2021;45(3):285-311. doi:10.4093/dmj.2020.0250
259. Buono G, Crispo A, Giuliano M, et al. Metabolic syndrome and early-stage breast cancer outcome: results from a prospective observational study. *Breast Cancer Res Treat.* 2020;182(2):401-409. doi:10.1007/s10549-020-05701-7
260. Chiefari E, Mirabelli M, La Vignera S, et al. Insulin Resistance and Cancer: In Search for a Causal Link. *Int J Mol Sci.* 2021;22(20):11137. Published 2021 Oct 15. doi:10.3390/ijms222011137
- Kong Y, Hsieh CH, Alonso LC. ANRIL: A lncRNA at the CDKN2A/B Locus With Roles in Cancer and Metabolic Disease. *Front Endocrinol (Lausanne).* 2018;9:405. Published 2018 Jul 24. doi:10.3389/fendo.2018.00405
261. Donohoe F, Wilkinson M, Baxter E, Brennan DJ. Mitogen-Activated Protein Kinase (MAPK) and Obesity-Related Cancer. *Int J Mol Sci.* 2020;21(4):1241. Published 2020 Feb 13. doi:10.3390/ijms21041241
- Zheng LD, Linarelli LE, Liu L, et al. Insulin resistance is associated with epigenetic and genetic regulation of mitochondrial DNA in obese humans. *Clin Epigenetics.* 2015;7(1):60. Published 2015 Jun 10. doi:10.1186/s13148-015-0093-1
- Jaye K, Li CG, Bhuyan DJ. The complex interplay of gut microbiota with the five most common cancer types: From carcinogenesis to therapeutics to prognoses. *Crit Rev Oncol Hematol.* 2021;165:103429. doi:10.1016/j.critrevonc.2021.103429
262. Nallamothe P, Nimmanapalli HD, Sachan A, Srinivasa Rao PV, Vishnubotla S. Insulin resistance in nondiabetic chronic kidney disease patients. *Saudi J Kidney Dis Transpl.* 2021;32(5):1300-1309. doi:10.4103/1319-2442.344749
263. Clarambeau F, Bale G, Lanthier N. Cirrhosis and insulin resistance: current knowledge, pathophysiological mechanisms, complications and potential treatments. *Clin Sci (Lond).* 2020;134(16):2117-2135. doi:10.1042/CS20200022



264. Fu YH, Liu WJ, Lee CL, Wang JS. Associations of insulin resistance and insulin secretion with bone mineral density and osteoporosis in a general population. *Front Endocrinol (Lausanne)*. 2022;13:971960. Published 2022 Sep 20. doi:10.3389/fendo.2022.971960
265. Balta I, Ekiz O, Ozuguz P, et al. Insulin resistance in patients with post-adolescent acne. *Int J Dermatol*. 2015;54(6):662-666. doi:10.1111/ijd.12426
266. Wang T, Laher I, Li S. Exercise snacks and physical fitness in sedentary populations. *Sports Med Health Sci*. 2024;7(1):1-7. Published 2024 Feb 27. doi:10.1016/j.smhs.2024.02.006
267. Muscogiuri G, Barrea L, Caprio M, et al. Nutritional guidelines for the management of insulin resistance. *Crit Rev Food Sci Nutr*. 2022;62(25):6947-6960. doi:10.1080/10408398.2021.1908223
268. Weinberg Sibony R, Segev O, Dor S, Raz I. Drug Therapies for Diabetes. *Int J Mol Sci*. 2023;24(24):17147. Published 2023 Dec 5. doi:10.3390/ijms242417147
269. Elian V, Popovici V, Karampelas O, Pircalabioru GG, Radulian G, Musat M. Risks and Benefits of SGLT-2 Inhibitors for Type 1 Diabetes Patients Using Automated Insulin Delivery Systems-A Literature Review. *Int J Mol Sci*. 2024;25(4):1972. Published 2024 Feb 6. doi:10.3390/ijms25041972
270. Zheng Z, Zong Y, Ma Y, et al. Glucagon-like peptide-1 receptor: mechanisms and advances in therapy. *Signal Transduct Target Ther*. 2024;9(1):234. Published 2024 Sep 18. doi:10.1038/s41392-024-01931-z
271. Yin R, Xu Y, Wang X, Yang L, Zhao D. Role of Dipeptidyl Peptidase 4 Inhibitors in Antidiabetic Treatment. *Molecules*. 2022;27(10):3055. Published 2022 May 10. doi:10.3390/molecules27103055
272. Consoli A, Czupryniak L, Duarte R, et al. Positioning sulphonylureas in a modern treatment algorithm for patients with type 2 diabetes: Expert opinion from a European consensus panel. *Diabetes Obes Metab*. 2020;22(10):1705-1713. doi:10.1111/dom.14102
273. Holst JJ. The incretin system in healthy humans: The role of GIP and GLP-1. *Metabolism*. 2019;96:46-55. doi:10.1016/j.metabol.2019.04.014
274. Rangraze, I., Patoulis, D., Karakasis, P., El-Tanani, M., & Rizzo, M. (2024). Tirzepatide, a novel, dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 receptor agonist for the ongoing diabetes epidemic: the dawn of a new era? *Expert Review of Clinical Pharmacology*, 17(10), 853–856. <https://doi.org/10.1080/17512433.2024.2408753>
275. Varney MJ, Benovic JL. The Role of G Protein-Coupled Receptors and Receptor Kinases in Pancreatic  $\beta$ -Cell Function and Diabetes. *Pharmacol Rev*. 2024;76(2):267-299. Published 2024 Feb 13. doi:10.1124/pharmrev.123.001015
276. Kim Y, Lee SW, Wang H, et al. DA-1241, a Novel GPR119 Agonist, Improves Hyperglycaemia by Inhibiting Hepatic Gluconeogenesis and Enhancing Insulin Secretion in Diabetic Mice. *Diabetes Metab J*. 2022;46(2):337-348. doi:10.4093/dmj.2021.0056
277. Parnova, R.G. GPR40/FFA1 Free Fatty Acid Receptors and Their Functional Role. *Neurosci Behav Physi* **51**, 256–264 (2021). <https://doi.org/10.1007/s11055-021-01064-8>
278. Liu L, Zhang Q, Ma Y, et al. Recent Developments in Drug Design of Oral Synthetic Free Fatty Acid Receptor 1 Agonists. *Drug Des Devel Ther*. 2024;18:5961-5983. Published 2024 Dec 11. doi:10.2147/DDDT.S487469
279. Cheng HS, Tan WR, Low ZS, Marvalim C, Lee JYH, Tan NS. Exploration and Development of PPAR Modulators in Health and Disease: An Update of Clinical Evidence. *Int J Mol Sci*. 2019;20(20):5055. Published 2019 Oct 11. doi:10.3390/ijms20205055
280. Li Y, Xu Z. Effects of Melatonin Supplementation on Insulin Levels and Insulin Resistance: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. *Horm Metab Res*. 2021;53(9):616-624. doi:10.1055/a-1544-8181
281. Dhankhar, S., Chauhan, S., Mehta, D.K. et al. Novel targets for potential therapeutic use in Diabetes mellitus. *Diabetol Metab Syndr* **15**, 17 (2023). <https://doi.org/10.1186/s13098-023-00983-5>
282. Gomez-Sanchez EP, Gomez-Sanchez CE.  $11\beta$ -hydroxysteroid dehydrogenases: A growing multi-tasking family. *Mol Cell Endocrinol*. 2021;526:111210. doi:10.1016/j.mce.2021.111210

283. Mir MM, Mir R, Alghamdi MAA, et al. Differential Association of Selected Adipocytokines, Adiponectin, Leptin, Resistin, Visfatin and Chemerin, with the Pathogenesis and Progression of Type 2 Diabetes Mellitus (T2DM) in the Asir Region of Saudi Arabia: A Case Control Study. *J Pers Med.* 2022;12(5):735. Published 2022 May 1. doi:10.3390/jpm12050735
284. Huang K, Liang Y, Ma Y, Wu J, Luo H, Yi B. The Variation and Correlation of Serum Adiponectin, Nesfatin-1, IL-6, and TNF- $\alpha$  Levels in Prediabetes. *Front Endocrinol (Lausanne).* 2022;13:774272. Published 2022 Mar 3. doi:10.3389/fendo.2022.774272
285. Chekol Abebe E, Tilahun Muche Z, Behaile T/Mariam A, et al. The structure, biosynthesis, and biological roles of fetuin-A: A review. *Front Cell Dev Biol.* 2022;10:945287. Published 2022 Jul 18. doi:10.3389/fcell.2022.945287
286. Hsu MC, Chen CH, Wang MC, et al. Apigenin targets fetuin-A to ameliorate obesity-induced insulin resistance. *Int J Biol Sci.* 2024;20(5):1563-1577. Published 2024 Feb 11. doi:10.7150/ijbs.91695
287. Semerena E, Nencioni A, Masternak K. Extracellular nicotinamide phosphoribosyltransferase: role in disease pathophysiology and as a biomarker. *Front Immunol.* 2023;14:1268756. Published 2023 Oct 17. doi:10.3389/fimmu.2023.1268756
288. Dong WS, Hu C, Hu M, et al. Metrn1: a promising biomarker and therapeutic target for cardiovascular and metabolic diseases. *Cell Commun Signal.* 2024;22(1):389. Published 2024 Aug 5. doi:10.1186/s12964-024-01767-8
289. Miao ZW, Hu WJ, Li ZY, Miao CY. Involvement of the secreted protein Metrn1 in human diseases. *Acta Pharmacol Sin.* 2020;41(12):1525-1530. doi:10.1038/s41401-020-00529-9
290. Huang KT, Lin CC, Tsai MC, Chen KD, Chiu KW. Pigment epithelium-derived factor in lipid metabolic disorders. *Biomed J.* 2018;41(2):102-108. doi:10.1016/j.bj.2018.02.004
291. Carnagarin R, Dharmarajan AM, Dass CR. PEDF-induced alteration of metabolism leading to insulin resistance. *Mol Cell Endocrinol.* 2015;401:98-104. doi:10.1016/j.mce.2014.11.00
292. Dimova R, Tankova T. The role of vaspin in the development of metabolic and glucose tolerance disorders and atherosclerosis. *Biomed Res Int.* 2015;2015:823481. doi:10.1155/2015/823481
293. Pilarski Ł, Pelczyńska M, Koperska A, Seraszek-Jaros A, Szulińska M, Bogdański P. Association of Serum Vaspin Concentration with Metabolic Disorders in Obese Individuals. *Biomolecules.* 2023;13(3):508. Published 2023 Mar 10. doi:10.3390/biom13030508
294. Sharma G, Hu C, Brigman JL, Zhu G, Hathaway HJ, Prossnitz ER. GPER deficiency in male mice results in insulin resistance, dyslipidemia, and a proinflammatory state. *Endocrinology.* 2013;154(11):4136-4145. doi:10.1210/en.2013-1357
295. Tryggestad JB, Wang JJ, Zhang SX, Thompson DM, Short KR. Elevated plasma pigment epithelium-derived factor in children with type 2 diabetes mellitus is attributable to obesity. *Pediatr Diabetes.* 2015;16(8):600-605. doi:10.1111/pedi.12226
296. Barton M, Prossnitz ER. Emerging roles of GPER in diabetes and atherosclerosis. *Trends Endocrinol Metab.* 2015;26(4):185-192. doi:10.1016/j.tem.2015.02.003
297. Khartabil N, Avoundjian A. Gene Therapy and Diabetes: A Narrative Review of Recent Advances and the Role of Multidisciplinary Healthcare Teams. *Genes (Basel).* 2025;16(1):107. Published 2025 Jan 20. doi:10.3390/genes16010107
298. Rohban R, Martins CP, Esni F. Advanced therapy to cure diabetes: mission impossible is now possible?. *Front Cell Dev Biol.* 2024;12:1484859. Published 2024 Nov 19. doi:10.3389/fcell.2024.1484859
299. Callejas D, Mann CJ, Ayuso E, et al. Treatment of diabetes and long-term survival after insulin and glucokinase gene therapy. *Diabetes.* 2013;62(5):1718-1729. doi:10.2337/db12-1113
300. Ropper AH, Gorson KC, Gooch CL, et al. Vascular endothelial growth factor gene transfer for diabetic polyneuropathy: a randomized, double-blinded trial. *Ann Neurol.* 2009;65(4):386-393. doi:10.1002/ana.21675

301. Kupczyńska D, Lubieniecki P, Antkiewicz M, et al. Complementary Gene Therapy after Revascularization with the Saphenous Vein in Diabetic Foot Syndrome. *Genes (Basel)*. 2023;14(10):1968. Published 2023 Oct 20. doi:10.3390/genes14101968
302. Zheng SY, Wan XX, Kambey PA, et al. Therapeutic role of growth factors in treating diabetic wound. *World J Diabetes*. 2023;14(4):364-395. doi:10.4239/wjd.v14.i4.364

**Disclaimer/Publisher's Note:** The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.